

CITATION REPORT

List of articles citing

Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis

DOI: 10.1126/science.1134108
Science, 2006, 314, 130-3.

Source: <https://exaly.com/paper-pdf/39645189/citation-report.pdf>

Version: 2024-04-19

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
2248	Early frontotemporal dementia targets neurons unique to apes and humans. 2006 , 60, 660-7		244
2247	Rates of cerebral atrophy differ in different degenerative pathologies. 2007 , 130, 1148-58		125
2246	A novel CpG-free vertebrate insulator silences the testis-specific SP-10 gene in somatic tissues: role for TDP-43 in insulator function. 2007 , 282, 36143-54		83
2245	Dissecting the complexity of frontotemporal dementia: genotypes, phenotypes, and phenocopies. 2007 , 69, 129-30		1
2244	Heterogeneity within a large kindred with frontotemporal dementia: a novel progranulin mutation. 2007 , 69, 140-7		70
2243	TDP-43 pathologic lesions and clinical phenotype in frontotemporal lobar degeneration with ubiquitin-positive inclusions. 2007 , 64, 1449-54		57
2242	Patterns of MRI atrophy in tau positive and ubiquitin positive frontotemporal lobar degeneration. 2007 , 78, 1375-8		43
2241	Clinicopathologic correlation in PGRN mutations. 2007 , 69, 1113-21		48
2240	A 34-year-old man with progressive behavioral and language disturbance. 2007 , 68, 68-74		4
2239	TDP-43 pathology in familial frontotemporal dementia and motor neuron disease without Progranulin mutations. 2007 , 130, 1375-85		83
2238	TDP-43 is deposited in the Guam parkinsonism-dementia complex brains. 2007 , 130, 1386-94		177
2237	A novel progranulin mutation associated with variable clinical presentation and tau, TDP43 and alpha-synuclein pathology. 2007 , 130, 1360-74		105
2236	Ubiquitinated TDP-43 is associated with FTLN and ALS. 2007 , 3, 7-8		
2235	Corticobasal syndrome associated with the A9D Progranulin mutation. 2007 , 66, 892-900		75
2234	Distinct antemortem profiles in patients with pathologically defined frontotemporal dementia. 2007 , 64, 1601-9		83
2233	Frontotemporal lobar degeneration with upper motor neuron disease/ primary lateral sclerosis. 2007 , 69, 1800-1		24
2232	Cognitive impairment in familial ALS. 2007 , 69, 1411-7		38

2231	Frontotemporal dementia and mania. 2007 , 164, 1811-6	28
2230	Frontotemporal lobar degeneration with ubiquitin-positive inclusions: a molecular genetic update. 2007 , 4, 227-35	20
2229	A screening assessment of cognitive impairment in patients with ALS. 2007 , 8, 362-5	35
2228	Cognition and amyotrophic lateral sclerosis (ALS). 2007 , 22, 300-12	36
2227	Chapter 7 Ubiquitinopathies. 2007 , 165-185	2
2226	TDP-43 proteinopathies: a new class of proteinopathies. 2007 , 2, 549-557	2
2225	Primary progressive aphasia: a 25-year retrospective. 2007 , 21, S8-S11	54
2224	FRONTOTEMPORAL DEMENTIA. 2007 , 13, 87-108	4
2223	The diagnosis and course of frontotemporal dementia. 2007 , 21, 155-63	82
2222	Links between frontotemporal lobar degeneration, corticobasal degeneration, progressive supranuclear palsy, and amyotrophic lateral sclerosis. 2007 , 21, S31-8	41
2221	The genetics of frontotemporal lobar degeneration. 2007 , 20, 693-8	6
2220	Pick complex--historical introduction. 2007 , 21, S5-7	5
2219	Longitudinal tracking of FTLT: toward developing clinical trial methodology. 2007 , 21, S58-63	11
2218	Frontotemporal dementia and semantic dementia: anatomic variations on the same disease or distinctive entities?. 2007 , 21, S19-22	6
2217	Frontotemporal dementia treatment: current symptomatic therapies and implications of recent genetic, biochemical, and neuroimaging studies. 2007 , 21, S79-87	52
2216	The neuropathology of FTD associated With ALS. 2007 , 21, S44-9	50
2215	Bibliography. Current world literature. Child and adolescent psychiatry. 2007 , 20, 417-22	1
2214	Update of atypical Parkinsonian disorders. 2007 , 20, 434-7	5

2213	Bibliography. Current world literature. Neuroimaging. 2007 , 20, 499-506	
2212	TDP-43 in the ubiquitin pathology of frontotemporal dementia with VCP gene mutations. 2007 , 66, 152-7	256
2211	Neuropathologic features of frontotemporal lobar degeneration with ubiquitin-positive inclusions with progranulin gene (PGRN) mutations. 2007 , 66, 142-51	150
2210	Location, location, location: altered transcription factor trafficking in neurodegeneration. 2007 , 66, 873-83	55
2209	TDP-43-positive white matter pathology in frontotemporal lobar degeneration with ubiquitin-positive inclusions. 2007 , 66, 177-83	169
2208	A reassessment of the neuropathology of frontotemporal dementia linked to chromosome 3. 2007 , 66, 884-91	106
2207	Evidence that TDP-43 is not the major ubiquitinated target within the pathological inclusions of amyotrophic lateral sclerosis. 2007 , 66, 1147-53	39
2206	Progranulin Mutations May Be a Significant Cause of Frontotemporal Dementia. 2007 , 7, 6	
2205	John Growdon. 2007 , 7, 28-30	
2204	The complex aetiology of frontotemporal lobar degeneration. 2007 , 206, 1-10	25
2203	TDP43 is a human low molecular weight neurofilament (hNFL) mRNA-binding protein. 2007 , 35, 320-7	266
2202	TDP-43 gene analysis in frontotemporal lobar degeneration. 2007 , 419, 1-4	40
2201	Lack of TDP-43 abnormalities in mutant SOD1 transgenic mice shows disparity with ALS. 2007 , 420, 128-32	88
2200	Appearance pattern of TDP-43 in Japanese frontotemporal lobar degeneration with ubiquitin-positive inclusions. 2007 , 419, 213-8	16
2199	Amyotrophic lateral sclerosis. 2007 , 369, 2031-2041	467
2198	Demencia frontotemporal. Demencia con cuerpos de Lewy. Concepto. Manifestaciones clínicas. Manejo terapéutico. 2007 , 9, 4953-4961	
2197	Linking selective vulnerability to cell death mechanisms in Parkinson's disease. 2007 , 170, 16-9	27
2196	TDP-43 in familial and sporadic frontotemporal lobar degeneration with ubiquitin inclusions. 2007 , 171, 227-40	376

2195	Functional multivesicular bodies are required for autophagic clearance of protein aggregates associated with neurodegenerative disease. 2007 , 179, 485-500	500
2194	The role of anti-inflammatory agents in Parkinson's disease. 2007 , 21, 789-97	70
2193	Frontotemporal lobar degeneration. 2007 , 25, 683-96, vi	23
2192	Parkinson-related dementias. 2007 , 25, 761-81, vii	24
2191	The genetics of frontotemporal dementia. 2007 , 25, 697-715, vi	13
2190	Quantitative proteomics identifies surfactant-resistant alpha-synuclein in cerebral cortex of Parkinsonism-dementia complex of Guam but not Alzheimer's disease or progressive supranuclear palsy. 2007 , 171, 993-1002	22
2189	Progranulin in frontotemporal lobar degeneration and neuroinflammation. 2007 , 4, 7	172
2188	A satellite- and model-based assessment of the 2003 Russian fires: Impact on the Arctic region. 2007 , 112,	66
2187	Neuropsychiatric features of Amyotrophic Lateral Sclerosis. 2007 , 22, 425-429	3
2186	Molecular neuropathology in familial and sporadic frontotemporal dementia. 208-256	
2185	Pathological TDP-43 distinguishes sporadic amyotrophic lateral sclerosis from amyotrophic lateral sclerosis with SOD1 mutations. 2007 , 61, 427-34	698
2184	TDP-43 immunoreactivity in hippocampal sclerosis and Alzheimer's disease. 2007 , 61, 435-45	605
2183	TDP-43 in amyotrophic lateral sclerosis: pathophysiology or patho-babel?. 2007 , 61, 382-4	24
2182	Progranulin null mutations in both sporadic and familial frontotemporal dementia. 2007 , 28, 846-55	143
2181	R6/2 neurons with intranuclear inclusions survive for prolonged periods in the brains of chimeric mice. 2007 , 505, 603-29	28
2180	Glia cells in amyotrophic lateral sclerosis: new clues to understanding an old disease?. 2007 , 35, 712-24	46
2179	Clinical proteomics in neurodegenerative diseases. 2007 , 1, 1342-50	17
2178	Methods for the purification of ubiquitinated proteins. 2007 , 7, 1016-22	23

2177	Biomarkers of neurodegeneration for diagnosis and monitoring therapeutics. 2007 , 6, 295-303	241
2176	Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide. 2007 , 8, 101-12	3692
2175	Hereditary frontotemporal dementia caused by Tau gene mutations. 2007 , 17, 63-73	158
2174	Frontotemporal lobar degeneration: current concepts in the light of recent advances. 2007 , 17, 104-14	61
2173	The Lewy body in Parkinson's disease: molecules implicated in the formation and degradation of alpha-synuclein aggregates. 2007 , 27, 494-506	297
2172	Progranulin: normal function and role in neurodegeneration. 2008 , 104, 287-97	96
2171	SHORT COMMUNICATIONS. 2007 , 14, 9-31	19
2170	Concurrence of TDP-43, tau and alpha-synuclein pathology in brains of Alzheimer's disease and dementia with Lewy bodies. 2007 , 1184, 284-94	278
2169	TDP-43: a novel neurodegenerative proteinopathy. 2007 , 17, 548-55	93
2168	Polymorphism in the intermediates and products of amyloid assembly. 2007 , 17, 48-57	324
2167	Neuromuscular disorders: therapeutic advances. 2007 , 6, 18-9	1
2166	Phenotypic variability associated with progranulin haploinsufficiency in patients with the common 1477C-->T (Arg493X) mutation: an international initiative. 2007 , 6, 857-68	174
2165	Genetic basis of frontotemporal dementia. 2007 , 6, 840-1	4
2164	Cognitive impairment in amyotrophic lateral sclerosis. 2007 , 6, 994-1003	402
2163	Semantic dementia: a unique clinicopathological syndrome. 2007 , 6, 1004-14	502
2162	[Progressive muscle atrophy. A rarely diagnosed variant of amyotrophic lateral sclerosis]. 2007 , 78, 1383-8	2
2161	RNA and protein-dependent mechanisms in tauopathies: consequences for therapeutic strategies. 2007 , 64, 1701-14	31
2160	Brain tau expression and correlation with the H1/H1 tau genotype in frontotemporal lobar degeneration patients. 2007 , 114, 1585-8	6

2159	Lrrk2 G2019S substitution in frontotemporal lobar degeneration with ubiquitin-immunoreactive neuronal inclusions. 2007 , 113, 601-6	45
2158	Ubiquitinated pathological lesions in frontotemporal lobar degeneration contain the TAR DNA-binding protein, TDP-43. 2007 , 113, 521-33	252
2157	TDP-43 immunoreactivity in neuronal inclusions in familial amyotrophic lateral sclerosis with or without SOD1 gene mutation. 2007 , 113, 535-42	229
2156	Absence of heterogeneous nuclear ribonucleoproteins and survival motor neuron protein in TDP-43 positive inclusions in frontotemporal lobar degeneration. 2007 , 113, 543-8	43
2155	The neuropathology and clinical phenotype of FTD with progranulin mutations. 2007 , 114, 49-54	101
2154	Valosin-containing protein and the pathogenesis of frontotemporal dementia associated with inclusion body myopathy. 2007 , 114, 55-61	51
2153	TDP-43 proteinopathy: the neuropathology underlying major forms of sporadic and familial frontotemporal lobar degeneration and motor neuron disease. 2007 , 114, 63-70	162
2152	TDP-43 in differential diagnosis of motor neuron disorders. 2007 , 114, 71-9	111
2151	Frontotemporal lobar degeneration: recent progress in antemortem diagnosis. 2007 , 114, 23-9	18
2150	Frontotemporal lobar degeneration: clinical and pathological relationships. 2007 , 114, 31-8	244
2149	Neuropathologic diagnostic and nosologic criteria for frontotemporal lobar degeneration: consensus of the Consortium for Frontotemporal Lobar Degeneration. 2007 , 114, 5-22	837
2148	Gene expression analysis of frontotemporal lobar degeneration of the motor neuron disease type with ubiquitinated inclusions. 2007 , 114, 81-94	65
2147	Progranulin and frontotemporal lobar degeneration. 2007 , 114, 39-47	22
2146	Frontotemporal lobar degeneration--a coming of age. 2007 , 114, 1-4	2
2145	Pathological TDP-43 in parkinsonism-dementia complex and amyotrophic lateral sclerosis of Guam. 2008 , 115, 133-45	142
2144	Co-morbidity of TDP-43 proteinopathy in Lewy body related diseases. 2007 , 114, 221-9	307
2143	Hippocampal sclerosis dementia: a reappraisal. 2007 , 114, 335-45	78
2142	Increase in the relative expression of tau with four microtubule binding repeat regions in frontotemporal lobar degeneration and progressive supranuclear palsy brains. 2007 , 114, 471-9	31

2141	TDP-43-immunoreactive neuronal and glial inclusions in the neostriatum in amyotrophic lateral sclerosis with and without dementia. 2008 , 115, 115-22	82
2140	Amyotrophic lateral sclerosis models and human neuropathology: similarities and differences. 2008 , 115, 97-114	100
2139	Severe subcortical TDP-43 pathology in sporadic frontotemporal lobar degeneration with motor neuron disease. 2008 , 115, 123-31	73
2138	TDP-43 immunoreactivity in neurodegenerative disorders: disease versus mechanism specificity. 2008 , 115, 147-9	19
2137	The molecular genetics and neuropathology of frontotemporal lobar degeneration: recent developments. 2007 , 8, 237-48	62
2136	The many ways to frontotemporal degeneration and beyond. 2007 , 28, 241-4	18
2135	The genetics of frontotemporal lobar degeneration. 2007 , 7, 434-42	36
2134	Basic pathologies of neurodegenerative dementias and their relevance for state-of-the-art molecular imaging studies. 2008 , 35 Suppl 1, S4-11	15
2133	[Molecular neuropathology of Non-Alzheimer dementia]. 2008 , 29, 434-41	2
2132	[Amyotrophic lateral sclerosis. Current clinical trials and underlying pathomechanisms]. 2008 , 79, 653-61	1
2131	Fine structural analysis of the neuronal inclusions of frontotemporal lobar degeneration with TDP-43 proteinopathy. 2008 , 115, 1661-71	41
2130	Spinal cord tau pathology in cervical spondylotic myelopathy. 2008 , 115, 185-92	12
2129	Basophilic inclusion body disease and neuronal intermediate filament inclusion disease: a comparative clinicopathological study. 2008 , 115, 561-75	55
2128	TDP-43 immunoreactivity in anoxic, ischemic and neoplastic lesions of the central nervous system. 2008 , 115, 305-11	47
2127	Phosphorylated Smad2/3 immunoreactivity in sporadic and familial amyotrophic lateral sclerosis and its mouse model. 2008 , 115, 327-34	40
2126	Clinical, neuropathological and genotypic variability in SNCA A53T familial Parkinson's disease. Variability in familial Parkinson's disease. 2008 , 116, 25-35	76
2125	Sporadic amyotrophic lateral sclerosis: two pathological patterns shown by analysis of distribution of TDP-43-immunoreactive neuronal and glial cytoplasmic inclusions. 2008 , 116, 169-82	129
2124	TDP-43 protein in plasma may index TDP-43 brain pathology in Alzheimer's disease and frontotemporal lobar degeneration. 2008 , 116, 141-6	115

2123	TDP-43-negative FTL-D-U is a significant new clinico-pathological subtype of FTL-D. 2008 , 116, 147-57	72
2122	Maturation process of TDP-43-positive neuronal cytoplasmic inclusions in amyotrophic lateral sclerosis with and without dementia. 2008 , 116, 193-203	91
2121	Frontotemporal lobar degeneration with ubiquitin-positive, but TDP-43-negative inclusions. 2008 , 116, 159-67	44
2120	Temporal lobar predominance of TDP-43 neuronal cytoplasmic inclusions in Alzheimer disease. 2008 , 116, 215-20	108
2119	White matter lesions in the brain with frontotemporal lobar degeneration with motor neuron disease: TDP-43-immunopositive inclusions co-localize with p62, but not ubiquitin. 2008 , 116, 183-91	40
2118	TAR DNA-binding protein-43 in amyotrophic lateral sclerosis, frontotemporal lobar degeneration, and Alzheimer disease. 2008 , 116, 135-40	17
2117	Ultrastructural localization of TDP-43 in filamentous neuronal inclusions in various neurodegenerative diseases. 2008 , 116, 205-13	94
2116	Immunohistochemical identification of messenger RNA-related proteins in basophilic inclusions of adult-onset atypical motor neuron disease. 2008 , 116, 439-45	55
2115	Amyotrophic lateral sclerosis: Protein chaperone dysfunction revealed by proteomic studies of animal models. 2008 , 2, 670-684	16
2114	Progranulin gene mutation with an unusual clinical and neuropathologic presentation. 2008 , 23, 1168-73	35
2113	Mutation analyses in amyotrophic lateral sclerosis/parkinsonism-dementia complex of the Kii peninsula, Japan. 2008 , 23, 2344-8	23
2112	Molecular characterization of novel progranulin (GRN) mutations in frontotemporal dementia. 2008 , 29, 512-21	61
2111	Granulin mutations associated with frontotemporal lobar degeneration and related disorders: an update. 2008 , 29, 1373-86	116
2110	TDP-43 A315T mutation in familial motor neuron disease. 2008 , 63, 535-8	497
2109	TDP-43 mutation in familial amyotrophic lateral sclerosis. 2008 , 63, 538-42	311
2108	Phosphorylated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. 2008 , 64, 60-70	484
2107	Frontotemporal dementia and related disorders: deciphering the enigma. 2008 , 64, 4-14	146
2106	Abeta amyloid and glucose metabolism in three variants of primary progressive aphasia. 2008 , 64, 388-401	363

2105	Neuropathological aspects of Alzheimer disease, Parkinson disease and frontotemporal dementia. 2008 , 5, 118-21	99
2104	Neuroscience: Standard model. 2008 , 454, 682-5	70
2103	Animal models of Alzheimer's disease and frontotemporal dementia. 2008 , 9, 532-44	535
2102	TARDBP mutations in individuals with sporadic and familial amyotrophic lateral sclerosis. 2008 , 40, 572-4	1171
2101	ALS patients request more information about cognitive symptoms. 2008 , 15, 497-500	35
2100	ALS and FTLD: two faces of TDP-43 proteinopathy. 2008 , 15, 772-80	104
2099	TDP-43, the signature protein of FTLD-U, is a neuronal activity-responsive factor. 2008 , 105, 797-806	275
2098	What determines the molecular composition of abnormal protein aggregates in neurodegenerative disease?. 2008 , 28, 351-65	43
2097	Spinal anterior horn cells in sporadic amyotrophic lateral sclerosis show ribosomal detachment from, and cisternal distention of the rough endoplasmic reticulum. 2008 , 34, 650-8	42
2096	Lack of TAR-DNA binding protein-43 (TDP-43) pathology in human prion diseases. 2008 , 34, 446-56	19
2095	TDP-43 expression in mouse models of amyotrophic lateral sclerosis and spinal muscular atrophy. 2008 , 9, 104	45
2094	Pedigree with frontotemporal lobar degeneration--motor neuron disease and Tar DNA binding protein-43 positive neuropathology: genetic linkage to chromosome 9. 2008 , 8, 32	64
2093	A90V TDP-43 variant results in the aberrant localization of TDP-43 in vitro. 2008 , 582, 2252-6	72
2092	Abnormal phosphorylation of Ser409/410 of TDP-43 in FTLD-U and ALS. 2008 , 582, 2899-904	142
2091	Nuclear bodies in neurodegenerative disease. 2008 , 1783, 2195-206	39
2090	Caspase-cleaved TAR DNA-binding protein-43 is a major pathological finding in Alzheimer's disease. 2008 , 1228, 189-98	59
2089	Ribonucleoprotein complexes in neurologic diseases. 2008 , 18, 516-23	33
2088	TARDBP mutations in amyotrophic lateral sclerosis with TDP-43 neuropathology: a genetic and histopathological analysis. 2008 , 7, 409-16	542

2087	Mutations in progranulin (GRN) within the spectrum of clinical and pathological phenotypes of frontotemporal dementia. 2008 , 7, 965-74	179
2086	Loss of progranulin function in frontotemporal lobar degeneration. 2008 , 24, 186-94	101
2085	Deletion of the progranulin gene in patients with frontotemporal lobar degeneration or Parkinson disease. 2008 , 31, 41-5	50
2084	Etiology and pathophysiology of frontotemporal dementia, Parkinson disease and Alzheimer disease: lessons from genetic studies. 2008 , 5, 122-5	27
2083	Anterior horn cells with abnormal TDP-43 immunoreactivities show fragmentation of the Golgi apparatus in ALS. 2008 , 269, 30-4	52
2082	Management of amyotrophic lateral sclerosis. 2008 , 68, 1037-48	29
2081	Diagnosis and management of motor neurone disease. 2008 , 336, 658-62	134
2080	Mutations in progranulin gene: clinical, pathological, and ribonucleic acid expression findings. 2008 , 63, 946-52	58
2079	Genetics of Parkinson's Disease. 2008 , 9-33	0
2078	Contribution of TARDBP mutations to sporadic amyotrophic lateral sclerosis. 2009 , 46, 112-4	138
2077	TDP-43: an emerging new player in neurodegenerative diseases. 2008 , 14, 479-85	90
2076	Epitope mapping of 2E2-D3, a monoclonal antibody directed against human TDP-43. 2008 , 434, 170-4	33
2075	VEGF and ALS. 2008 , 62, 71-7	34
2074	Genetic studies of GRN and IFT74 in amyotrophic lateral sclerosis. 2008 , 29, 1279-82	8
2073	Neurochemical approaches of cerebrospinal fluid diagnostics in neurodegenerative diseases. 2008 , 44, 289-98	31
2072	Role of axonal transport in neurodegenerative diseases. 2008 , 31, 151-73	567
2071	The two faces of protein misfolding: gain- and loss-of-function in neurodegenerative diseases. 2008 , 27, 336-49	279
2070	Disrupted membrane homeostasis and accumulation of ubiquitinated proteins in a mouse model of infantile neuroaxonal dystrophy caused by PLA2G6 mutations. 2008 , 172, 406-16	130

2069	Enrichment of C-terminal fragments in TAR DNA-binding protein-43 cytoplasmic inclusions in brain but not in spinal cord of frontotemporal lobar degeneration and amyotrophic lateral sclerosis. 2008 , 173, 182-94	225
2068	New directions for frontotemporal dementia drug discovery. 2008 , 4, 89-93	25
2067	Eyes on the prize: federal Alzheimer's research effort aims to facilitate interventions. 2008 , 4, S37-47	6
2066	Progranulin mutation causes frontotemporal dementia in the Swedish Karolinska family. 2008 , 4, 414-20	13
2065	TDP-43 is a culprit in human neurodegeneration, and not just an innocent bystander. 2008 , 19, 299-305	61
2064	TDP-43 mutations in familial and sporadic amyotrophic lateral sclerosis. <i>Science</i> , 2008 , 319, 1668-72	33.3 1877
2063	The syndromes of frontotemporal dysfunction in amyotrophic lateral sclerosis. 2008 , 9, 323-38	101
2062	Current and future directions in genomics of amyotrophic lateral sclerosis. 2008 , 19, 461-77, viii	2
2061	Cognitive and behavioral impairment in amyotrophic lateral sclerosis. 2008 , 19, 607-17, xi	27
2060	TDP-43 in neurodegenerative disorders. 2008 , 8, 969-78	31
2059	Progranulin genetic variability contributes to amyotrophic lateral sclerosis. 2008 , 71, 253-9	135
2058	Progressive anomia revisited: focal degeneration associated with progranulin gene mutation. 2007 , 13, 366-77	12
2057	Dementia and motor neuron disease. 2008 , 89, 431-41	
2056	Targeting angiogenin in therapy of amyotrophic lateral sclerosis. 2008 , 12, 1229-42	32
2055	Frontotemporal lobar degeneration: clinical and pathologic overview. 2008 , 89, 343-64	7
2054	Epidemiological aspects of frontotemporal dementia. 2008 , 89, 331-41	5
2053	Protein biomarkers for amyotrophic lateral sclerosis. 2008 , 5, 249-62	41
2052	Neuropathologic classification of dementias: introduction. 2008 , 89, 147-59	2

2051	Genetics of amyotrophic lateral sclerosis. 2008 , 19, 429-39, vii	18
2050	Progranulin functions as a neurotrophic factor to regulate neurite outgrowth and enhance neuronal survival. 2008 , 181, 37-41	322
2049	Variations in the progranulin gene affect global gene expression in frontotemporal lobar degeneration. 2008 , 17, 1349-62	96
2048	ESCRT functions in autophagy and associated disease. 2008 , 7, 1166-72	82
2047	Distinct genetic forms of frontotemporal dementia. 2008 , 71, 1220-6	160
2046	An aggregate-inducing peripherin isoform generated through intron retention is upregulated in amyotrophic lateral sclerosis and associated with disease pathology. 2008 , 28, 1833-40	55
2045	Association between progranulin and beta-amyloid in dementia with Lewy bodies. 2008 , 23, 488-93	11
2044	Evidence of multisystem disorder in whole-brain map of pathological TDP-43 in amyotrophic lateral sclerosis. 2008 , 65, 636-41	216
2043	A distinct clinical, neuropsychological and radiological phenotype is associated with progranulin gene mutations in a large UK series. 2008 , 131, 706-20	198
2042	Atypical frontotemporal lobar degeneration with ubiquitin-positive, TDP-43-negative neuronal inclusions. 2008 , 131, 1282-93	120
2041	Newly identified ADAR-mediated A-to-I editing positions as a tool for ALS research. 2008 , 5, 193-7	24
2040	Colocalization of transactivation-responsive DNA-binding protein 43 and huntingtin in inclusions of Huntington disease. 2008 , 67, 1159-65	165
2039	Hsp104: a weapon to combat diverse neurodegenerative disorders. 2008 , 16, 63-74	96
2038	PENN neurodegenerative disease research - in the spirit of Benjamin Franklin. 2008 , 16, 5-10	7
2037	TDP-43 proteinopathies: neurodegenerative protein misfolding diseases without amyloidosis. 2008 , 16, 41-51	101
2036	Motor neuron disease and frontotemporal lobar degeneration: a tale of two disorders linked to TDP-43. 2008 , 16, 85-90	12
2035	Descriptive epidemiology of amyotrophic lateral sclerosis: new evidence and unsolved issues. 2008 , 79, 6-11	293
2034	The 'smoking gun' in ALS. 2008 , 1, 177-177	

2033	The ALS/PDC syndrome of Guam and the cycad hypothesis. 2008 , 70, 1984-90	87
2032	Missense mutations in the progranulin gene linked to frontotemporal lobar degeneration with ubiquitin-immunoreactive inclusions reduce progranulin production and secretion. 2008 , 283, 1744-1753	135
2031	TDP-43 overexpression enhances exon 7 inclusion during the survival of motor neuron pre-mRNA splicing. 2008 , 283, 28852-9	144
2030	Clinical aspects of TDP-43 proteinopathy, neurofilament inclusion body disease and dementias lacking distinctive proteinopathy. 2008 , 89, 377-82	2
2029	Primary progressive aphasia and kindred disorders. 2008 , 89, 573-87	30
2028	Novel mutations in TARDBP (TDP-43) in patients with familial amyotrophic lateral sclerosis. 2008 , 4, e1000193	339
2027	TDP-43 accumulation in inclusion body myopathy muscle suggests a common pathogenic mechanism with frontotemporal dementia. 2008 , 79, 1186-9	206
2026	Longitudinal decline in autopsy-defined frontotemporal lobar degeneration. 2008 , 70, 2036-45	67
2025	Translational Research in ALS. 2008 , 267-310	1
2024	Distinct MRI atrophy patterns in autopsy-proven Alzheimer's disease and frontotemporal lobar degeneration. 2007 , 22, 474-88	195
2023	Patient care and management of frontotemporal lobar degeneration. 2008 , 23, 125-31	13
2022	Neuropathology of hereditary forms of frontotemporal dementia and parkinsonism. 2008 , 89, 393-414	9
2021	TDP-43 regulates retinoblastoma protein phosphorylation through the repression of cyclin-dependent kinase 6 expression. 2008 , 105, 3785-9	186
2020	TDP-43 in cerebrospinal fluid of patients with frontotemporal lobar degeneration and amyotrophic lateral sclerosis. 2008 , 65, 1481-7	158
2019	Two German kindreds with familial amyotrophic lateral sclerosis due to TARDBP mutations. 2008 , 65, 1185-9	118
2018	Disturbance of nuclear and cytoplasmic TAR DNA-binding protein (TDP-43) induces disease-like redistribution, sequestration, and aggregate formation. 2008 , 283, 13302-9	408
2017	Neuron-specific expression of mutant superoxide dismutase is sufficient to induce amyotrophic lateral sclerosis in transgenic mice. 2008 , 28, 2075-88	183
2016	Structural determinants of the cellular localization and shuttling of TDP-43. 2008 , 121, 3778-85	375

2015	Refining frontotemporal dementia with parkinsonism linked to chromosome 17: introducing FTDP-17 (MAPT) and FTDP-17 (PGRN). 2008 , 65, 460-4	140
2014	Frequency and clinical characteristics of progranulin mutation carriers in the Manchester frontotemporal lobar degeneration cohort: comparison with patients with MAPT and no known mutations. 2008 , 131, 721-31	163
2013	Phenotype variability in progranulin mutation carriers: a clinical, neuropsychological, imaging and genetic study. 2008 , 131, 732-46	275
2012	Abnormal TDP-43 immunoreactivity in AD modifies clinicopathologic and radiologic phenotype. 2008 , 70, 1850-7	176
2011	Challenges and new opportunities in the investigation of new drug therapies to treat frontotemporal dementia. 2008 , 12, 1367-76	7
2010	Impaired action knowledge in amyotrophic lateral sclerosis. 2008 , 71, 1396-401	129
2009	A yeast TDP-43 proteinopathy model: Exploring the molecular determinants of TDP-43 aggregation and cellular toxicity. 2008 , 105, 6439-44	317
2008	Progressive aphasia secondary to Alzheimer disease vs FTLN pathology. 2008 , 70, 25-34	121
2007	Brain magnetic resonance imaging structural changes in a pedigree of asymptomatic progranulin mutation carriers. 2008 , 11, 585-95	75
2006	Concomitant TAR-DNA-binding protein 43 pathology is present in Alzheimer disease and corticobasal degeneration but not in other tauopathies. 2008 , 67, 555-64	268
2005	A recipe for ALS. 2008 , 35, 125-6	1
2004	ESCRTing autophagic clearance of aggregating proteins. 2008 , 4, 233-236	28
2003	Metal-dependent generation of reactive oxygen species from amyloid proteins implicated in neurodegenerative disease. 2008 , 36, 1293-8	69
2002	4. Progress of Study on Neurodegenerative Disease. 2008 , 97, 2243-2249	
2001	[Recent progress in ALS research: ALS and TDP-43]. 2008 , 48, 625-33	2
2000	[Frontotemporal dementia (FTD) and genetic mutations including progranulin gene]. 2008 , 48, 990-3	
1999	[Significance of the TDP-43 deposition in FTLN-U and ALS]. 2008 , 48, 994-7	1
1998	Very early semantic dementia with progressive temporal lobe atrophy: an 8-year longitudinal study. 2008 , 65, 1659-63	24

1997	Current world literature. Trauma and rehabilitation. 2008 , 21, 762-4	
1996	NEUROIMAGING OF DISORDERS LEADING TO DEMENTIA. 2008 , 14, 144-163	1
1995	TAR DNA-binding protein 43 immunohistochemistry reveals extensive neuritic pathology in FTLD-U: a midwest-southwest consortium for FTLD study. 2008 , 67, 271-9	49
1994	Neuropathologic features of frontotemporal lobar degeneration with ubiquitin-positive inclusions visualized with ubiquitin-binding protein p62 immunohistochemistry. 2008 , 67, 280-98	71
1993	Update on recent molecular and genetic advances in frontotemporal lobar degeneration. 2008 , 67, 635-48	26
1992	TAR-DNA binding protein 43 in Pick disease. 2008 , 67, 62-7	64
1991	White matter tauopathy with globular glial inclusions: a distinct sporadic frontotemporal lobar degeneration. 2008 , 67, 963-75	95
1990	Selective functional, regional, and neuronal vulnerability in frontotemporal dementia. 2008 , 21, 701-7	166
1989	New approaches to the treatment of frontotemporal lobar degeneration. 2008 , 21, 708-16	44
1988	Frontotemporal dementia: a topical review. 2008 , 21, 127-33	13
1987	The role of transactive response DNA-binding protein-43 in amyotrophic lateral sclerosis and frontotemporal dementia. 2008 , 21, 693-700	91
1986	GENETICS OF DEMENTIA. 2008 , 14, 29-48	
1985	Delusions and hallucinations in frontotemporal dementia: a clinicopathologic case report. 2008 , 21, 107-10	14
1984	News & Views. 2008 , 36, 373-375	
1983	An update on the toxicity of Abeta in Alzheimer's disease. 2008 , 4, 1033-42	28
1982	Molecular pathogenesis of frontotemporal lobar degeneration: basic science seminar in neurology. 2008 , 65, 700-4	2
1981	Neurogenetics of dementia. 27-44	
1980	Ubiquitin-positive foam cells are identified in the aortic and mitral valves with atherosclerotic involvement. 2009 , 16, 472-9	7

1979	No TARDBP mutations in a French Canadian population of patients with Parkinson disease. 2009 , 66, 281-2	11
1978	Characterization of detergent-insoluble proteins in ALS indicates a causal link between nitrative stress and aggregation in pathogenesis. 2009 , 4, e8130	85
1977	Neuropathology of dementia. 142-160	2
1976	TARDBP in amyotrophic lateral sclerosis: identification of a novel variant but absence of copy number variation. 2009 , 80, 1283-5	25
1975	The molecular basis of frontotemporal dementia. 2009 , 11, e23	57
1974	TDP-43 M311V mutation in familial amyotrophic lateral sclerosis. 2009 , 80, 354-5	45
1973	Rapamycin rescues TDP-43 mislocalization and the associated low molecular mass neurofilament instability. 2009 , 284, 27416-24	118
1972	Prodromal dizziness in vestibular neuritis: frequency and clinical implication. 2009 , 80, 355-6	18
1971	Mutations in TDP-43 link glycine-rich domain functions to amyotrophic lateral sclerosis. 2009 , 18, R156-62	217
1970	TDP-43 is intrinsically aggregation-prone, and amyotrophic lateral sclerosis-linked mutations accelerate aggregation and increase toxicity. 2009 , 284, 20329-39	512
1969	TDP-43 depletion induces neuronal cell damage through dysregulation of Rho family GTPases. 2009 , 284, 22059-22066	78
1968	Truncation and pathogenic mutations facilitate the formation of intracellular aggregates of TDP-43. 2009 , 18, 3353-64	221
1967	Reciprocal efficiency of RNQ1 and polyglutamine detoxification in the cytosol and nucleus. 2009 , 20, 4162-73	33
1966	Potential of amyotrophic lateral sclerosis (ALS)-associated TDP-43 aggregation by the proteasome-targeting factor, ubiquilin 1. 2009 , 284, 8083-92	100
1965	VCP mutations causing frontotemporal lobar degeneration disrupt localization of TDP-43 and induce cell death. 2009 , 284, 12384-98	83
1964	ALS motor phenotype heterogeneity, focality, and spread: deconstructing motor neuron degeneration. 2009 , 73, 805-11	406
1963	Neuropathological investigation of regions responsible for semantic aphasia in frontotemporal lobar degeneration. 2009 , 27, 214-23	5
1962	A novel TARDBP mutation in an Australian amyotrophic lateral sclerosis kindred. 2009 , 80, 1286-8	23

1961	Clinical features and diagnosis of frontotemporal dementia. 2009 , 24, 140-148	10
1960	MRI correlates of protein deposition and disease severity in postmortem frontotemporal lobar degeneration. 2009 , 6, 106-17	43
1959	Nerve injection of viral vectors efficiently transfers transgenes into motor neurons and delivers RNAi therapy against ALS. 2009 , 11, 1523-34	21
1958	Brains with medial temporal lobe neurofibrillary tangles but no neuritic amyloid plaques are a diagnostic dilemma but may have pathogenetic aspects distinct from Alzheimer disease. 2009 , 68, 774-84	73
1957	Animal models for Alzheimer's disease and frontotemporal dementia: a perspective. 2009 , 1,	27
1956	Plasma progranulin levels predict progranulin mutation status in frontotemporal dementia patients and asymptomatic family members. 2009 , 132, 583-91	315
1955	Transactive response DNA-binding protein 43 burden in familial Alzheimer disease and Down syndrome. 2009 , 66, 1483-8	54
1954	Genetic screen identifies serpin5 as a regulator of the toll pathway and CHMP2B toxicity associated with frontotemporal dementia. 2009 , 106, 12168-73	66
1953	Diffusion tensor imaging in sporadic and familial (D90A SOD1) forms of amyotrophic lateral sclerosis. 2009 , 66, 109-15	35
1952	Mutations in FUS cause FALS and SALS in French and French Canadian populations. 2009 , 73, 1176-9	110
1951	[TDP-43 proteinopathies: ALS and frontotemporal dementias]. 2009 , 77 Suppl 1, S25-7	3
1950	Mimicking aspects of frontotemporal lobar degeneration and Lou Gehrig's disease in rats via TDP-43 overexpression. 2009 , 17, 607-13	69
1949	Amyloidplaque-Bildgebung in der Demenzdiagnostik. 2009 , 32, 170-177	1
1948	Frontotemporal dementia neuroimaging: a guide for clinicians. 2009 , 24, 160-167	12
1947	Chromosome 9p-linked families with frontotemporal dementia associated with motor neuron disease. 2009 , 72, 1669-76	82
1946	Molecular neuropathology of TDP-43 proteinopathies. 2009 , 10, 232-46	106
1945	With or without FUS, it is the anatomy that dictates the dementia phenotype. 2009 , 132, 2906-8	36
1944	Abnormal hippocampal distribution of TDP-43 in patients with-late onset psychosis. 2009 , 43, 739-45	19

1943	Biochemical and genetic evidence for a role of IGHMBP2 in the translational machinery. 2009 , 18, 2115-26	48
1942	Neurology of anomia in the semantic variant of primary progressive aphasia. 2009 , 132, 2553-65	99
1941	A new subtype of frontotemporal lobar degeneration with FUS pathology. 2009 , 132, 2922-31	535
1940	Lysosomal modulatory drugs for a broad strategy against protein accumulation disorders. 2009 , 6, 438-45	13
1939	Absence of ubiquitinated inclusions in hypocretin neurons of patients with narcolepsy. 2009 , 73, 511-7	25
1938	Cause of death and clinical grading criteria in a cohort of amyotrophic lateral sclerosis cases undergoing autopsy from the Scottish Motor Neurone Disease Register. 2009 , 80, 84-7	48
1937	Functional mapping of the interaction between TDP-43 and hnRNP A2 in vivo. 2009 , 37, 4116-26	162
1936	Expression of TDP-43 C-terminal Fragments in Vitro Recapitulates Pathological Features of TDP-43 Proteinopathies. 2009 , 284, 8516-24	262
1935	Neuropathological spectrum of frontal lobe dementias. 2009 , 24, 149-159	4
1934	Inhibition of autophagy induction delays neuronal cell loss caused by dysfunctional ESCRT-III in frontotemporal dementia. 2009 , 29, 8506-11	100
1933	Valosin-containing protein (VCP) is required for autophagy and is disrupted in VCP disease. 2009 , 187, 875-88	393
1932	Another gene for ALS: mutations in sporadic cases and the rare variant hypothesis. 2009 , 73, 1172-3	10
1931	The complement factor C5a receptor is upregulated in NFL ^{-/-} mouse motor neurons. 2009 , 210, 52-62	30
1930	Progranulin is expressed within motor neurons and promotes neuronal cell survival. 2009 , 10, 130	128
1929	Divergent patterns of cytosolic TDP-43 and neuronal progranulin expression following axotomy: implications for TDP-43 in the physiological response to neuronal injury. 2009 , 1249, 202-11	173
1928	Cytosolic TDP-43 expression following axotomy is associated with caspase 3 activation in NFL ^{-/-} mice: support for a role for TDP-43 in the physiological response to neuronal injury. 2009 , 1296, 176-86	73
1927	Tar DNA binding protein of 43 kDa (TDP-43), 14-3-3 proteins and copper/zinc superoxide dismutase (SOD1) interact to modulate NFL mRNA stability. Implications for altered RNA processing in amyotrophic lateral sclerosis (ALS). 2009 , 1305, 168-82	157
1926	Phosphorylated and ubiquitinated TDP-43 pathological inclusions in ALS and FTLD-U are recapitulated in SH-SY5Y cells. 2009 , 583, 394-400	95

1925	Depletion of TDP-43 affects <i>Drosophila</i> motoneurons terminal synapsis and locomotive behavior. 2009 , 583, 1586-92	225
1924	Methylene blue and dimebon inhibit aggregation of TDP-43 in cellular models. 2009 , 583, 2419-24	86
1923	Biomarkers in amyotrophic lateral sclerosis. 2009 , 8, 94-109	340
1922	Epigenetic mechanisms in neurological diseases: genes, syndromes, and therapies. 2009 , 8, 1056-72	473
1921	TARDBP mutations in motoneuron disease with frontotemporal lobar degeneration. 2009 , 65, 470-3	240
1920	Serum biomarker for progranulin-associated frontotemporal lobar degeneration. 2009 , 65, 603-9	185
1919	High frequency of TARDBP gene mutations in Italian patients with amyotrophic lateral sclerosis. 2009 , 30, 688-94	155
1918	TDP-43, a neuro-pathosignature factor, is essential for early mouse embryogenesis. 2010 , 48, 56-62	140
1917	Synergistic effect between proteasome and autophagosome in the clearance of polyubiquitinated TDP-43. 2010 , 88, 784-97	78
1916	Clinical and pathological characteristics of patients with leucine-rich repeat kinase-2 mutations. 2009 , 24, 32-9	38
1915	Handedness does not predict side of onset of motor symptoms in Parkinson's disease. 2009 , 24, 1836-9	18
1914	TARDBP variation associated with frontotemporal dementia, supranuclear gaze palsy, and chorea. 2009 , 24, 1843-7	148
1913	No evidence for cognitive dysfunction or depression in patients with mild restless legs syndrome. 2009 , 24, 1840-2	51
1912	Sarcoplasmic redistribution of nuclear TDP-43 in inclusion body myositis. 2009 , 40, 19-31	143
1911	TDP-43: a reliable immunohistochemistry marker for inclusion body myositis?. 2009 , 40, 8-9	2
1910	The granulin gene family: from cancer to dementia. 2009 , 31, 1245-54	258
1909	Frontotemporal dementia in a large Swedish family is caused by a progranulin null mutation. 2009 , 10, 27-34	13
1908	Concentrations of beta-amyloid precursor protein processing products in cerebrospinal fluid of patients with amyotrophic lateral sclerosis and frontotemporal lobar degeneration. 2009 , 116, 1169-78	22

1907	Sporadic amyotrophic lateral sclerosis of long duration is associated with relatively mild TDP-43 pathology. 2009 , 117, 45-53	50
1906	Progression of hippocampal degeneration in amyotrophic lateral sclerosis with or without memory impairment: distinction from Alzheimer disease. 2009 , 117, 35-44	61
1905	Increased TDP-43 protein in cerebrospinal fluid of patients with amyotrophic lateral sclerosis. 2009 , 117, 55-62	148
1904	Nomenclature for neuropathologic subtypes of frontotemporal lobar degeneration: consensus recommendations. 2009 , 117, 15-8	325
1903	Accumulation of phosphorylated TDP-43 in brains of patients with argyrophilic grain disease. 2009 , 117, 151-8	80
1902	TDP-43 accumulation is common in myopathies with rimmed vacuoles. 2009 , 117, 209-11	48
1901	Phosphorylation of S409/410 of TDP-43 is a consistent feature in all sporadic and familial forms of TDP-43 proteinopathies. 2009 , 117, 137-49	358
1900	Phosphorylated TDP-43 in Alzheimer's disease and dementia with Lewy bodies. 2009 , 117, 125-36	248
1899	Clinicopathological characterization of Pick's disease versus frontotemporal lobar degeneration with ubiquitin/TDP-43-positive inclusions. 2009 , 117, 429-44	59
1898	TDP-43 pathology in familial British dementia. 2009 , 118, 303-11	22
1897	TDP-43 in ubiquitinated inclusions in the inferior olives in frontotemporal lobar degeneration and in other neurodegenerative diseases: a degenerative process distinct from normal ageing. 2009 , 118, 359-69	25
1896	Hippocampal sclerosis with four-repeat tau-positive round inclusions in the dentate gyrus: a new type of four-repeat tauopathy. 2009 , 117, 713-8	25
1895	Evaluation of subcortical pathology and clinical correlations in FTLD-U subtypes. 2009 , 118, 349-58	103
1894	Selective occurrence of TDP-43-immunoreactive inclusions in the lower motor neurons in Machado-Joseph disease. 2009 , 118, 553-60	33
1893	TARDBP 3'-UTR variant in autopsy-confirmed frontotemporal lobar degeneration with TDP-43 proteinopathy. 2009 , 118, 633-45	110
1892	Persistent cleavage and nuclear translocation of apoptosis-inducing factor in motor neurons in the spinal cord of sporadic amyotrophic lateral sclerosis patients. 2009 , 118, 755-62	9
1891	Plasma phosphorylated-TDP-43 protein levels correlate with brain pathology in frontotemporal lobar degeneration. 2009 , 118, 647-58	65
1890	FUS pathology in basophilic inclusion body disease. 2009 , 118, 617-27	198

1889	The management of amyotrophic lateral sclerosis. 2009 , 256, 176-86	32
1888	Amyotrophic lateral sclerosis, frontotemporal dementia and beyond: the TDP-43 diseases. 2009 , 256, 1205-14	141
1887	Frequency of progranulin mutations in a German cohort of 79 frontotemporal dementia patients. 2009 , 256, 2043-51	9
1886	Recent advances in the genetics of amyotrophic lateral sclerosis. 2009 , 9, 198-205	91
1885	TDP-43 and frontotemporal dementia. 2009 , 9, 353-8	12
1884	Amyloid imaging in Alzheimer's disease and other dementias. 2009 , 3, 246-61	23
1883	Versatile somatic gene transfer for modeling neurodegenerative diseases. 2009 , 16, 329-42	10
1882	[Chronic progressive aphasia]. 2009 , 80, 1452-61	1
1881	Motor-neuron disease: Rogue gene in the family. 2009 , 458, 415-7	7
1880	Geochemistry: A glacial hangover. 2009 , 458, 417-8	7
1879	Genetics of motor neuron disorders: new insights into pathogenic mechanisms. 2009 , 10, 769-82	226
1878	Brain banking: opportunities, challenges and meaning for the future. 2009 , 10, 70-8	90
1877	Frontotemporal lobar degeneration with ubiquitinated tau-negative inclusions and additional alpha-synuclein pathology but also unusual cerebellar ubiquitinated p62-positive, TDP-43-negative inclusions. 2009 , 29, 466-71	16
1876	Sporadic amyotrophic lateral sclerosis: Widespread multisystem degeneration with TDP-43 pathology in a patient after long-term survival on a respirator. 2009 , 29, 689-96	29
1875	Regional distribution of TDP-43 inclusions in Alzheimer disease (AD) brains: their relation to AD common pathology. 2009 , 29, 566-73	62
1874	TDP-43 is consistently co-localized with ubiquitinated inclusions in sporadic and Guam amyotrophic lateral sclerosis but not in familial amyotrophic lateral sclerosis with and without SOD1 mutations. 2009 , 29, 672-83	98
1873	Tau phosphorylation at threonine-175 leads to fibril formation and enhanced cell death: implications for amyotrophic lateral sclerosis with cognitive impairment. 2009 , 108, 634-43	28
1872	Proteolytic processing of TAR DNA binding protein-43 by caspases produces C-terminal fragments with disease defining properties independent of progranulin. 2009 , 110, 1082-94	132

1871 Wednesday Oral Session. **2009**, 110, 132-147

1870 TDP-43 is recruited to stress granules in conditions of oxidative insult. **2009**, 111, 1051-61 347

1869 Protein Folding and Misfolding: Neurodegenerative Diseases. **2009**, 5

1868 Proteomics analysis reveals novel components in the detergent-insoluble subproteome in Alzheimer's disease. **2009**, 8, 5069-79 67

1867 Axonopathy and cytoskeletal disruption in degenerative diseases of the central nervous system. **2009**, 80, 217-23 56

1866 Alternative splicing and disease. **2009**, 1792, 14-26 381

1865 Identification of casein kinase-1 phosphorylation sites on TDP-43. **2009**, 382, 405-9 77

1864 Recent insights into the molecular genetics of dementia. **2009**, 32, 451-61 47

1863 No association of TDP-43 with sporadic frontotemporal dementia. **2009**, 30, 157-9 29

1862 Prominent phenotypic variability associated with mutations in Progranulin. **2009**, 30, 739-51 150

1861 Neuronal inclusion protein TDP-43 has no primary genetic role in FTD and ALS. **2009**, 30, 1329-31 59

1860 Novel PSEN1 and PGRN mutations in early-onset familial frontotemporal dementia. **2009**, 30, 1825-33 36

1859 Ubiquitin associated protein 1 is a risk factor for frontotemporal lobar degeneration. **2009**, 30, 656-65 29

1858 Wobbler mice modeling motor neuron disease display elevated transactive response DNA binding protein. **2009**, 158, 745-50 44

1857 Axonal ligation induces transient redistribution of TDP-43 in brainstem motor neurons. **2009**, 164, 1565-78 51

1856 Upper motor neuron and extra-motor neuron involvement in amyotrophic lateral sclerosis: a clinical and brain imaging review. **2009**, 19, 53-8 60

1855 Valosin-containing protein disease: inclusion body myopathy with Paget's disease of the bone and fronto-temporal dementia. **2009**, 19, 308-15 164

1854 Pallidonigral TDP-43 pathology in Perry syndrome. **2009**, 15, 281-6 72

1853	Frontotemporal dementia and motor neurone disease: overlapping clinic-pathological disorders. 2009 , 16, 1131-5	112
1852	TDP-43 localizes in mRNA transcription and processing sites in mammalian neurons. 2009 , 167, 235-41	58
1851	Riluzole protects against glutamate-induced slowing of neurofilament axonal transport. 2009 , 454, 161-4	30
1850	Mutation analysis for DJ-1 in sporadic and familial parkinsonism: screening strategy in parkinsonism. 2009 , 455, 159-61	15
1849	Mislocalization of TDP-43 in the G93A mutant SOD1 transgenic mouse model of ALS. 2009 , 458, 70-4	49
1848	Phosphorylation-dependent TDP-43 antibody detects intraneuronal dot-like structures showing morphological characters of granulovacuolar degeneration. 2009 , 463, 87-92	41
1847	TDP-43 is not present in brain tissue of patients with schizophrenia. 2009 , 108, 297-8	8
1846	Progranulin (PGRN) expression in ALS: an immunohistochemical study. 2009 , 276, 9-13	35
1845	Screening for TARDBP mutations in Japanese familial amyotrophic lateral sclerosis. 2009 , 284, 69-71	43
1844	[Parkinson disease and amyotrophic lateral sclerosis. Tauopathies, TDP-43 and SOD mutations]. 2009 , 165, 15-30	3
1843	Amyotrophic lateral sclerosis. 2009 , 4, 3	630
1842	Frontotemporal dementia and amyotrophic lateral sclerosis-associated disease protein TDP-43 promotes dendritic branching. 2009 , 2, 30	101
1841	The molecular links between TDP-43 dysfunction and neurodegeneration. 2009 , 66, 1-34	75
1840	Cellular Signaling in Health and Disease. 2009 ,	6
1839	Aberrant cleavage of TDP-43 enhances aggregation and cellular toxicity. 2009 , 106, 7607-12	433
1838	Frontotemporal dementia presenting as schizophrenia-like psychosis in young people: clinicopathological series and review of cases. 2009 , 194, 298-305	133
1837	Frontotemporal dementias: update on recent developments in molecular genetics and neuropathology. 2009 , 60, 117-22	5
1836	THEME 5 GENETICS. 2009 , 10, 122-136	

1835	Structural insights into TDP-43 in nucleic-acid binding and domain interactions. 2009 , 37, 1799-808		212
1834	Correlation between pyramidal tract degeneration and widespread white matter involvement in amyotrophic lateral sclerosis: a study with tractography and diffusion-tensor imaging. 2009 , 10, 288-94		48
1833	THEME 3 IN VITRO EXPERIMENTAL MODELS. 2009 , 10, 97-113		
1832	Non-cell autonomous toxicity in neurodegenerative disorders: ALS and beyond. 2009 , 187, 761-72		777
1831	Rethinking ALS: the FUS about TDP-43. 2009 , 136, 1001-4		455
1830	TDP-43 mutant transgenic mice develop features of ALS and frontotemporal lobar degeneration. 2009 , 106, 18809-14		519
1829	Amyotrophic lateral sclerosis-plus syndrome with TAR DNA-binding protein-43 pathology. 2009 , 66, 121-4		43
1828	Mutations in FUS, an RNA processing protein, cause familial amyotrophic lateral sclerosis type 6. <i>Science</i> , 2009 , 323, 1208-1211	33.3	1890
1827	Consensus criteria for the diagnosis of frontotemporal cognitive and behavioural syndromes in amyotrophic lateral sclerosis. 2009 , 10, 131-46		391
1826	MicroRNA-206 delays ALS progression and promotes regeneration of neuromuscular synapses in mice. <i>Science</i> , 2009 , 326, 1549-54	33.3	561
1825	Neurobiology of cognitive disorders. 2009 , 22, 546-51		20
1824	[TDP-43 proteinopathies, toward understanding of the molecular pathogenesis]. 2009 , 49, 783-5		1
1823	[Exploration of pathogenesis and therapy development for ALS employing sporadic disease model]. 2009 , 49, 811-3		0
1822	Frontotemporal dementia. 45-55		
1821	Animal models of dementia. 131-141		
1820	Early clinical features of the parkinsonian-related dementias. 197-212		2
1819	Dementia treatment. 213-253		2
1818	Longitudinal cortical atrophy in amyotrophic lateral sclerosis with frontotemporal dementia. 2009 , 66, 138-9		12

1817	Decreased cystatin C immunoreactivity in spinal motor neurons and astrocytes in amyotrophic lateral sclerosis. 2009 , 68, 1200-6	22
1816	The role of CHMP2B in frontotemporal dementia. 2009 , 37, 208-12	52
1815	Survival profiles of patients with frontotemporal dementia and motor neuron disease. 2009 , 66, 1359-64	72
1814	Recent advances in motor neuron disease. 2009 , 22, 486-92	53
1813	Nuclear TAR DNA binding protein 43 expression in spinal cord neurons correlates with the clinical course in amyotrophic lateral sclerosis. 2009 , 68, 37-47	43
1812	TAR DNA-Binding protein 43 accumulation in protein aggregate myopathies. 2009 , 68, 262-73	75
1811	Transactivation response DNA-binding protein 43 microvasculopathy in frontotemporal degeneration and familial Lewy body disease. 2009 , 68, 1167-76	40
1810	Inflammatory myopathies: disease mechanisms. 2009 , 22, 516-23	23
1809	Autobiography Series. 2010 , 69, 1168-1172	
1808	Neurobehavioral features in frontotemporal dementia with amyotrophic lateral sclerosis. 2010 , 67, 826-30	103
1807	Frontotemporal dementia and pharmacologic interventions. 2010 , 22, 19-29	19
1806	Drosophila melanogaster in the study of human neurodegeneration. 2010 , 9, 504-23	128
1805	Cognition and behaviour in motor neurone disease. 2010 , 23, 638-42	12
1804	Sporadic inclusion body myositis: possible pathogenesis inferred from biomarkers. 2010 , 23, 482-8	42
1803	Neuropathology of variants of progressive supranuclear palsy. 2010 , 23, 394-400	244
1802	Biomarkers in frontotemporal lobar degeneration. 2010 , 23, 643-8	13
1801	Discovering the connection between familial and sporadic amyotrophic lateral sclerosis: pathology trumps genetics. 2010 , 5, 625-628	1
1800	Amyotrophic lateral sclerosis-frontotemporal lobar dementia in 3 families with p.Ala382Thr TARDBP mutations. 2010 , 67, 1002-9	46

1799	Alzheimer disease-like phenotype associated with the c.154delA mutation in progranulin. 2010 , 67, 171-7	51
1798	From FUS to Fibs: what's new in frontotemporal dementia?. 2010 , 21, 349-60	12
1797	[FTLD/ALS as TDP-43 proteinopathies]. 2010 , 50, 1022-4	1
1796	[Assessing frontal lobe function in patients with amyotrophic lateral sclerosis by frontal assessment battery]. 2010 , 50, 379-84	6
1795	[Molecular dissection of TDP-43 in ALS and FTLD]. 2010 , 50, 937-9	
1794	[Clinicopathological features of sporadic frontotemporal lobar degeneration with TDP-43-positive inclusions]. 2010 , 50, 1018-21	
1793	[A case of amyotrophic lateral sclerosis/frontotemporal lobar degeneration with apraxia of eyelid opening]. 2010 , 50, 645-50	2
1792	[Creation of an animal model of ALS by overexpression of TDP-43]. 2010 , 50, 943-4	
1791	[Implications of microRNA dysfunction in the pathogenesis of ALS]. 2010 , 50, 979-81	3
1790	Pathological 43-kDa transactivation response DNA-binding protein in older adults with and without severe mental illness. 2010 , 67, 1238-50	74
1789	Biomarkers for brain disorders. 2010 , 7, 321-336	1
1788	C. elegans models of neuromuscular diseases expedite translational research. 2010 , 1,	13
1787	Brain progranulin expression in GRN-associated frontotemporal lobar degeneration. 2010 , 119, 111-22	56
1786	Sporadic corticobasal syndrome due to FTLD-TDP. 2010 , 119, 365-74	46
1785	Amyotrophic lateral sclerosis is a non-amyloid disease in which extensive misfolding of SOD1 is unique to the familial form. 2010 , 119, 335-44	147
1784	Protein coding of neurodegenerative dementias: the neuropathological basis of biomarker diagnostics. 2010 , 119, 389-408	79
1783	Loss of murine TDP-43 disrupts motor function and plays an essential role in embryogenesis. 2010 , 119, 409-19	240
1782	TDP-43 pathology in sporadic ALS occurs in motor neurons lacking the RNA editing enzyme ADAR2. 2010 , 120, 75-84	84

1781	TDP-43 pathology in primary progressive aphasia and frontotemporal dementia with pathologic Alzheimer disease. 2010 , 120, 43-54	59
1780	Amyotrophic lateral sclerosis: dash-like accumulation of phosphorylated TDP-43 in somatodendritic and axonal compartments of somatomotor neurons of the lower brainstem and spinal cord. 2010 , 120, 67-74	47
1779	FUS pathology defines the majority of tau- and TDP-43-negative frontotemporal lobar degeneration. 2010 , 120, 33-41	198
1778	Phosphorylated TDP-43 pathology and hippocampal sclerosis in progressive supranuclear palsy. 2010 , 120, 55-66	77
1777	Involvement of the peripheral nervous system in synucleinopathies, tauopathies and other neurodegenerative proteinopathies of the brain. 2010 , 120, 1-12	106
1776	Age-related motor neuron degeneration in DNA repair-deficient Ercc1 mice. 2010 , 120, 461-75	67
1775	Brain biopsy in dementia: clinical indications and diagnostic approach. 2010 , 120, 327-41	49
1774	Effect of topographical distribution of β -synuclein pathology on TDP-43 accumulation in Lewy body disease. 2010 , 120, 789-801	24
1773	Quantitative proton magnetic resonance spectroscopy detects abnormalities in dorsolateral prefrontal cortex and motor cortex of patients with frontotemporal lobar degeneration. 2010 , 257, 114-21	10
1772	Frequency of ubiquitin and FUS-positive, TDP-43-negative frontotemporal lobar degeneration. 2010 , 257, 747-53	116
1771	Broad clinical phenotypes associated with TAR-DNA binding protein (TARDBP) mutations in amyotrophic lateral sclerosis. 2010 , 11, 217-25	68
1770	RNA processing pathways in amyotrophic lateral sclerosis. 2010 , 11, 275-90	54
1769	Neurodegenerative dementia and parkinsonism. 2010 , 14, 37-44	4
1768	Moving toward a predictive and personalized clinical approach in amyotrophic lateral sclerosis: novel developments and future directions in diagnosis, genetics, pathogenesis and therapies. 2010 , 1, 329-41	14
1767	Progranulin promotes neurite outgrowth and neuronal differentiation by regulating GSK-3 β . 2010 , 1, 552-62	93
1766	Amyloid-plaque imaging in early and differential diagnosis of dementia. 2010 , 24, 55-66	27
1765	TDP-43 dimerizes in human cells in culture. 2010 , 30, 641-52	66
1764	TDP-43 and FUS in amyotrophic lateral sclerosis and frontotemporal dementia. 2010 , 9, 995-1007	661

1763	Neurodegenerative models in <i>Drosophila</i> : polyglutamine disorders, Parkinson disease, and amyotrophic lateral sclerosis. 2010 , 40, 29-39	49
1762	Progressive motor weakness in transgenic mice expressing human TDP-43. 2010 , 40, 404-14	150
1761	A cellular perspective on conformational disease: the role of genetic background and proteostasis networks. 2010 , 20, 23-32	89
1760	In the swim of things: recent insights to neurogenetic disorders from zebrafish. 2010 , 26, 373-81	44
1759	Aberrant RNA processing events in neurological disorders. 2010 , 1338, 67-77	65
1758	Quantification of cystatin C in cerebrospinal fluid from various neurological disorders and correlation with G73A polymorphism in CST3. 2010 , 1361, 140-5	23
1757	Progranulin deficiency leads to enhanced cell vulnerability and TDP-43 translocation in primary neuronal cultures. 2010 , 1366, 1-8	51
1756	Calcium dysregulation in amyotrophic lateral sclerosis. 2010 , 47, 165-74	223
1755	Oxidative stress in ALS: key role in motor neuron injury and therapeutic target. 2010 , 48, 629-41	415
1754	Zinc induces depletion and aggregation of endogenous TDP-43. 2010 , 48, 1152-61	44
1753	Basic mechanisms of neurodegeneration: a critical update. 2010 , 14, 457-87	174
1752	FUS-immunoreactive inclusions are a common feature in sporadic and non-SOD1 familial amyotrophic lateral sclerosis. 2010 , 67, 739-48	225
1751	Sigma nonopioid intracellular receptor 1 mutations cause frontotemporal lobar degeneration-motor neuron disease. 2010 , 68, 639-49	147
1750	Aberrant control of motoneuronal excitability in amyotrophic lateral sclerosis: excitatory glutamate/D-serine vs. inhibitory glycine/gamma-aminobutanoic acid (GABA). 2010 , 7, 1479-90	13
1749	Interplay between protein homeostasis networks in protein aggregation and proteotoxicity. 2010 , 93, 229-36	21
1748	Parkinsonism and motor neuron diseases: twenty-seven patients with diverse overlap syndromes. 2010 , 25, 1868-75	53
1747	RNA processing defects associated with diseases of the motor neuron. 2010 , 41, 5-17	25
1746	Association between novel TARDBP mutations and Chinese patients with amyotrophic lateral sclerosis. 2010 , 11, 8	33

1745	Phosphorylation regulates proteasomal-mediated degradation and solubility of TAR DNA binding protein-43 C-terminal fragments. 2010 , 5, 33	90
1744	Progranulin modulates zebrafish motoneuron development in vivo and rescues truncation defects associated with knockdown of Survival motor neuron 1. 2010 , 5, 41	49
1743	Age-dependent changes in TDP-43 levels in a mouse model of Alzheimer disease are linked to A β oligomers accumulation. 2010 , 5, 51	25
1742	The pathobiology of splicing. 2010 , 220, 152-63	277
1741	Caudate atrophy on MRI is a characteristic feature of FTL-D-FUS. 2010 , 17, 969-75	72
1740	Mutations in CHMP2B are not a cause of frontotemporal lobar degeneration in Finnish patients. 2010 , 17, 1393-5	11
1739	Increased caspase activation and decreased TDP-43 solubility in progranulin knockout cortical cultures. 2010 , 115, 735-47	51
1738	Increased expression of TDP-43 in the skin of amyotrophic lateral sclerosis. 2010 , 122, 367-72	43
1737	Nuclear factor TDP-43 can affect selected microRNA levels. 2010 , 277, 2268-81	164
1736	Review: Recent progress in frontotemporal lobar degeneration. 2010 , 36, 4-16	6
1735	Review: transactive response DNA-binding protein 43 (TDP-43): mechanisms of neurodegeneration. 2010 , 36, 97-112	55
1734	HtrA2/Omi-immunoreactive intraneuronal inclusions in the anterior horn of patients with sporadic and Cu/Zn superoxide dismutase (SOD1) mutant amyotrophic lateral sclerosis. 2010 , 36, 331-44	5
1733	Relationship between Bunina bodies and TDP-43 inclusions in spinal anterior horn in amyotrophic lateral sclerosis. 2010 , 36, 345-52	12
1732	Dementia and the TAR DNA binding protein 43. 2010 , 88, 555-8	3
1731	Knockdown of transactive response DNA-binding protein (TDP-43) downregulates histone deacetylase 6. 2010 , 29, 209-21	185
1730	ALS-associated fused in sarcoma (FUS) mutations disrupt Transportin-mediated nuclear import. 2010 , 29, 2841-57	587
1729	Neurons don't appreciate FUSsing in the cytoplasm. 2010 , 29, 2769-71	4
1728	Ataxin-2 intermediate-length polyglutamine expansions are associated with increased risk for ALS. 2010 , 466, 1069-75	844

1727	Flightless flies: Drosophila models of neuromuscular disease. 2010 , 1184, e1-20	98
1726	Neurodegeneration: An expansion in ALS genetics. 2010 , 466, 1052-3	24
1725	Neuronal caspase-3 signaling: not only cell death. 2010 , 17, 1104-14	278
1724	Common variants at 7p21 are associated with frontotemporal lobar degeneration with TDP-43 inclusions. 2010 , 42, 234-9	361
1723	Deciphering genetic susceptibility to frontotemporal lobar dementia. 2010 , 42, 189-90	7
1722	Open chromatin and diabetes risk. 2010 , 42, 190-2	9
1721	Modeling the association between 43 different clinical and pathological variables and the severity of cognitive impairment in a large autopsy cohort of elderly persons. 2010 , 20, 66-79	168
1720	TDP-43 redistribution is an early event in sporadic amyotrophic lateral sclerosis. 2010 , 20, 351-60	108
1719	FUS-immunoreactive intranuclear inclusions in neurodegenerative disease. 2010 , 20, 589-97	78
1718	Extensive FUS-immunoreactive pathology in juvenile amyotrophic lateral sclerosis with basophilic inclusions. 2010 , 20, 1069-76	108
1717	The neurobiology of amyotrophic lateral sclerosis. 2010 , 31, 2247-65	63
1716	Sporadic amyotrophic lateral sclerosis with pallido-nigro-luysian degeneration: a TDP-43 immunohistochemical study. 2010 , 30, 149-53	14
1715	Abnormal TDP-43 expression is identified in the neocortex in cases of dementia pugilistica, but is mainly confined to the limbic system when identified in high and moderate stages of Alzheimer's disease. 2010 , 30, 408-19	83
1714	Phosphorylated and cleaved TDP-43 in ALS, FTLN and other neurodegenerative disorders and in cellular models of TDP-43 proteinopathy. 2010 , 30, 170-81	87
1713	AMPA receptor-mediated neuronal death in sporadic ALS. 2010 , 30, 182-8	66
1712	Amyotrophic lateral sclerosis and frontotemporal lobar degeneration: a spectrum of TDP-43 proteinopathies. 2010 , 30, 103-12	135
1711	Ubiquitin-positive tau-negative intraneuronal inclusions in dementia with motor neuron disease: The 50th Anniversary of Japanese Society of Neuropathology. 2010 , 30, 486-9	3
1710	DCTN1 mutations are implicated in multiple neurodegenerative disorders. 2010 , 77, 32-4	1

1709 Neuroimaging of other dementing disorders. 371-394

1708 Frontotemporal Dementia. **2010**, 428-432

1707 The Relationship between Parkin and Protein Aggregation in Neurodegenerative Diseases. **2010**, 1, 15 10

1706 MicroRNA-29b regulates the expression level of human progranulin, a secreted glycoprotein implicated in frontotemporal dementia. **2010**, 5, e10551 68

1705 TDP-43-mediated neuron loss in vivo requires RNA-binding activity. **2010**, 5, e12247 149

1704 Progranulin is neurotrophic in vivo and protects against a mutant TDP-43 induced axonopathy. **2010**, 5, e13368 100

1703 The C-terminal TDP-43 fragments have a high aggregation propensity and harm neurons by a dominant-negative mechanism. **2010**, 5, e15878 130

1702 Biopsy Pathology of Neurodegenerative Disorders in Adults. **2010**, 551-571

1701 Parkinsonism: Genetics. **2010**, 413-416

1700 FUS/TLS genetic variability in sporadic frontotemporal lobar degeneration. **2010**, 19, 1317-22 2

1699 Amyotrophic lateral sclerosis: applications of stem cells - an update. **2010**, 3, 145-56 5

1698 TDP-43 models coverage. **2010**, 21, 1403-8 2

1697 FUS mutations in sporadic juvenile ALS: another step toward understanding ALS pathogenesis. **2010**, 75, 584-5 5

1696 The spectrum of mutations in progranulin: a collaborative study screening 545 cases of neurodegeneration. **2010**, 67, 161-70 143

1695 Exaggerated inflammation, impaired host defense, and neuropathology in progranulin-deficient mice. **2010**, 207, 117-28 341

1694 The small heat shock protein B8 (HspB8) promotes autophagic removal of misfolded proteins involved in amyotrophic lateral sclerosis (ALS). **2010**, 19, 3440-56 261

1693 Error in Figure in: Cellular Mechanisms of Central Nervous System Repair by Natural Autoreactive Monoclonal Antibodies. **2010**, 67, 147

1692 Characterization of alternative isoforms and inclusion body of the TAR DNA-binding protein-43. **2010**, 285, 608-19 103

1691	Neural-specific deletion of FIP200 leads to cerebellar degeneration caused by increased neuronal death and axon degeneration. 2010 , 285, 3499-509	158
1690	Amyotrophic lateral sclerosis-associated proteins TDP-43 and FUS/TLS function in a common biochemical complex to co-regulate HDAC6 mRNA. 2010 , 285, 34097-105	160
1689	Mutant FUS proteins that cause amyotrophic lateral sclerosis incorporate into stress granules. 2010 , 19, 4160-75	378
1688	Progress on progranulin. 2010 , 67, 145-7	3
1687	Genetic causes of frontotemporal degeneration. 2010 , 23, 260-8	20
1686	Elevated expression of TDP-43 in the forebrain of mice is sufficient to cause neurological and pathological phenotypes mimicking FTLD-U. 2010 , 207, 1661-73	160
1685	Deletion of TDP-43 down-regulates Tbc1d1, a gene linked to obesity, and alters body fat metabolism. 2010 , 107, 16320-4	211
1684	Gain and loss of function of ALS-related mutations of TARDBP (TDP-43) cause motor deficits in vivo. 2010 , 19, 671-83	296
1683	TDP-43 proteinopathy and motor neuron disease in chronic traumatic encephalopathy. 2010 , 69, 918-29	461
1682	Transgenic mice expressing mutant forms VCP/p97 recapitulate the full spectrum of IBMPFD including degeneration in muscle, brain and bone. 2010 , 19, 1741-55	138
1681	Kana versus kanji in amyotrophic lateral sclerosis: a clinoradiological study of writing errors. 2010 , 64, 148-55	13
1680	Wild-type human TDP-43 expression causes TDP-43 phosphorylation, mitochondrial aggregation, motor deficits, and early mortality in transgenic mice. 2010 , 30, 10851-9	373
1679	Interaction with polyglutamine aggregates reveals a Q/N-rich domain in TDP-43. 2010 , 285, 26304-14	116
1678	Sporadic ALS has compartment-specific aberrant exon splicing and altered cell-matrix adhesion biology. 2010 , 19, 313-28	96
1677	A prospective cohort study of neuropsychological test performance in ALS. 2010 , 11, 312-20	45
1676	TARDBP mutations in frontotemporal lobar degeneration: frequency, clinical features, and disease course. 2010 , 13, 509-17	65
1675	No evidence of HIV pol gene in spinal cord tissues in sporadic ALS by real-time RT-PCR. 2010 , 11, 91-6	7
1674	Advances in the application of MRI to amyotrophic lateral sclerosis. 2010 , 4, 483-496	51

1673	TDP-43 is a developmentally regulated protein essential for early embryonic development. 2010 , 285, 6826-34	262
1672	Multiplex SILAC analysis of a cellular TDP-43 proteinopathy model reveals protein inclusions associated with SUMOylation and diverse polyubiquitin chains. 2010 , 9, 705-18	80
1671	The role of RNA processing in the pathogenesis of motor neuron degeneration. 2010 , 12, e21	26
1670	TDP-43 in skeletal muscle of patients affected with amyotrophic lateral sclerosis. 2010 , 11, 240-3	15
1669	Cytoplasmic mislocalization of TDP-43 is toxic to neurons and enhanced by a mutation associated with familial amyotrophic lateral sclerosis. 2010 , 30, 639-49	347
1668	Phosphorylation promotes neurotoxicity in a <i>Caenorhabditis elegans</i> model of TDP-43 proteinopathy. 2010 , 30, 16208-19	148
1667	A <i>Drosophila</i> model for TDP-43 proteinopathy. 2010 , 107, 3169-74	210
1666	TDP-43 transgenic mice develop spastic paralysis and neuronal inclusions characteristic of ALS and frontotemporal lobar degeneration. 2010 , 107, 3858-63	417
1665	Altered distributions of Gemini of coiled bodies and mitochondria in motor neurons of TDP-43 transgenic mice. 2010 , 107, 16325-30	244
1664	Ubiquilin modifies TDP-43 toxicity in a <i>Drosophila</i> model of amyotrophic lateral sclerosis (ALS). 2010 , 285, 11068-72	103
1663	Nuclear import impairment causes cytoplasmic trans-activation response DNA-binding protein accumulation and is associated with frontotemporal lobar degeneration. 2010 , 133, 1763-71	137
1662	Boxing-related head injuries. 2010 , 38, 18-26	10
1661	Genetic contribution of FUS to frontotemporal lobar degeneration. 2010 , 74, 366-71	172
1660	Four familial ALS pedigrees discordant for two SOD1 mutations: are all SOD1 mutations pathogenic?. 2010 , 81, 572-7	49
1659	Genetics of frontotemporal lobar degeneration. 2010 , 13, S55-62	3
1658	Cognitive and behavioural deficits associated with the orbitomedial prefrontal cortex in amyotrophic lateral sclerosis. 2010 , 133, 3444-57	83
1657	A mutation affecting the sodium/proton exchanger, SLC9A6, causes mental retardation with tau deposition. 2010 , 133, 1391-402	90
1656	Pathogenic TARDBP mutations in amyotrophic lateral sclerosis and frontotemporal dementia: disease-associated pathways. 2010 , 21, 251-72	44

1655	Assessment of white matter tract damage in patients with amyotrophic lateral sclerosis: a diffusion tensor MR imaging tractography study. 2010 , 31, 1457-61	117
1654	Frontotemporal dementias: Recent advances and current controversies. 2010 , 13, S74-80	12
1653	Transgenic rat model of neurodegeneration caused by mutation in the TDP gene. 2010 , 6, e1000887	153
1652	Juvenile ALS with basophilic inclusions is a FUS proteinopathy with FUS mutations. 2010 , 75, 611-8	145
1651	Neurotoxic effects of TDP-43 overexpression in <i>C. elegans</i> . 2010 , 19, 3206-18	168
1650	Caspase-cleaved transactivation response DNA-binding protein 43 in Parkinson's disease and dementia with Lewy bodies. 2010 , 7, 243-50	20
1649	Valosin-containing protein (VCP) in novel feedback machinery between abnormal protein accumulation and transcriptional suppression. 2010 , 285, 21736-49	25
1648	Common variant in GRN is a genetic risk factor for hippocampal sclerosis in the elderly. 2010 , 7, 170-4	71
1647	Expansive gene transfer in the rat CNS rapidly produces amyotrophic lateral sclerosis relevant sequelae when TDP-43 is overexpressed. 2010 , 18, 2064-74	51
1646	The multiple roles of TDP-43 in pre-mRNA processing and gene expression regulation. 2010 , 7, 420-9	187
1645	ALS-associated mutations in TDP-43 increase its stability and promote TDP-43 complexes with FUS/TLS. 2010 , 107, 13318-23	317
1644	Molecular Dynamics Approach to Aggregation of Polymer Chains with Monomers Connected by Springs. 2010 , 79, 104002	9
1643	The present and the future of neuroimaging in amyotrophic lateral sclerosis. 2010 , 31, 1769-77	97
1642	Protein-DNA interaction at the origin of neurological diseases: a hypothesis. 2010 , 22, 375-91	33
1641	Targeting mitochondrial dysfunction in neurodegenerative disease: Part II. 2010 , 14, 497-511	37
1640	Targeting intrinsically disordered proteins in neurodegenerative and protein dysfunction diseases: another illustration of the D(2) concept. 2010 , 7, 543-64	100
1639	Multiple brain pathologies in dementia are common. 2010 , 1, 259-265	17
1638	The evidence for altered RNA metabolism in amyotrophic lateral sclerosis (ALS). 2010 , 288, 1-12	137

1637	Occurrence of basophilic inclusions and FUS-immunoreactive neuronal and glial inclusions in a case of familial amyotrophic lateral sclerosis. 2010 , 293, 6-11	17
1636	An immunohistochemical study of ubiquitin in the skin of sporadic amyotrophic lateral sclerosis. 2010 , 298, 52-6	17
1635	Prion-like disorders: blurring the divide between transmissibility and infectivity. 2010 , 123, 1191-201	231
1634	Primary progressive aphasia: clinicopathological correlations. 2010 , 6, 88-97	292
1633	FUS mutations in amyotrophic lateral sclerosis: clinical, pathological, neurophysiological and genetic analysis. 2010 , 81, 639-45	177
1632	Phosphoproteomic analysis reveals site-specific changes in GFAP and NDRG2 phosphorylation in frontotemporal lobar degeneration. 2010 , 9, 6368-79	66
1631	Induction of amyloid fibrils by the C-terminal fragments of TDP-43 in amyotrophic lateral sclerosis. 2010 , 132, 1186-7	106
1630	Global analysis of TDP-43 interacting proteins reveals strong association with RNA splicing and translation machinery. 2010 , 9, 1104-20	328
1629	TDP-43 physically interacts with amyotrophic lateral sclerosis-linked mutant CuZn superoxide dismutase. 2010 , 57, 906-13	19
1628	Degradation of TDP-43 and its pathogenic form by autophagy and the ubiquitin-proteasome system. 2010 , 469, 112-6	160
1627	Mutant superoxide dismutase 1 overexpression in NSC-34 cells: effect of trehalose on aggregation, TDP-43 localization and levels of co-expressed glycoproteins. 2010 , 475, 145-9	42
1626	Alterations in subcellular localization of TDP-43 immunoreactivity in the anterior horns in sporadic amyotrophic lateral sclerosis. 2010 , 478, 72-6	27
1625	TDP-43: a DNA and RNA binding protein with roles in neurodegenerative diseases. 2010 , 42, 1606-9	46
1624	Animal models reveal role for tau phosphorylation in human disease. 2010 , 1802, 860-71	63
1623	Mechanisms underlying inflammation in neurodegeneration. 2010 , 140, 918-34	2275
1622	Biomarkers: Parkinson disease with dementia and dementia with Lewy bodies. 2010 , 16, 307-15	23
1621	Sortilin-mediated endocytosis determines levels of the frontotemporal dementia protein, progranulin. 2010 , 68, 654-67	368
1620	Exome sequencing reveals VCP mutations as a cause of familial ALS. 2010 , 68, 857-64	939

1619	Capturing VCP: another molecular piece in the ALS jigsaw puzzle. 2010 , 68, 812-4	19
1618	Amyotrophic lateral sclerosis mutant vesicle-associated membrane protein-associated protein-B transgenic mice develop TAR-DNA-binding protein-43 pathology. 2010 , 167, 774-85	61
1617	Mutant TAR DNA-binding protein-43 induces oxidative injury in motor neuron-like cell. 2010 , 169, 1621-9	88
1616	Two Australian families with inclusion-body myopathy, Paget's disease of bone and frontotemporal dementia: novel clinical and genetic findings. 2010 , 20, 330-4	45
1615	RNA metabolism and the pathogenesis of motor neuron diseases. 2010 , 33, 249-58	56
1614	Molecular pathways of frontotemporal lobar degeneration. 2010 , 33, 71-88	34
1613	Alteration of biochemical and pathological properties of TDP-43 protein by a lipid mediator, 15-deoxy-Delta(12,14)-prostaglandin J(2). 2010 , 222, 296-303	15
1612	Dementia induces correlated reductions in white matter integrity and cortical thickness: a multivariate neuroimaging study with sparse canonical correlation analysis. 2010 , 50, 1004-16	140
1611	Imaging correlates of pathology in corticobasal syndrome. 2010 , 75, 1879-87	175
1610	Accelerated lipofuscinosis and ubiquitination in granulin knockout mice suggest a role for progranulin in successful aging. 2010 , 177, 311-24	214
1609	miR-107 regulates granulin/progranulin with implications for traumatic brain injury and neurodegenerative disease. 2010 , 177, 334-45	146
1608	Guidelines for preclinical animal research in ALS/MND: A consensus meeting. 2010 , 11, 38-45	234
1607	Amyotrophic lateral sclerosis pathogenesis: a journey through the secretory pathway. 2010 , 13, 1955-89	48
1606	TAR DNA-binding protein 43 in neurodegenerative disease. 2010 , 6, 211-20	322
1605	TDP-43 and ubiquitinated cytoplasmic aggregates in sporadic ALS are low frequency and widely distributed in the lower motor neuron columns independent of disease spread. 2010 , 11, 321-7	18
1604	Role of progranulin as a biomarker for Alzheimer's disease. 2010 , 4, 37-50	19
1603	Applying Hsp104 to protein-misfolding disorders. 2010 , 88, 1-13	69
1602	TDP-43 and FUS/TLS: emerging roles in RNA processing and neurodegeneration. 2010 , 19, R46-64	695

1601	Frontotemporal lobar degeneration: epidemiology, pathophysiology, diagnosis and management. 2010 , 24, 375-98	263
1600	Insight in ALS: awareness of behavioral change in patients with and without FTD. 2010 , 11, 52-6	30
1599	Proteostasis and movement disorders: Parkinson's disease and amyotrophic lateral sclerosis. 2011 , 3, a007500	43
1598	Mutations in UBQLN2 cause dominant X-linked juvenile and adult-onset ALS and ALS/dementia. 2011 , 477, 211-5	846
1597	Clinical, genetic and pathological heterogeneity of frontotemporal dementia: a review. 2011 , 82, 476-86	408
1596	An ALS-associated mutation affecting TDP-43 enhances protein aggregation, fibril formation and neurotoxicity. 2011 , 18, 822-30	222
1595	A "two-hit" hypothesis for inclusion formation by carboxyl-terminal fragments of TDP-43 protein linked to RNA depletion and impaired microtubule-dependent transport. 2011 , 286, 18845-55	90
1594	Neuropathologie des démences lobaires frontotemporales. 2011 , 2, 47-51	1
1593	Modeling human trinucleotide repeat diseases in Drosophila. 2011 , 99, 191-212	13
1592	Neurodegenerative diseases and neuroprotection: current views and prospects. 2011 , 9, 173-183	40
1591	Dysregulation of axonal transport and motorneuron diseases. 2011 , 103, 87-107	26
1590	Searching for neuropathology: gliosis in schizophrenia. 2011 , 69, 134-9	77
1589	Using yeast models to probe the molecular basis of amyotrophic lateral sclerosis. 2011 , 39, 1482-7	20
1588	High-throughput yeast plasmid overexpression screen. 2011 ,	4
1587	Amyloid Remodeling by Hsp104. 2011 , 235-259	1
1586	Biomarkers in amyotrophic lateral sclerosis: opportunities and limitations. 2011 , 7, 631-8	74
1585	Elevated CSF TDP-43 levels in amyotrophic lateral sclerosis: specificity, sensitivity, and a possible prognostic value. 2011 , 12, 140-3	72
1584	The range and clinical impact of cognitive impairment in French patients with ALS: a cross-sectional study of neuropsychological test performance. 2011 , 12, 372-8	41

1583	Clinicopathological study of diffuse neurofibrillary tangles with calcification. With special reference to TDP-43 proteinopathy and alpha-synucleinopathy. 2011 , 301, 77-85	10
1582	Peripherin partially localizes in Bunina bodies in amyotrophic lateral sclerosis. 2011 , 302, 14-8	22
1581	Behavioral changes in early ALS correlate with voxel-based morphometry and diffusion tensor imaging. 2011 , 307, 34-40	67
1580	Frontal lobe-mediated behavioral changes in amyotrophic lateral sclerosis: are they independent of physical disabilities?. 2011 , 309, 136-40	28
1579	Increased progranulin in the skin of amyotrophic lateral sclerosis: an immunohistochemical study. 2011 , 309, 110-4	11
1578	Animal Models of Dementia. 2011 ,	7
1577	In vivo positron emission tomographic imaging of glial responses to amyloid-beta and tau pathologies in mouse models of Alzheimer's disease and related disorders. 2011 , 31, 4720-30	111
1576	Nosologie des démences lobaires frontotemporales. 2011 , 2, 53-63	
1575	Neurodegeneration. 2011 ,	7
1574	Amyotrophic lateral sclerosis: pathophysiology, diagnosis and management. 2011 , 25, 1-15	62
1573	The preclinical discovery of amyotrophic lateral sclerosis drugs. 2011 , 6, 1127-38	10
1572	Progranulin is a chemoattractant for microglia and stimulates their endocytic activity. 2011 , 178, 284-95	86
1571	The seeds of neurodegeneration: prion-like spreading in ALS. 2011 , 147, 498-508	263
1570	Zebrafish models for the functional genomics of neurogenetic disorders. 2011 , 1812, 335-45	83
1569	Molecular properties of TAR DNA binding protein-43 fragments are dependent upon its cleavage site. 2011 , 1812, 1577-83	24
1568	Tetranor PGDM analyses for the amyotrophic lateral sclerosis: positive and simple diagnosis and evaluation of drug effect. 2011 , 415, 539-44	6
1567	Amyotrophic Lateral Sclerosis. 2011 , 143-166	1
1566	Spinal cord and parkinsonism: neuromorphological evidences in humans and experimental studies. 2011 , 42, 327-40	11

1565	TDP-43 functions and pathogenic mechanisms implicated in TDP-43 proteinopathies. 2011 , 17, 659-67	142
1564	Transcription factors expressed in olfactory bulb local progenitor cells revealed by genome-wide transcriptome profiling. 2011 , 46, 548-61	9
1563	RNA targets of TDP-43 identified by UV-CLIP are deregulated in ALS. 2011 , 47, 167-80	130
1562	Diacetylbis(N(4)-methylthiosemicarbazonato) copper(II) (Cull(atasm)) protects against peroxynitrite-induced nitrosative damage and prolongs survival in amyotrophic lateral sclerosis mouse model. 2011 , 286, 44035-44044	97
1561	TDP-43 toxicity in yeast. 2011 , 53, 238-45	25
1560	TDP-43 and FUS: a nuclear affair. 2011 , 34, 339-48	154
1559	Biomarker-based dissection of neurodegenerative diseases. 2011 , 95, 520-34	66
1558	Biomarkers in frontotemporal lobar degenerations--progress and challenges. 2011 , 95, 636-48	30
1557	On the development of markers for pathological TDP-43 in amyotrophic lateral sclerosis with and without dementia. 2011 , 95, 649-62	43
1556	Molecular basis of amyotrophic lateral sclerosis. 2011 , 35, 370-2	24
1555	ALS pathogenesis: recent insights from genetics and mouse models. 2011 , 35, 363-9	36
1554	Mutational analysis of TARDBP in neurodegenerative diseases. 2011 , 32, 2096-9	36
1553	FUS, TARDBP, and SOD1 mutations in a Taiwanese cohort with familial ALS. 2011 , 32, 553.e13-21	51
1552	Frontotemporal lobar degeneration genome wide association study replication confirms a risk locus shared with amyotrophic lateral sclerosis. 2011 , 32, 758.e1-7	28
1551	Extracellular progranulin protects cortical neurons from toxic insults by activating survival signaling. 2011 , 32, 2326.e5-16	78
1550	Functional genomic analyses identify pathways dysregulated by progranulin deficiency, implicating Wnt signaling. 2011 , 71, 1030-42	105
1549	A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. 2011 , 72, 257-68	3018
1548	FTD and ALS: genetic ties that bind. 2011 , 72, 189-90	24

1547	Progranulin enhances neural progenitor cell proliferation through glycogen synthase kinase 3 β phosphorylation. 2011 , 185, 106-15	49
1546	Local RNA translation at the synapse and in disease. 2011 , 31, 16086-93	221
1545	Emerging drugs for amyotrophic lateral sclerosis. 2011 , 16, 537-58	34
1544	Ataxin-2 repeat-length variation and neurodegeneration. 2011 , 20, 3207-12	128
1543	The role of mutant TAR DNA-binding protein 43 in amyotrophic lateral sclerosis and frontotemporal lobar degeneration. 2011 , 39, 954-9	14
1542	Molecular pathways of motor neuron injury in amyotrophic lateral sclerosis. 2011 , 7, 616-30	428
1541	Cyclin-dependent kinases in brain development and disease. 2011 , 27, 465-91	244
1540	Identification of neuronal RNA targets of TDP-43-containing ribonucleoprotein complexes. 2011 , 286, 1204-15	306
1539	Fighting neurodegeneration with rapamycin: mechanistic insights. 2011 , 12, 437-52	371
1538	Expanded ATXN2 CAG repeat size in ALS identifies genetic overlap between ALS and SCA2. 2011 , 76, 2066-72	126
1537	Nuclear localization sequence of FUS and induction of stress granules by ALS mutants. 2011 , 32, 2323.e27-40	142
1536	Building an integrated neurodegenerative disease database at an academic health center. 2011 , 7, e84-93	45
1535	Amyotrophic lateral sclerosis. 2011 , 377, 942-55	1665
1534	Intra-familial clinical heterogeneity due to FTLD-U with TDP-43 proteinopathy caused by a novel deletion in progranulin gene (PGRN). 2010 , 22, 1123-33	16
1533	The overlapping syndromes of the pick complex. 2011 , 8, 224-8	5
1532	A lady with weakness, fasciculations, and failing memory. 90-97	
1531	. 2011 ,	1
1530	Autoimmunity in amyotrophic lateral sclerosis: past and present. 2011 , 2011, 497080	40

1529	Proteomic analysis of hippocampal dentate granule cells in frontotemporal lobar degeneration: application of laser capture technology. 2011 , 2, 24	13
1528	When Does ALS Start? ADAR2-GluA2 Hypothesis for the Etiology of Sporadic ALS. 2011 , 4, 33	31
1527	TDP-43 potentiates alpha-synuclein toxicity to dopaminergic neurons in transgenic mice. 2011 , 7, 234-43	29
1526	Neuronal function and dysfunction of Drosophila dTDP. 2011 , 6, e20371	62
1525	Hyperphosphorylation as a defense mechanism to reduce TDP-43 aggregation. 2011 , 6, e23075	66
1524	Lack of effect of methylene blue in the SOD1 G93A mouse model of amyotrophic lateral sclerosis. 2011 , 6, e23141	14
1523	Amyotrophic lateral sclerosis multiprotein biomarkers in peripheral blood mononuclear cells. 2011 , 6, e25545	98
1522	The Neuropathology of the Dementing Disorders. 2011 , 235-261	
1521	Common Themes in RNA Subcellular Transport, Stress Granule Formation and Abnormal Protein Aggregation. 2011 , 5,	
1520	Recent breakthroughs in the understanding of frontotemporal lobar degeneration and its related disorders. 2011 , 8, 222-3	
1519	NA Metabolism in Neurodegenerative Disease. 2011 , 5,	
1518	Amyotrophic lateral sclerosis: an update. 2011 , 24, 497-503	38
1517	Genetic contributors to frontotemporal lobar degeneration: beyond monogenic disease. 2011 , 11, 988-1001	1
1516	Valosin containing protein associated fronto-temporal lobar degeneration: clinical presentation, pathologic features and pathogenesis. 2011 , 8, 252-60	35
1515	Accumulation of transactive response DNA binding protein 43 in mild cognitive impairment and Alzheimer disease. 2011 , 70, 788-98	53
1514	The potential role of glycogen synthase kinase 3 inhibitors as amyotrophic lateral sclerosis pharmacological therapy. 2011 , 18, 3028-34	24
1513	Spinal inhibitory interneuron pathology follows motor neuron degeneration independent of glial mutant superoxide dismutase 1 expression in SOD1-ALS mice. 2011 , 70, 662-77	40
1512	Regulation of gene expression by TDP-43 and FUS/TLS in frontotemporal lobar degeneration. 2011 , 8, 237-45	10

1511	Transforming growth factor- β signaling in motor neuron diseases. 2011 , 11, 48-56	44
1510	FTD and ALS: a tale of two diseases. 2011 , 8, 273-94	149
1509	Helping the FTD patient-caregiver dyad. 2011 , 38, 671-2	
1508	Identifying potential risk factors for developing amyotrophic lateral sclerosis. 2011 , 1, 463-471	4
1507	Dysregulation of the ALS-associated gene TDP-43 leads to neuronal death and degeneration in mice. 2011 , 121, 726-38	284
1506	Frontotemporal Dementia. 2011 , 145-178	1
1505	Large proportion of amyotrophic lateral sclerosis cases in Sardinia due to a single founder mutation of the TARDBP gene. 2011 , 68, 594-8	85
1504	[Dementia: progress in diagnosis and treatment: topics, V. Recent topics; 4. Detection of novel dementia-related genes; 1) TDP-43]. 2011 , 100, 2200-6	
1503	[108th Scientific Meeting of the Japanese Society of Internal Medicine: symposium: 1. Progress in dementia research--dementia disorders and protein; (5) TDP-43]. 2011 , 100, 2489-94	
1502	Genetic strategies to study TDP-43 in rodents and to develop preclinical therapeutics for amyotrophic lateral sclerosis. 2011 , 34, 1179-88	16
1501	An autopsied case of sporadic adult-onset amyotrophic lateral sclerosis with FUS-positive basophilic inclusions. 2011 , 31, 71-6	20
1500	Numerous FUS-positive inclusions in an elderly woman with motor neuron disease. 2011 , 31, 170-6	13
1499	Ubiquitinated, p62 immunopositive cerebellar cortical neuronal inclusions are evident across the spectrum of TDP-43 proteinopathies but are only rarely additionally immunopositive for phosphorylation-dependent TDP-43. 2011 , 31, 239-49	52
1498	Enhancement of native and phosphorylated TDP-43 immunoreactivity by proteinase K treatment following autoclave heating. 2011 , 31, 401-4	6
1497	Coexistence of TDP-43 and tau pathology in neurodegeneration with brain iron accumulation type 1 (NBIA-1, formerly Hallervorden-Spatz syndrome). 2011 , 31, 531-9	12
1496	Accumulation of histone deacetylase 6, an aggresome-related protein, is specific to Lewy bodies and glial cytoplasmic inclusions. 2011 , 31, 561-8	57
1495	In sporadic inclusion body myositis muscle fibres TDP-43-positive inclusions are less frequent and robust than p62 inclusions, and are not associated with paired helical filaments. 2011 , 37, 315-20	21
1494	TDP-43 pathology occurs infrequently in multiple system atrophy. 2011 , 37, 358-65	20

1493	Synaptic changes in frontotemporal lobar degeneration: correlation with MAPT haplotype and APOE genotype. 2011 , 37, 366-80	8
1492	Biochemical and histopathological alterations in TAR DNA-binding protein-43 after acute ischemic stroke in rats. 2011 , 116, 957-65	31
1491	Regulation of TDP-43 aggregation by phosphorylation and p62/SQSTM1. 2011 , 116, 248-59	146
1490	TDP-43: the relationship between protein aggregation and neurodegeneration in amyotrophic lateral sclerosis and frontotemporal lobar degeneration. 2011 , 278, 3539-49	82
1489	TDP-43: new aspects of autoregulation mechanisms in RNA binding proteins and their connection with human disease. 2011 , 278, 3530-8	39
1488	TDP-43 and FUS/TLS: cellular functions and implications for neurodegeneration. 2011 , 278, 3550-68	54
1487	TDP-43 and FUS/TLS: sending a complex message about messenger RNA in amyotrophic lateral sclerosis?. 2011 , 278, 3569-77	19
1486	Characterizing the RNA targets and position-dependent splicing regulation by TDP-43. 2011 , 14, 452-8	745
1485	Long pre-mRNA depletion and RNA missplicing contribute to neuronal vulnerability from loss of TDP-43. 2011 , 14, 459-68	827
1484	TDP-43: multiple targets, multiple disease mechanisms?. 2011 , 14, 403-5	16
1483	CLC-3 spices up GABAergic synaptic vesicles. 2011 , 14, 405-7	13
1482	TDP-43 regulates its mRNA levels through a negative feedback loop. 2011 , 30, 277-88	374
1481	PET/CT in diagnosis of dementia. 2011 , 1228, 81-92	54
1480	Unfolded proteins and endoplasmic reticulum stress in neurodegenerative disorders. 2011 , 15, 2025-39	232
1479	Both cytoplasmic and nuclear accumulations of the protein are neurotoxic in Drosophila models of TDP-43 proteinopathies. 2011 , 41, 398-406	73
1478	Inflammation in the early stages of neurodegenerative pathology. 2011 , 238, 1-11	160
1477	Cytoplasmic dynein in neurodegeneration. 2011 , 130, 348-63	75
1476	Energy metabolism in amyotrophic lateral sclerosis. 2011 , 10, 75-82	354

1475	Understanding the role of TDP-43 and FUS/TLS in ALS and beyond. 2011 , 21, 904-19	261
1474	Survival motor neuron (SMN) protein in the spinal anterior horn cells of patients with sporadic amyotrophic lateral sclerosis. 2011 , 1372, 152-9	7
1473	β-amyloid triggers ALS-associated TDP-43 pathology in AD models. 2011 , 1386, 191-9	44
1472	MG132 enhances neurite outgrowth in neurons overexpressing mutant TAR DNA-binding protein-43 via increase of HO-1. 2011 , 1397, 1-9	19
1471	Protein folding stress in neurodegenerative diseases: a glimpse into the ER. 2011 , 23, 239-52	183
1470	RNA granules: the good, the bad and the ugly. 2011 , 23, 324-34	205
1469	Conjoint pathologic cascades mediated by ALS/FTLD-U linked RNA-binding proteins TDP-43 and FUS. 2011 , 77, 1636-43	57
1468	Domain-specific monoclonal antibodies produced against human PGRN. 2011 , 30, 271-8	10
1467	Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. 2011 , 72, 245-56	3267
1466	The Cerebral Cortex and Complex Cerebral Functions. 2011 , 711-809	1
1465	RNA splicing: disease and therapy. 2011 , 10, 151-64	62
1464	New neuropathological findings in Unverricht-Lundborg disease: neuronal intranuclear and cytoplasmic inclusions. 2011 , 121, 421-7	26
1463	Distinct pathological subtypes of FTLD-FUS. 2011 , 121, 207-18	116
1462	Risk genotypes at TMEM106B are associated with cognitive impairment in amyotrophic lateral sclerosis. 2011 , 121, 373-80	82
1461	Cytoplasmic accumulation of TDP-43 in circulating lymphomonocytes of ALS patients with and without TARDBP mutations. 2011 , 121, 611-22	51
1460	Motor neuron disease clinically limited to the lower motor neuron is a diffuse TDP-43 proteinopathy. 2011 , 121, 509-17	44
1459	Granular expression of prolyl-peptidyl isomerase PIN1 is a constant and specific feature of Alzheimer's disease pathology and is independent of tau, Aβ and TDP-43 pathology. 2011 , 121, 635-49	18
1458	The most common type of FTLD-FUS (aFTLD-U) is associated with a distinct clinical form of frontotemporal dementia but is not related to mutations in the FUS gene. 2011 , 122, 99-110	90

1457	Neuropathological background of phenotypical variability in frontotemporal dementia. 2011 , 122, 137-53	311
1456	A harmonized classification system for FTLD-TDP pathology. 2011 , 122, 111-3	656
1455	Cell stress induces TDP-43 pathological changes associated with ERK1/2 dysfunction: implications in ALS. 2011 , 122, 259-70	74
1454	Simulated brain biopsy for diagnosing neurodegeneration using autopsy-confirmed cases. 2011 , 122, 737-45	13
1453	Clinical and neuropathologic heterogeneity of c9FTD/ALS associated with hexanucleotide repeat expansion in C9ORF72. 2011 , 122, 673-90	245
1452	Acute and chronically increased immunoreactivity to phosphorylation-independent but not pathological TDP-43 after a single traumatic brain injury in humans. 2011 , 122, 715-26	63
1451	p62 positive, TDP-43 negative, neuronal cytoplasmic and intranuclear inclusions in the cerebellum and hippocampus define the pathology of C9orf72-linked FTLD and MND/ALS. 2011 , 122, 691-702	369
1450	Molecular pathology and genetic advances in amyotrophic lateral sclerosis: an emerging molecular pathway and the significance of glial pathology. 2011 , 122, 657-71	120
1449	C9ORF72, the new gene on the block, causes C9FTD/ALS: new insights provided by neuropathology. 2011 , 122, 653-5	8
1448	Familial frontotemporal dementia with amyotrophic lateral sclerosis and a shared haplotype on chromosome 9p. 2011 , 258, 647-55	71
1447	Broadening the phenotype of TARDBP mutations: the TARDBP Ala382Thr mutation and Parkinson's disease in Sardinia. 2011 , 12, 203-9	67
1446	Dementia and cognitive impairment in amyotrophic lateral sclerosis: a review. 2011 , 32, 9-16	60
1445	TAR-DNA binding protein-43 and alterations in the hippocampus. 2011 , 118, 683-9	22
1444	How does the genetic assassin select its neuronal target?. 2011 , 22, 139-47	1
1443	SOD1 and TDP-43 animal models of amyotrophic lateral sclerosis: recent advances in understanding disease toward the development of clinical treatments. 2011 , 22, 420-48	102
1442	[Motor neuron diseases]. 2011 , 82, 697-706	2
1441	[German consortium for frontotemporal lobar degeneration]. 2011 , 82, 1002-5	26
1440	Modes of A β toxicity in Alzheimer's disease. 2011 , 68, 3359-75	68

1439	Arylsulfanyl pyrazolones block mutant SOD1-G93A aggregation. Potential application for the treatment of amyotrophic lateral sclerosis. 2011 , 19, 613-22	16
1438	Defective protein folding and aggregation as the basis of neurodegenerative diseases: the darker aspect of proteins. 2011 , 61, 237-50	52
1437	TDP-43 variants of frontotemporal lobar degeneration. 2011 , 45, 390-401	20
1436	Model organisms reveal insight into human neurodegenerative disease: ataxin-2 intermediate-length polyglutamine expansions are a risk factor for ALS. 2011 , 45, 676-83	34
1435	FUS immunogold labeling TEM analysis of the neuronal cytoplasmic inclusions of neuronal intermediate filament inclusion disease: a frontotemporal lobar degeneration with FUS proteinopathy. 2011 , 45, 409-21	21
1434	Cellular effects of progranulin in health and disease. 2011 , 45, 549-60	77
1433	Human genetics as a tool to identify progranulin regulators. 2011 , 45, 532-7	4
1432	Structure, function, and mechanism of progranulin; the brain and beyond. 2011 , 45, 538-48	97
1431	Molecular dissection of TDP-43 proteinopathies. 2011 , 45, 480-5	40
1430	TDP-43 autoregulation: implications for disease. 2011 , 45, 473-9	38
1429	Biomarkers to identify the pathological basis for frontotemporal lobar degeneration. 2011 , 45, 366-71	5
1428	The frontotemporal syndromes of ALS. Clinicopathological correlates. 2011 , 45, 648-55	32
1427	Rodent models of TDP-43 proteinopathy: investigating the mechanisms of TDP-43-mediated neurodegeneration. 2011 , 45, 486-99	50
1426	Progranulin and TDP-43: mechanistic links and future directions. 2011 , 45, 561-73	44
1425	Making connections: pathology and genetics link amyotrophic lateral sclerosis with frontotemporal lobe dementia. 2011 , 45, 663-75	59
1424	Expression of human FUS/TLS in yeast leads to protein aggregation and cytotoxicity, recapitulating key features of FUS proteinopathy. 2011 , 2, 141-9	70
1423	Expression of human FUS protein in Drosophila leads to progressive neurodegeneration. 2011 , 2, 477-86	78
1422	Research advances in amyotrophic lateral sclerosis, 2009 to 2010. 2011 , 11, 67-77	38

1421	Adenylyl cyclase type 3, a marker of primary cilia, is reduced in primary cell culture and in lumbar spinal cord in situ in G93A SOD1 mice. 2011 , 12, 71	17
1420	FTLD-TDP with motor neuron disease, visuospatial impairment and a progressive supranuclear palsy-like syndrome: broadening the clinical phenotype of TDP-43 proteinopathies. A report of three cases. 2011 , 11, 50	22
1419	C-Jun N-terminal kinase controls TDP-43 accumulation in stress granules induced by oxidative stress. 2011 , 6, 57	85
1418	TDP-43 knockdown impairs neurite outgrowth dependent on its target histone deacetylase 6. 2011 , 6, 64	44
1417	Expression of mutant TDP-43 induces neuronal dysfunction in transgenic mice. 2011 , 6, 73	113
1416	Aberrant septin 11 is associated with sporadic frontotemporal lobar degeneration. 2011 , 6, 82	13
1415	Severe brain atrophy after long-term survival seen in siblings with familial amyotrophic lateral sclerosis and a mutation in the optineurin gene: a case series. 2011 , 5, 573	5
1414	Altered microRNA expression in frontotemporal lobar degeneration with TDP-43 pathology caused by progranulin mutations. 2011 , 12, 527	39
1413	Amino acid analog toxicity in primary rat neuronal and astrocyte cultures: implications for protein misfolding and TDP-43 regulation. 2011 , 89, 1471-7	12
1412	PRO-MINE: A bioinformatics repository and analytical tool for TARDBP mutations. 2011 , 32, E1948-58	7
1411	Stress signaling from the endoplasmic reticulum: A central player in the pathogenesis of amyotrophic lateral sclerosis. 2011 , 63, 754-63	43
1410	Delineation of the core aggregation sequences of TDP-43 C-terminal fragment. 2011 , 12, 2495-501	64
1409	Hippocampal sclerosis in advanced age: clinical and pathological features. 2011 , 134, 1506-18	178
1408	Unpicking frontotemporal lobar degeneration. 2011 , 134, 2453-5	1
1407	Different clinical and neuropathologic phenotypes of familial ALS with A315E TARDBP mutation. 2011 , 77, 1427-31	30
1406	Behavioral genetics of neurodegenerative disorders. 2012 , 12, 615-31	3
1405	MRI as a frontrunner in the search for amyotrophic lateral sclerosis biomarkers?. 2011 , 5, 79-81	19
1404	Genetic and clinical features of progranulin-associated frontotemporal lobar degeneration. 2011 , 68, 488-97	93

1403	Chronic traumatic encephalopathy in an Iraqi war veteran with posttraumatic stress disorder who committed suicide. 2011 , 31, E3	156
1402	Genetic mouse models of neurodegenerative diseases. 2011 , 100, 419-82	33
1401	A comparative clinical, pathological, biochemical and genetic study of fused in sarcoma proteinopathies. 2011 , 134, 2548-64	65
1400	FET proteins TAF15 and EWS are selective markers that distinguish FTLD with FUS pathology from amyotrophic lateral sclerosis with FUS mutations. 2011 , 134, 2595-609	204
1399	Social cognition in amyotrophic lateral sclerosis. 2011 , 1, 397-405	22
1398	Towards unveiling the genetics of neurodegenerative diseases. 2011 , 31, 531-41	52
1397	Modeling ALS and FTLD proteinopathies in yeast: an efficient approach for studying protein aggregation and toxicity. 2011 , 5, 250-7	20
1396	Atlas Klinische Neuroradiologie des Gehirns. 2011 ,	17
1395	Recent insights into the involvement of progranulin in frontotemporal dementia. 2011 , 9, 632-42	12
1394	Identification of novel FUS mutations in sporadic cases of amyotrophic lateral sclerosis. 2011 , 12, 113-7	27
1393	TDP-43 is a transcriptional repressor: the testis-specific mouse acrv1 gene is a TDP-43 target in vivo. 2011 , 286, 10970-82	46
1392	Ataxin-2 intermediate-length polyglutamine expansions in European ALS patients. 2011 , 20, 1697-700	112
1391	Novel progranulin mutation detected in 2 patients with FTLD. 2011 , 25, 173-8	8
1390	Targeting oligomers in neurodegenerative disorders: lessons from β -synuclein, tau, and amyloid- β peptide. 2011 , 24 Suppl 2, 223-32	84
1389	TDP-43 neurotoxicity and protein aggregation modulated by heat shock factor and insulin/IGF-1 signaling. 2011 , 20, 1952-65	91
1388	Protein localization in disease and therapy. 2011 , 124, 3381-92	248
1387	Degeneration of the mid-cingulate cortex in amyotrophic lateral sclerosis detected in vivo with MR spectroscopy. 2011 , 32, 403-7	23
1386	ALS risk but not phenotype is affected by ataxin-2 intermediate length polyglutamine expansion. 2011 , 76, 2030-1	24

1385	RNA-binding proteins with prion-like domains in ALS and FTLD-U. 2011 , 5, 179-87	114
1384	Intracellular localization and splicing regulation of FUS/TLS are variably affected by amyotrophic lateral sclerosis-linked mutations. 2011 , 39, 2781-98	112
1383	Oxidative stress in neurodegeneration. 2011 , 2011, 572634	149
1382	Predicting survival in frontotemporal dementia with motor neuron disease. 2011 , 76, 1886-93	36
1381	Amyotrophic lateral sclerosis and language dysfunction: kana, kanji and a prescient report in Japanese by Watanabe (1893). 2011 , 65, 144-9	5
1380	Pathological hallmarks of amyotrophic lateral sclerosis/frontotemporal lobar degeneration in transgenic mice produced with TDP-43 genomic fragments. 2011 , 134, 2610-26	179
1379	Wild-type and A315T mutant TDP-43 exert differential neurotoxicity in a Drosophila model of ALS. 2011 , 20, 2308-21	118
1378	Analysis of alternative splicing associated with aging and neurodegeneration in the human brain. 2011 , 21, 1572-82	149
1377	A seeding reaction recapitulates intracellular formation of Sarkosyl-insoluble transactivation response element (TAR) DNA-binding protein-43 inclusions. 2011 , 286, 18664-72	179
1376	A Drosophila model of FUS-related neurodegeneration reveals genetic interaction between FUS and TDP-43. 2011 , 20, 2510-23	153
1375	Association of long ATXN2 CAG repeat sizes with increased risk of amyotrophic lateral sclerosis. 2011 , 68, 739-42	63
1374	Enhancement of nicotinic receptors alleviates cytotoxicity in neurological disease models. 2011 , 2, 197-208	11
1373	Atypical parkinsonism, parkinsonism-plus syndromes, and secondary parkinsonian disorders. 2011 , 197-240	2
1372	Sense and sensitivity of novel criteria for frontotemporal dementia. 2011 , 134, 2450-3	2
1371	Motor neuron disease: urgently needed-biomarkers for amyotrophic lateral sclerosis. 2011 , 7, 13-4	12
1370	TDP-43-based animal models of neurodegeneration: new insights into ALS pathology and pathophysiology. 2011 , 8, 262-74	78
1369	Amnesia in frontotemporal dementia with amyotrophic lateral sclerosis, masquerading Alzheimer's disease. 2011 , 3, 242-7	2
1368	Implications of the prion-related Q/N domains in TDP-43 and FUS. 2011 , 5, 1-5	83

1367	Motor neuron dysfunction in frontotemporal dementia. 2011 , 134, 2582-94	219
1366	Familial versus sporadic amyotrophic lateral sclerosis--a false dichotomy?. 2011 , 134, 3429-31	18
1365	Regulation of autophagy by neuropathological protein TDP-43. 2011 , 286, 44441-8	113
1364	TDP-43-induced death is associated with altered regulation of BIM and Bcl-xL and attenuated by caspase-mediated TDP-43 cleavage. 2011 , 286, 13171-83	80
1363	TDP-43 is directed to stress granules by sorbitol, a novel physiological osmotic and oxidative stressor. 2011 , 31, 1098-108	232
1362	Deregulation of TDP-43 in amyotrophic lateral sclerosis triggers nuclear factor κ B-mediated pathogenic pathways. 2011 , 208, 2429-47	221
1361	Aggregation of the 35-kDa fragment of TDP-43 causes formation of cytoplasmic inclusions and alteration of RNA processing. 2011 , 25, 2344-53	53
1360	A yeast functional screen predicts new candidate ALS disease genes. 2011 , 108, 20881-90	302
1359	A raw nerve. 2011 , 17, 1333-5	1
1358	How common are behavioural changes in amyotrophic lateral sclerosis?. 2011 , 12, 45-51	138
1357	THEME 8 IN VITRO EXPERIMENTAL MODELS. 2011 , 12, 125-140	
1356	Abhorring the vacuum: use of Alzheimer's disease medications in frontotemporal dementia. 2011 , 11, 709-17	43
1355	Rescue of progranulin deficiency associated with frontotemporal lobar degeneration by alkalizing reagents and inhibition of vacuolar ATPase. 2011 , 31, 1885-94	109
1354	ENU mutagenesis screen to establish motor phenotypes in wild-type mice and modifiers of a pre-existing motor phenotype in tau mutant mice. 2011 , 2011, 130947	6
1353	PolyQ repeat expansions in ATXN2 associated with ALS are CAA interrupted repeats. 2011 , 6, e17951	64
1352	An algorithm for genetic testing of frontotemporal lobar degeneration. 2011 , 76, 475-83	57
1351	Protein misdirection inside and outside motor neurons in Amyotrophic Lateral Sclerosis (ALS): a possible clue for therapeutic strategies. 2011 , 12, 6980-7003	16
1350	A yeast model of FUS/TLS-dependent cytotoxicity. 2011 , 9, e1001052	148

1349	Molecular determinants and genetic modifiers of aggregation and toxicity for the ALS disease protein FUS/TLS. 2011 , 9, e1000614	321
1348	Progressive and widespread brain damage in ALS: MRI voxel-based morphometry and diffusion tensor imaging study. 2011 , 12, 59-69	67
1347	Altered RNA metabolism and amyotrophic lateral sclerosis. 2011 , 14, 239-44	4
1346	Molecular motor proteins and amyotrophic lateral sclerosis. 2011 , 12, 9057-82	16
1345	Mesial prefrontal cortex degeneration in amyotrophic lateral sclerosis: a high-field proton MR spectroscopy study. 2011 , 32, 1677-80	14
1344	Genetic rodent models of amyotrophic lateral sclerosis. 2011 , 2011, 348765	36
1343	FDG-PET findings in fronto-temporal dementia: A case report and review of literature. 2011 , 26, 96-8	1
1342	A neurodegenerative disease mutation that accelerates the clearance of apoptotic cells. 2011 , 108, 4441-6	95
1341	TDP-43 Proteinopatileri: Nörodegeneratif Konformasyon Bozukluđ Hastalıklarında Yeni Bir Oyuncu. 2012 , 18, 1-10	
1340	Can regional spreading of amyotrophic lateral sclerosis motor symptoms be explained by prion-like propagation?. 2012 , 83, 739-45	91
1339	Alzheimer's disease models and functional genomics-How many needles are there in the haystack?. 2012 , 3, 320	14
1338	TDP-43 plasma levels are higher in amyotrophic lateral sclerosis. 2012 , 13, 446-51	53
1337	Entorhinal cortical neurons are the primary targets of FUS mislocalization and ubiquitin aggregation in FUS transgenic rats. 2012 , 21, 4602-14	52
1336	The ALS disease protein TDP-43 is actively transported in motor neuron axons and regulates axon outgrowth. 2012 , 21, 3703-18	159
1335	TDP-43 regulates global translational yield by splicing of exon junction complex component SKAR. 2012 , 40, 2668-82	67
1334	The non-death role of metacaspase proteases. 2012 , 2, 78	19
1333	From Transcriptome to Noncoding RNAs: Implications in ALS Mechanism. 2012 , 2012, 278725	13
1332	Longitudinal epidemiologic clinical-pathologic studies of aging and Alzheimer's disease. 2012 , 9, 617-20	16

1331	Amyotrophic lateral sclerosis: update and new developments. 2012 , 2012, 1-14	56
1330	Requirements for stress granule recruitment of fused in sarcoma (FUS) and TAR DNA-binding protein of 43 kDa (TDP-43). 2012 , 287, 23079-94	191
1329	Whole-genome sequencing reveals a coding non-pathogenic variant tagging a non-coding pathogenic hexanucleotide repeat expansion in C9orf72 as cause of amyotrophic lateral sclerosis. 2012 , 21, 2412-9	27
1328	High-content RNAi screening identifies the Type 1 inositol triphosphate receptor as a modifier of TDP-43 localization and neurotoxicity. 2012 , 21, 4845-56	30
1327	Distinct clinical and pathological characteristics of frontotemporal dementia associated with C9ORF72 mutations. 2012 , 135, 693-708	420
1326	Motor neuron-specific disruption of proteasomes, but not autophagy, replicates amyotrophic lateral sclerosis. 2012 , 287, 42984-94	141
1325	Cause or Effect: Misregulation of microRNA Pathways in Neurodegeneration. 2012 , 6, 48	65
1324	Lithium lacks effect on survival in amyotrophic lateral sclerosis: a phase IIb randomised sequential trial. 2012 , 83, 557-64	58
1323	Amyotrophic lateral sclerosis and frontotemporal lobar degeneration in association with CADASIL. 2012 , 18, 92-5	1
1322	Amyotrophic lateral sclerosis. 2012 , 25, 530-5	74
1321	How do C9ORF72 repeat expansions cause amyotrophic lateral sclerosis and frontotemporal dementia: can we learn from other noncoding repeat expansion disorders?. 2012 , 25, 689-700	136
1320	Post-aggregation oxidation of mutant huntingtin controls the interactions between aggregates. 2012 , 287, 34764-75	19
1319	Neurodegeneration-associated TDP-43 interacts with fragile X mental retardation protein (FMRP)/Staufen (STAU1) and regulates SIRT1 expression in neuronal cells. 2012 , 287, 22560-72	40
1318	VAPB interacts with the mitochondrial protein PTPIP51 to regulate calcium homeostasis. 2012 , 21, 1299-311	304
1317	C9orf72 hexanucleotide repeat expansions as the causative mutation for chromosome 9p21-linked amyotrophic lateral sclerosis and frontotemporal dementia. 2012 , 69, 1159-63	16
1316	Pathologic lesions in neurodegenerative diseases. 2012 , 107, 1-40	16
1315	FDG-PET in der Demenzdiagnostik. 2012 , 35, 75-81	0
1314	AUTOPHAGY IN AMYOTROPHIC LATERAL SCLEROSIS. 2012 , 205-235	

1313	TLS/FUS: a protein in cancer and ALS. 2012 , 11, 3349-50	12
1312	Non-human primate model of amyotrophic lateral sclerosis with cytoplasmic mislocalization of TDP-43. 2012 , 135, 833-46	75
1311	Clinical and pathological features of familial frontotemporal dementia caused by C9ORF72 mutation on chromosome 9p. 2012 , 135, 709-22	172
1310	Motor Neuron Diseases. 2012 , 801-814	
1309	Molecular pathology in neurodegenerative diseases. 2012 , 13, 1548-59	22
1308	Different 8-hydroxyquinolines protect models of TDP-43 protein, β synuclein, and polyglutamine proteotoxicity through distinct mechanisms. 2012 , 287, 4107-20	63
1307	A novel TARDBP insertion/deletion mutation in the flail arm variant of amyotrophic lateral sclerosis. 2012 , 13, 465-70	11
1306	[ALS and frontotemporal dementia - case report and review of the literature]. 2012 , 80, 711-9	2
1305	Inherited myelopathies. 2012 , 32, 114-22	7
1304	The molecular basis of the frontotemporal lobar degeneration-amyotrophic lateral sclerosis spectrum. 2012 , 44, 817-28	141
1303	Demenzdiagnostik mit der Amyloid-PET. 2012 , 35, 82-92	3
1302	Supranuclear ophthalmoparesis and vacuolar degeneration of the cerebral white matter in amyotrophic lateral sclerosis: a clinicopathological study. 2012 , 13, 74-83	5
1301	Novel TARDBP mutations in Nordic ALS patients. 2012 , 57, 316-9	25
1300	Slow development of ALS-like spinal cord pathology in mutant valosin-containing protein gene knock-in mice. 2012 , 3, e374	56
1299	TDP-43 toxicity and the usefulness of junk. 2012 , 44, 1289-91	3
1298	TDP-43 promotes microRNA biogenesis as a component of the Drosha and Dicer complexes. 2012 , 109, 3347-52	298
1297	Abnormal regenerative responses and impaired axonal outgrowth after nerve crush in TDP-43 transgenic mouse models of amyotrophic lateral sclerosis. 2012 , 32, 18186-95	20
1296	An early onset progressive motor neuron disorder in Scyl1-deficient mice is associated with mislocalization of TDP-43. 2012 , 32, 16560-73	26

1295	Progranulin: a proteolytically processed protein at the crossroads of inflammation and neurodegeneration. 2012 , 287, 32298-306	149
1294	Targeted depletion of TDP-43 expression in the spinal cord motor neurons leads to the development of amyotrophic lateral sclerosis-like phenotypes in mice. 2012 , 287, 27335-44	118
1293	Amyotrophic lateral sclerosis: new insights into underlying molecular mechanisms and opportunities for therapeutic intervention. 2012 , 17, 1277-330	50
1292	The ubiquitin-proteasome system and the autophagic-lysosomal system in Alzheimer disease. 2012 , 2,	119
1291	Frontotemporal dementia: implications for understanding Alzheimer disease. 2012 , 2, a006254	101
1290	Regulation of nuclear TDP-43 by NR2A-containing NMDA receptors and PTEN. 2012 , 125, 1556-67	32
1289	Caenorhabditis elegans RNA-processing protein TDP-1 regulates protein homeostasis and life span. 2012 , 287, 8371-82	44
1288	Need for a paradigm shift in therapeutic approaches to CNS injury. 2012 , 12, 409-20	7
1287	Redox signalling directly regulates TDP-43 via cysteine oxidation and disulphide cross-linking. 2012 , 31, 1241-52	133
1286	Neurochemical biomarkers in Alzheimer's disease and related disorders. 2012 , 5, 335-48	15
1285	A systematic review of behavioural changes in motor neuron disease. 2012 , 13, 493-501	46
1284	Stem Cells and Cancer Stem Cells, Volume 2. 2012 ,	
1283	Parkinson-like features in ALS with predominant upper motor neuron involvement. 2012 , 13, 137-43	15
1282	Cellular model of TAR DNA-binding protein 43 (TDP-43) aggregation based on its C-terminal Gln/Asn-rich region. 2012 , 287, 7512-25	87
1281	Strategies for Inhibiting Protein Aggregation: Therapeutic Approaches to Protein-Aggregation Diseases. 2012 , 433-560	
1280	Widespread neuronal and glial hyperphosphorylated tau deposition in ALS with cognitive impairment. 2012 , 13, 178-93	38
1279	Clinico-pathological correlations of the most common neurodegenerative dementias. 2012 , 3, 68	23
1278	Drosophila Answers to TDP-43 Proteinopathies. 2012 , 2012, 356081	18

1277	Neuromuscular junction protection for the potential treatment of amyotrophic lateral sclerosis. 2012 , 2012, 379657	32
1276	Dysregulation of the autophagy-endolysosomal system in amyotrophic lateral sclerosis and related motor neuron diseases. 2012 , 2012, 498428	43
1275	The Neuroinflammatory Response in ALS: The Roles of Microglia and T Cells. 2012 , 2012, 803701	52
1274	ALS and Frontotemporal Dysfunction: A Review. 2012 , 2012, 806306	48
1273	RNA-Binding Proteins in Amyotrophic Lateral Sclerosis and Neurodegeneration. 2012 , 2012, 432780	19
1272	Misregulation of human sortilin splicing leads to the generation of a nonfunctional progranulin receptor. 2012 , 109, 21510-5	61
1271	Roles of ataxin-2 in pathological cascades mediated by TAR DNA-binding protein 43 (TDP-43) and Fused in Sarcoma (FUS). 2012 , 287, 41310-23	34
1270	ALS mutations in FUS cause neuronal dysfunction and death in <i>Caenorhabditis elegans</i> by a dominant gain-of-function mechanism. 2012 , 21, 1-9	121
1269	Evaluating the role of the FUS/TLS-related gene EWSR1 in amyotrophic lateral sclerosis. 2012 , 21, 2899-911	207
1268	Recent biomarker approaches in the diagnosis of frontotemporal lobar degeneration/Neurochemische Ansätze in der Diagnose der Frontotemporalen Lobendegeneration. 2012 , 36,	1
1267	Association of skin with the pathogenesis and treatment of neurodegenerative amyloidosis. 2012 , 3, 5	14
1266	Comparison of parallel high-throughput RNA sequencing between knockout of TDP-43 and its overexpression reveals primarily nonreciprocal and nonoverlapping gene expression changes in the central nervous system of <i>Drosophila</i> . 2012 , 2, 789-802	45
1265	Biomarkers in amyotrophic lateral sclerosis: is there a neurovascular pathway?. 2012 , 9, 302-9	4
1264	Multitarget Drugs for Stabilization of Calcium Cycling and Neuroprotection in Neurodegenerative Diseases and Stroke. 2012 , 123-200	2
1263	[Intracellular seeded aggregation of TDP-43]. 2012 , 52, 1056-8	
1262	Ask the Experts: Progress in diagnosing frontotemporal lobar dementia. 2012 , 2, 251-254	
1261	An Attempt to Treat Amyotrophic Lateral Sclerosis by Intracellular Copper Modification Using Ammonium Tetrathiomolybdate and/or Metallothionein: Fundamentals and Perspective. 2012 , 379-431	
1260	Deficits in concept formation in amyotrophic lateral sclerosis. 2012 , 26, 422-9	32

1259	TDP-43 and FUS RNA-binding proteins bind distinct sets of cytoplasmic messenger RNAs and differently regulate their post-transcriptional fate in motoneuron-like cells. 2012 , 287, 15635-47	190
1258	Novel mutation in VCP gene causes atypical amyotrophic lateral sclerosis. 2012 , 79, 2201-8	43
1257	Cerebrovascular atherosclerosis correlates with Alzheimer pathology in neurodegenerative dementias. 2012 , 135, 3749-56	179
1256	Divergent roles of ALS-linked proteins FUS/TLS and TDP-43 intersect in processing long pre-mRNAs. 2012 , 15, 1488-97	483
1255	TMEM106B, the risk gene for frontotemporal dementia, is regulated by the microRNA-132/212 cluster and affects progranulin pathways. 2012 , 32, 11213-27	143
1254	TMEM106B risk variant is implicated in the pathologic presentation of Alzheimer disease. 2012 , 79, 717-8	63
1253	The neuropathology and neurobiology of traumatic brain injury. 2012 , 76, 886-99	426
1252	The syndrome of cognitive impairment in amyotrophic lateral sclerosis: a population-based study. 2012 , 83, 102-8	465
1251	Quantitative analysis of the detergent-insoluble brain proteome in frontotemporal lobar degeneration using SILAC internal standards. 2012 , 11, 2721-38	51
1250	Nucleus Accumbens 1, a Pox virus and Zinc finger/Bric-a-brac Tramtrack Broad protein binds to TAR DNA-binding protein 43 and has a potential role in Amyotrophic Lateral Sclerosis. 2012 , 227, 44-54	9
1249	TDP-43 in central nervous system development and function: clues to TDP-43-associated neurodegeneration. 2012 , 393, 589-94	55
1248	TARDBP mutation analysis in TDP-43 proteinopathies and deciphering the toxicity of mutant TDP-43. 2013 , 33 Suppl 1, S35-45	31
1247	The self-interaction of native TDP-43 C terminus inhibits its degradation and contributes to early proteinopathies. 2012 , 3, 766	56
1246	Co-aggregation of RNA binding proteins in ALS spinal motor neurons: evidence of a common pathogenic mechanism. 2012 , 124, 733-47	91
1245	Amyotrophic lateral sclerosis and organ donation: is there risk of disease transmission?. 2012 , 72, 832-6	13
1244	Localization of fused in sarcoma (FUS) protein to the post-synaptic density in the brain. 2012 , 124, 383-94	33
1243	Coexistence of Huntington's disease and amyotrophic lateral sclerosis: a clinicopathologic study. 2012 , 124, 749-60	34
1242	The genetics and neuropathology of frontotemporal lobar degeneration. 2012 , 124, 353-72	206

1241	Mechanisms of disease in frontotemporal lobar degeneration: gain of function versus loss of function effects. 2012 , 124, 373-82	69
1240	The RNA-binding motif 45 (RBM45) protein accumulates in inclusion bodies in amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration with TDP-43 inclusions (FTLD-TDP) patients. 2012 , 124, 717-32	57
1239	Frontotemporal lobar degeneration: current knowledge and future challenges. 2012 , 259, 2278-86	31
1238	Different molecular pathologies result in similar spatial patterns of cellular inclusions in neurodegenerative disease: a comparative study of eight disorders. 2012 , 119, 1551-60	17
1237	Differential expression of TAR DNA-binding protein (TDP-43) in the central nervous system of horses afflicted with equine motor neuron disease (EMND): a preliminary study of a potential pathologic marker. 2012 , 36, 221-6	5
1236	Misregulated RNA processing in amyotrophic lateral sclerosis. 2012 , 1462, 3-15	124
1235	Induced pluripotent stem cell models of progranulin-deficient frontotemporal dementia uncover specific reversible neuronal defects. 2012 , 2, 789-98	103
1234	Endosomal sorting related protein CHMP2B is localized in Lewy bodies and glial cytoplasmic inclusions in Synucleinopathy. 2012 , 527, 16-21	18
1233	Full-length TDP-43 and its C-terminal fragments activate mitophagy in NSC34 cell line. 2012 , 530, 144-9	54
1232	Epigenetics-Based Therapeutics for Neurodegenerative Disorders. 2012 , 1, 229-236	33
1231	Neuroimaging in amyotrophic lateral sclerosis. 2012 , 6, 319-37	112
1230	Association of UBQLN1 mutation with Brown-Vialetto-Van Laere syndrome but not typical ALS. 2012 , 48, 391-8	15
1229	Progranulin axis and recent developments in frontotemporal lobar degeneration. 2012 , 4, 4	14
1228	Genetic counseling for FTD/ALS caused by the C9ORF72 hexanucleotide expansion. 2012 , 4, 27	27
1227	Expanding the genetics of amyotrophic lateral sclerosis and frontotemporal dementia. 2012 , 4, 30	6
1226	Magnetic resonance imaging of pathological processes in rodent models of amyotrophic lateral sclerosis. 2012 , 13, 288-301	7
1225	The interplay of turn formation and hydrophobic interactions on the early kinetic events in protein folding. 2012 , 48, 487-97	10
1224	Frontotemporale Demenz wird epidemiologisch unterschätzt. 2012 , 14, 57-63	

1223	Large-scale screening of TARDBP mutation in amyotrophic lateral sclerosis in Japanese. 2012 , 33, 786-90	37
1222	TARDBP gene mutations among Chinese patients with sporadic amyotrophic lateral sclerosis. 2012 , 33, 1015.e1-6	14
1221	Alteration in cell cycle-related proteins in lymphoblasts from carriers of the c.709-1G>A PGRN mutation associated with FTLN-TDP dementia. 2012 , 33, 429.e7-20	18
1220	A meta-analysis of diffusion tensor imaging studies in amyotrophic lateral sclerosis. 2012 , 33, 1833-8	56
1219	FUS and TDP43 genetic variability in FTD and CBS. 2012 , 33, 1016.e9-17	57
1218	C/EBP β expression in activated microglia in amyotrophic lateral sclerosis. 2012 , 33, 2186-99	21
1217	Ataxin-2 polyQ expansions in FTLN-ALS spectrum disorders in Flanders-Belgian cohorts. 2012 , 33, 1004.e17-20	27
1216	VCP mutations in familial and sporadic amyotrophic lateral sclerosis. 2012 , 33, 837.e7-13	84
1215	Granulin mutation drives brain damage and reorganization from preclinical to symptomatic FTLN. 2012 , 33, 2506-20	81
1214	Wide phenotypic spectrum of the TARDBP gene: homozygosity of A382T mutation in a patient presenting with amyotrophic lateral sclerosis, Parkinson's disease, and frontotemporal lobar degeneration, and in neurologically healthy subject. 2012 , 33, 1846.e1-4	32
1213	ATAXIN2 CAG-repeat length in Italian patients with amyotrophic lateral sclerosis: risk factor or variant phenotype? Implication for genetic testing and counseling. 2012 , 33, 1847.e15-21	24
1212	Screening for C9ORF72 repeat expansion in FTLN. 2012 , 33, 1850.e1-11	40
1211	Screening of the TARDBP gene in familial and sporadic amyotrophic lateral sclerosis patients of Chinese origin. 2012 , 33, 2229.e11-2229.e18	19
1210	UBQLN2 mutations are rare in French and French-Canadian amyotrophic lateral sclerosis. 2012 , 33, 2230.e1-2230.e5	5
1209	UBQLN2/ubiquilin 2 mutation and pathology in familial amyotrophic lateral sclerosis. 2012 , 33, 2527.e3-10	95
1208	Analysis of C9orf72 repeat expansion in 563 Japanese patients with amyotrophic lateral sclerosis. 2012 , 33, 2527.e11-6	81
1207	Methylene blue administration fails to confer neuroprotection in two amyotrophic lateral sclerosis mouse models. 2012 , 209, 136-43	26
1206	Alteration of protein folding and degradation in motor neuron diseases: Implications and protective functions of small heat shock proteins. 2012 , 97, 83-100	59

1205	Dysfunction of constitutive and inducible ubiquitin-proteasome system in amyotrophic lateral sclerosis: implication for protein aggregation and immune response. 2012 , 97, 101-26	108
1204	Neurodegeneration the RNA way. 2012 , 97, 173-89	68
1203	The ubiquitin proteasome system in neurodegenerative diseases: culprit, accomplice or victim?. 2012 , 96, 190-207	97
1202	Cdc37/Hsp90 protein complex disruption triggers an autophagic clearance cascade for TDP-43 protein. 2012 , 287, 24814-20	52
1201	EPHA4 is a disease modifier of amyotrophic lateral sclerosis in animal models and in humans. 2012 , 18, 1418-22	208
1200	The clinical and pathological phenotype of C9ORF72 hexanucleotide repeat expansions. 2012 , 135, 723-35	226
1199	Dynein and dynactin components modulate neurodegeneration induced by excitotoxicity. 2012 , 122, 162-74	8
1198	Molecular analysis and biochemical classification of TDP-43 proteinopathy. 2012 , 135, 3380-91	75
1197	Cognitive decline typical of frontotemporal lobar degeneration in transgenic mice expressing the 25-kDa C-terminal fragment of TDP-43. 2012 , 180, 293-302	40
1196	UG repeats/TDP-43 interactions near 5' splice sites exert unpredictable effects on splicing modulation. 2012 , 415, 46-60	22
1195	Propagation of the prion phenomenon: beyond the seeding principle. 2012 , 421, 491-8	26
1194	Endogenous TDP-43 localized to stress granules can subsequently form protein aggregates. 2012 , 60, 415-24	108
1193	Overexpression of TDP-43 causes partially p53-dependent G2/M arrest and p53-independent cell death in HeLa cells. 2012 , 506, 271-6	7
1192	The abnormal processing of TDP-43 is not an upstream event of reduced ADAR2 activity in ALS motor neurons. 2012 , 73, 153-60	12
1191	Activities of daily living in motor neuron disease: role of behavioural and motor changes. 2012 , 19, 552-6	18
1190	Epitope mapping of antibodies against TDP-43 and detection of protease-resistant fragments of pathological TDP-43 in amyotrophic lateral sclerosis and frontotemporal lobar degeneration. 2012 , 417, 116-21	17
1189	The N-terminus of TDP-43 promotes its oligomerization and enhances DNA binding affinity. 2012 , 425, 219-24	68
1188	The anatomy of cognitive impairment in amyotrophic lateral sclerosis: more than frontal lobe dysfunction. 2012 , 48, 166-82	86

1187	Cell-free formation of RNA granules: bound RNAs identify features and components of cellular assemblies. 2012 , 149, 768-79	564
1186	Frontotemporal Lobar Degeneration. 2012 , 724, 114-27	10
1185	The genetics and neuropathology of amyotrophic lateral sclerosis. 2012 , 124, 339-52	299
1184	Saccadic abnormalities in frontotemporal dementia. 2012 , 78, 1816-23	36
1183	A novel monoclonal antibody reveals a conformational alteration shared by amyotrophic lateral sclerosis-linked SOD1 mutants. 2012 , 72, 739-49	53
1182	Cognitive impairment in lacunar strokes: the SPS3 trial. 2012 , 72, 351-62	83
1181	Asparaginyl endopeptidase cleaves TDP-43 in brain. 2012 , 12, 2455-63	41
1180	Inhibition of RNA lariat debranching enzyme suppresses TDP-43 toxicity in ALS disease models. 2012 , 44, 1302-9	170
1179	ALS-associated ataxin 2 polyQ expansions enhance stress-induced caspase 3 activation and increase TDP-43 pathological modifications. 2012 , 32, 9133-42	62
1178	Autophagy activators rescue and alleviate pathogenesis of a mouse model with proteinopathies of the TAR DNA-binding protein 43. 2012 , 109, 15024-9	277
1177	Awaji criteria for the diagnosis of amyotrophic lateral sclerosis:a systematic review. 2012 , 69, 1410-6	160
1176	Frontotemporal lobar degeneration: epidemiology, pathology, diagnosis and management. 2012 , 26, 841-70	91
1175	XBP1 depletion precedes ubiquitin aggregation and Golgi fragmentation in TDP-43 transgenic rats. 2012 , 123, 406-16	26
1174	Genetics of frontotemporal lobar degeneration. 2012 , 3, 52	28
1173	The complex molecular biology of amyotrophic lateral sclerosis (ALS). 2012 , 107, 215-62	101
1172	RNA dysregulation in diseases of motor neurons. 2012 , 7, 323-52	17
1171	Advances in understanding the molecular basis of frontotemporal dementia. 2012 , 8, 423-34	306
1170	Pick's disease. 2012 , 724, 300-16	10

1169	The TRK-fused gene is mutated in hereditary motor and sensory neuropathy with proximal dominant involvement. 2012 , 91, 320-9	76
1168	Altered transcription factor trafficking in oxidatively-stressed neuronal cells. 2012 , 1822, 1773-82	11
1167	Mitochondrial dysfunction in human TDP-43 transfected NSC34 cell lines and the protective effect of dimethoxy curcumin. 2012 , 89, 185-90	55
1166	Comparison of phosphorylated TDP-43-positive inclusions in oculomotor neurons in patients with non-ALS and ALS disorders. 2012 , 315, 20-5	9
1165	Tunicamycin produces TDP-43 cytoplasmic inclusions in cultured brain organotypic slices. 2012 , 317, 66-73	12
1164	ATXN2 with intermediate-length CAG/CAA repeats does not seem to be a risk factor in hereditary spastic paraplegia. 2012 , 321, 100-2	7
1163	Copper complexes as therapeutic agents. 2012 , 4, 127-38	197
1162	A panel of macroautophagy markers in lymphomonocytes of patients with amyotrophic lateral sclerosis. 2012 , 13, 119-24	9
1161	Digenic inheritance and Mendelian disease. 2012 , 44, 1291-2	50
1160	Neuroimaging in frontotemporal lobar degeneration--predicting molecular pathology. 2012 , 8, 131-42	54
1159	Lafora disease E3 ubiquitin ligase malin is recruited to the processing bodies and regulates the microRNA-mediated gene silencing process via the decapping enzyme Dcp1a. 2012 , 9, 1440-9	15
1158	Hsp90 modulation for the treatment of Alzheimer's disease. 2012 , 64, 1-25	43
1157	Endoplasmic reticulum stress and the ER mitochondrial calcium cycle in amyotrophic lateral sclerosis. 2012 , 13, 166-77	52
1156	Frontotemporal lobar degeneration: new understanding brings new approaches. 2012 , 22, 83-97, viii	2
1155	A role for calpain-dependent cleavage of TDP-43 in amyotrophic lateral sclerosis pathology. 2012 , 3, 1307	109
1154	[TDP-43 proteinopathies - from frontotemporal lobar degeneration to inclusion body myositis]. 2012 , 46, 384-91	1
1153	Mutant induced pluripotent stem cell lines recapitulate aspects of TDP-43 proteinopathies and reveal cell-specific vulnerability. 2012 , 109, 5803-8	254
1152	Frontal cortex neuropathology in dementia pugilistica. 2012 , 29, 1054-70	66

1151 Splicing and Disease. **2012**, 119-128

1150 Widespread binding of FUS along nascent RNA regulates alternative splicing in the brain. **2012**, 2, 603 194

1149 Proteomic analysis identifies dysfunction in cellular transport, energy, and protein metabolism in different brain regions of atypical frontotemporal lobar degeneration. **2012**, 11, 2533-43 38

1148 Gains or losses: molecular mechanisms of TDP43-mediated neurodegeneration. **2011**, 13, 38-50 450

1147 Endogenous TDP-43, but not FUS, contributes to stress granule assembly via G3BP. **2012**, 7, 54 83

1146 Does a loss of TDP-43 function cause neurodegeneration?. **2012**, 7, 27 68

1145 Shared resistance to aging and ALS in neuromuscular junctions of specific muscles. **2012**, 7, e34640 155

1144 Aberrant localization of FUS and TDP43 is associated with misfolding of SOD1 in amyotrophic lateral sclerosis. **2012**, 7, e35050 128

1143 TDP-43 identified from a genome wide RNAi screen for SOD1 regulators. **2012**, 7, e35818 10

1142 Microglial activation correlates with disease progression and upper motor neuron clinical symptoms in amyotrophic lateral sclerosis. **2012**, 7, e39216 155

1141 Methylene blue protects against TDP-43 and FUS neuronal toxicity in *C. elegans* and *D. rerio*. **2012**, 7, e42117 75

1140 Inhibition of TDP-43 accumulation by bis(thiosemicarbazonato)-copper complexes. **2012**, 7, e42277 35

1139 Co-occurrence of TDP-43 mislocalization with reduced activity of an RNA editing enzyme, ADAR2, in aged mouse motor neurons. **2012**, 7, e43469 22

1138 Grey and white matter changes across the amyotrophic lateral sclerosis-frontotemporal dementia continuum. **2012**, 7, e43993 139

1137 Conserved acidic amino acid residues in a second RNA recognition motif regulate assembly and function of TDP-43. **2012**, 7, e52776 13

1136 Widespread structural and functional connectivity changes in amyotrophic lateral sclerosis: insights from advanced neuroimaging research. **2012**, 2012, 473538 16

1135 Genome-wide approaches to dissect the roles of RNA binding proteins in translational control: implications for neurological diseases. **2012**, 6, 144 40

1134 Protein Aggregates in Pathological Inclusions of Amyotrophic Lateral Sclerosis. **2012**, 10

1133	Staufen: from embryo polarity to cellular stress and neurodegeneration. 2012 , 4, 432-52	12
1132	Genetics of Familial Amyotrophic Lateral Sclerosis. 2012 ,	
1131	Amyotrophic lateral sclerosis. 214-227	
1130	Genetics of Amyotrophic Lateral Sclerosis. 2012 ,	
1129	NEURODEGENERATIVE DISEASES AND TAU: PATHOLOGICAL EVENTS AND MOLECULAR TARGETS. 2012 ,	
1128	Alzheimer's disease and related dementias. 17-31	
1127	Amyotrophic lateral sclerosis and other disorders of the lower motor neuron. 136-147	
1126	A Major Genetic Factor at Chromosome 9p Implicated in Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Lobar Degeneration (FTLD). 2012 ,	1
1125	Glial Cells as Therapeutic Targets for ALS. 2012 ,	
1124	The Roles of ESCRT Proteins in Healthy Cells and in Disease. 2012 ,	1
1123	Staufen from embryo polarity to cellular stress and neurodegeneration. 2012 , S4, 432-452	9
1122	On the 'classification' of neurodegenerative disorders: discrete entities, overlap or continuum?. 2012 , 50, 201-8	21
1121	Genetics of Neurodegenerative Diseases. 2012 , 719-736	0
1120	Ageing--RNA in development and disease. 2012 , 3, 133-43	13
1119	RNA-binding proteins in neurodegenerative disease: TDP-43 and beyond. 2012 , 3, 265-85	36
1118	Neurotrophic bone marrow cellular nests prevent spinal motoneuron degeneration in amyotrophic lateral sclerosis patients: a pilot safety study. 2012 , 30, 1277-85	85
1117	Drug screening for ALS using patient-specific induced pluripotent stem cells. 2012 , 4, 145ra104	390
1116	p62/sequestosome 1 binds to TDP-43 in brains with frontotemporal lobar degeneration with TDP-43 inclusions. 2012 , 90, 2034-42	49

1115	Cellular ageing, increased mortality and FTLT-DTP-associated neuropathology in progranulin knockout mice. 2012 , 228, 67-76	92
1114	Quantifying change in individual subjects affected by frontotemporal lobar degeneration using automated longitudinal MRI volumetry. 2012 , 33, 1526-35	22
1113	CSF biomarkers cutoffs: the importance of coincident neuropathological diseases. 2012 , 124, 23-35	138
1112	The use of P300-based BCIs in amyotrophic lateral sclerosis: from augmentative and alternative communication to cognitive assessment. 2012 , 2, 479-98	45
1111	The value of cerebrospinal fluid biomarkers for the differential diagnosis of dementia. 2012 , 2, 211-219	1
1110	The advent of AAV9 expands applications for brain and spinal cord gene delivery. 2012 , 12, 757-66	87
1109	Recent advances in the genetics of the ALS-FTLD complex. 2012 , 12, 243-50	45
1108	TDP-43 pathology in a case of hereditary spastic paraplegia with a NIPA1/SPG6 mutation. 2012 , 124, 285-91	18
1107	Pattern of ubiquilin pathology in ALS and FTLD indicates presence of C9ORF72 hexanucleotide expansion. 2012 , 123, 825-39	148
1106	Neuronal sensitivity to TDP-43 overexpression is dependent on timing of induction. 2012 , 123, 807-23	43
1105	Distinct TDP-43 pathology in ALS patients with ataxin 2 intermediate-length polyQ expansions. 2012 , 124, 221-30	32
1104	TDP-43 regulates the mammalian spinogenesis through translational repression of Rac1. 2012 , 124, 231-45	44
1103	Sporadic juvenile amyotrophic lateral sclerosis caused by mutant FUS/TLS: possible association of mental retardation with this mutation. 2012 , 259, 1039-44	33
1102	Epigenetics DNA methylation in the core ataxin-2 gene promoter: novel physiological and pathological implications. 2012 , 131, 625-38	41
1101	Clinical phenotypes and genetic biomarkers of FTLD. 2012 , 119, 851-60	16
1100	Autophagy dysregulation in amyotrophic lateral sclerosis. 2012 , 22, 110-6	118
1099	Phosphorylation of microtubule-associated protein tau by AMPK-related kinases. 2012 , 120, 165-76	44
1098	Tau-targeted treatment strategies in Alzheimer's disease. 2012 , 165, 1246-59	94

1097	High frequency of the TARDBP p.Ala382Thr mutation in Sardinian patients with amyotrophic lateral sclerosis. 2012 , 81, 172-8	36
1096	New drugs for ALS: how do we get there?. 2012 , 233, 112-7	7
1095	Frontotemporal lobar degeneration-related proteins induce only subtle memory-related deficits when bilaterally overexpressed in the dorsal hippocampus. 2012 , 233, 807-14	10
1094	Wild type TDP-43 induces neuro-inflammation and alters APP metabolism in lentiviral gene transfer models. 2012 , 235, 297-305	30
1093	Recent advances in p97/VCP/Cdc48 cellular functions. 2012 , 1823, 130-7	149
1092	The tip of the iceberg: RNA-binding proteins with prion-like domains in neurodegenerative disease. 2012 , 1462, 61-80	450
1091	FUS-related proteinopathies: lessons from animal models. 2012 , 1462, 44-60	49
1090	Progranulin: an emerging target for FTLD therapies. 2012 , 1462, 118-28	33
1089	RNA-binding proteins in microsatellite expansion disorders: mediators of RNA toxicity. 2012 , 1462, 100-11	69
1088	Role of selected mutations in the Q/N rich region of TDP-43 in EGFP-12xQ/N-induced aggregate formation. 2012 , 1462, 139-50	37
1087	TDP-43 aggregation in neurodegeneration: are stress granules the key?. 2012 , 1462, 16-25	151
1086	HO-1 induction in motor cortex and intestinal dysfunction in TDP-43 A315T transgenic mice. 2012 , 1460, 88-95	51
1085	Rodent models of TDP-43: recent advances. 2012 , 1462, 26-39	89
1084	A C9orf72 promoter repeat expansion in a Flanders-Belgian cohort with disorders of the frontotemporal lobar degeneration-amyotrophic lateral sclerosis spectrum: a gene identification study. 2012 , 11, 54-65	489
1083	Frequency of the C9orf72 hexanucleotide repeat expansion in patients with amyotrophic lateral sclerosis and frontotemporal dementia: a cross-sectional study. 2012 , 11, 323-30	830
1082	Nucleolar proteins with altered expression in leukemic cell lines. 2012 , 36, 232-6	11
1081	Oxidative stress induced by glutathione depletion reproduces pathological modifications of TDP-43 linked to TDP-43 proteinopathies. 2012 , 45, 862-70	67
1080	TDP-43: gumming up neurons through protein-protein and protein-RNA interactions. 2012 , 37, 237-47	123

1079	MicroRNAs in neurodegenerative diseases and their therapeutic potential. 2012 , 133, 142-50	161
1078	Characterization of the Asian myopathy patients with VCP mutations. 2012 , 19, 501-9	47
1077	Primary lateral sclerosis: upper-motor-predominant amyotrophic lateral sclerosis with frontotemporal lobar degeneration--immunohistochemical and biochemical analyses of TDP-43. 2012 , 32, 373-84	45
1076	Neuropathology and omics in motor neuron diseases. 2012 , 32, 458-62	13
1075	An MND/ALS phenotype associated with C9orf72 repeat expansion: abundant p62-positive, TDP-43-negative inclusions in cerebral cortex, hippocampus and cerebellum but without associated cognitive decline. 2012 , 32, 505-14	99
1074	RNA-binding proteins involved in RNA localization and their implications in neuronal diseases. 2012 , 35, 1818-36	33
1073	TDP-43 toxicity is mediated by the unfolded protein response-unrelated induction of C/EBP homologous protein expression. 2012 , 90, 641-7	21
1072	Progranulin genetic screening in frontotemporal lobar degeneration patients from central Italy. 2012 , 32, 13-6	9
1071	Microglial activation and TDP-43 pathology correlate with executive dysfunction in amyotrophic lateral sclerosis. 2012 , 123, 395-407	80
1070	Clinical and pathological features of amyotrophic lateral sclerosis caused by mutation in the C9ORF72 gene on chromosome 9p. 2012 , 123, 409-17	127
1069	Widespread aggregation of mutant VAPB associated with ALS does not cause motor neuron degeneration or modulate mutant SOD1 aggregation and toxicity in mice. 2013 , 8, 1	41
1068	Therapeutic neuroprotective agents for amyotrophic lateral sclerosis. 2013 , 70, 4729-45	54
1067	Sumoylation in neurodegenerative diseases. 2013 , 70, 2123-38	87
1066	The role of Yca1 in proteostasis. Yca1 regulates the composition of the insoluble proteome. 2013 , 81, 24-30	18
1065	A cellular model for sporadic ALS using patient-derived induced pluripotent stem cells. 2013 , 56, 355-64	212
1064	Modeling key pathological features of frontotemporal dementia with C9ORF72 repeat expansion in iPSC-derived human neurons. 2013 , 126, 385-99	261
1063	Cerebrospinal fluid neurofilament light chain protein levels in subtypes of frontotemporal dementia. 2013 , 13, 54	96
1062	Spinal cord: motor neuron diseases. 2013 , 31, 219-39	15

1061	Clinical perspective on oxidative stress in sporadic amyotrophic lateral sclerosis. 2013 , 65, 509-527	208
1060	Chronic cerebral ischemia induces redistribution and abnormal phosphorylation of transactivation-responsive DNA-binding protein-43 in mice. 2013 , 1533, 131-40	8
1059	Expression of TMEM106B, the frontotemporal lobar degeneration-associated protein, in normal and diseased human brain. 2013 , 1, 36	19
1058	Exon array analysis of alternative splicing of genes in SOD1G93A transgenic mice. 2013 , 170, 301-19	4
1057	Could dysregulation of UPS be a common underlying mechanism for cancer and neurodegeneration? Lessons from UCHL1. 2013 , 67, 45-53	36
1056	Generalized myoclonus as a prominent symptom in a patient with FTLTDP. 2013 , 260, 1681-3	2
1055	Overexpression of ALS-associated p.M337V human TDP-43 in mice worsens disease features compared to wild-type human TDP-43 mice. 2013 , 48, 22-35	66
1054	Similar dose-dependence of motor neuron cell death caused by wild type human TDP-43 and mutants with ALS-associated amino acid substitutions. 2013 , 20, 33	8
1053	Converging mechanisms in ALS and FTD: disrupted RNA and protein homeostasis. 2013 , 79, 416-38	1038
1052	Harnessing the power of yeast to unravel the molecular basis of neurodegeneration. 2013 , 127, 438-52	69
1051	Clinic, neuropathology and molecular genetics of frontotemporal dementia: a mini-review. 2013 , 2, 8	37
1050	Robust cytoplasmic accumulation of phosphorylated TDP-43 in transgenic models of tauopathy. 2013 , 126, 39-50	20
1049	Protein aggregation in amyotrophic lateral sclerosis. 2013 , 125, 777-94	347
1048	Frontotemporal dementia-amyotrophic lateral sclerosis syndrome locus on chromosome 16p12.1-q12.2: genetic, clinical and neuropathological analysis. 2013 , 125, 523-33	18
1047	Altered ribostasis: RNA-protein granules in degenerative disorders. 2013 , 154, 727-36	423
1046	Aberrant splicing in neurological diseases. 2013 , 4, 631-49	27
1045	Sirtuin deacetylases in neurodegenerative diseases of aging. 2013 , 23, 746-58	149
1044	Motor Neuron Disease. 2013 , 1-22	3

1043	Prion-like properties of pathological TDP-43 aggregates from diseased brains. 2013 , 4, 124-34	322
1042	Hexanucleotide repeats in ALS/FTD form length-dependent RNA foci, sequester RNA binding proteins, and are neurotoxic. 2013 , 5, 1178-86	334
1041	Frontotemporal lobar degeneration: diversity of FTLD lesions. 2013 , 169, 786-92	4
1040	TARDBP and FUS mutations associated with amyotrophic lateral sclerosis: summary and update. 2013 , 34, 812-26	171
1039	FUS-mediated alternative splicing in the nervous system: consequences for ALS and FTLD. 2013 , 91, 1343-54	27
1038	TDP-43 pathology, cognitive decline, and dementia in old age. 2013 , 70, 1418-24	151
1037	Ethoxyquin prevents chemotherapy-induced neurotoxicity via Hsp90 modulation. 2013 , 74, 893-904	25
1036	RNA and splicing regulation in neurodegeneration. 2013 , 56, 404-5	1
1035	TDP-43 high throughput screening analyses in neurodegeneration: advantages and pitfalls. 2013 , 56, 465-74	23
1034	Utility of transcranial magnetic stimulation in delineating amyotrophic lateral sclerosis pathophysiology. 2013 , 116, 561-75	28
1033	Amyotrophic lateral sclerosis: an update on recent genetic insights. 2013 , 260, 2917-27	50
1032	Clinical and genetic heterogeneity of amyotrophic lateral sclerosis. 2013 , 83, 408-16	78
1031	Targeting RNA foci in iPSC-derived motor neurons from ALS patients with a C9ORF72 repeat expansion. 2013 , 5, 208ra149	488
1030	The epidemiology of ALS: a conspiracy of genes, environment and time. 2013 , 9, 617-28	461
1029	Rescue of amyotrophic lateral sclerosis phenotype in a mouse model by intravenous AAV9-ADAR2 delivery to motor neurons. 2013 , 5, 1710-9	52
1028	Amyotrophic lateral sclerosis--a model of corticofugal axonal spread. 2013 , 9, 708-14	310
1027	Characterization of human sporadic ALS biomarkers in the familial ALS transgenic mSOD1(G93A) mouse model. 2013 , 22, 4720-5	16
1026	Comparative survey of the topographical distribution of signature molecular lesions in major neurodegenerative diseases. 2013 , 521, 4339-55	41

1025	Modeling neurodegenerative diseases in <i>Caenorhabditis elegans</i> . 2013 , 250, 94-103	82
1024	U1 small nuclear ribonucleoprotein complex and RNA splicing alterations in Alzheimer's disease. 2013 , 110, 16562-7	200
1023	Neurodegenerative Diseases: Integrative PPPM Approach as the Medicine of the Future. 2013 ,	3
1022	Does variation in neurodegenerative disease susceptibility and phenotype reflect cerebral differences at the network level?. 2013 , 14, 487-93	21
1021	The Importance of Olfactory and Motor Endpoints for Zebrafish Models of Neurodegenerative Disease. 2013 , 651-678	
1020	Proteopathic Seeds and Neurodegenerative Diseases. 2013 ,	4
1019	RNA dysfunction and aggregopathy at the centre of an amyotrophic lateral sclerosis/frontotemporal dementia disease continuum. 2013 , 136, 1345-60	69
1018	Age-dependent increases in tau phosphorylation in the brains of type 2 diabetic rats correlate with a reduced expression of p62. 2013 , 248, 441-50	36
1017	Early-onset alopecia and amyotrophic lateral sclerosis: a cohort study. 2013 , 178, 1146-9	11
1016	The role of TDP-43 in the pathogenesis of ALS and FTL. 2013 , 41, 1536-40	52
1015	FUS regulates genes coding for RNA-binding proteins in neurons by binding to their highly conserved introns. 2013 , 19, 498-509	77
1014	Functional diversity of protein fibrillar aggregates from physiology to RNA granules to neurodegenerative diseases. 2013 , 1832, 1271-8	17
1013	Analysis of TDP-43 and its binding partners in neurodegenerative diseases. 2013 , 8,	78
1012	The long non-coding RNA nuclear-enriched abundant transcript 1_2 induces paraspeckle formation in the motor neuron during the early phase of amyotrophic lateral sclerosis. 2013 , 6, 31	165
1011	The p.A382T TARDBP gene mutation in Sardinian patients affected by Parkinson's disease and other degenerative parkinsonisms. 2013 , 14, 161-6	30
1010	TDP-43 regulates the microprocessor complex activity during in vitro neuronal differentiation. 2013 , 48, 952-63	46
1009	Sumoylation of critical proteins in amyotrophic lateral sclerosis: emerging pathways of pathogenesis. 2013 , 15, 760-70	10
1008	Systemic dysregulation of TDP-43 binding microRNAs in amyotrophic lateral sclerosis. 2013 , 1, 42	108

1007	Calcium-dependent protein folding in amyotrophic lateral sclerosis. 2013 , 54, 132-43	43
1006	Frontotemporal lobar degeneration and amyotrophic lateral sclerosis: molecular similarities and differences. 2013 , 169, 793-8	19
1005	Genetics of frontotemporal lobar degeneration: an up-date and diagnosis algorithm. 2013 , 169, 811-9	30
1004	Controversies and priorities in amyotrophic lateral sclerosis. 2013 , 12, 310-22	377
1003	Changes in cognition and behaviour in amyotrophic lateral sclerosis: nature of impairment and implications for assessment. 2013 , 12, 368-80	287
1002	Brain banking for neurological disorders. 2013 , 12, 1096-105	64
1001	Amyotrophic lateral sclerosis: Problems and prospects. 2013 , 74, 309-16	104
1000	Cellular toxicity induced by the 26-kDa fragment and amyotrophic lateral sclerosis-associated mutant forms of TAR DNA-binding protein 43 in human embryonic stem cell-derived motor neurons. 2013 , 1, 24-31	1
999	Transportin 1 colocalization with Fused in Sarcoma (FUS) inclusions is not characteristic for amyotrophic lateral sclerosis-FUS confirming disrupted nuclear import of mutant FUS and distinguishing it from frontotemporal lobar degeneration with FUS inclusions. 2013 , 39, 553-61	22
998	TDP-43 associates with stalled ribosomes and contributes to cell survival during cellular stress. 2013 , 126, 288-300	45
997	Progranulin peripheral levels as a screening tool for the identification of subjects with progranulin mutations in a Portuguese cohort. 2014 , 13, 214-23	22
996	Delineating the membrane-disrupting and seeding properties of the TDP-43 amyloidogenic core. 2013 , 49, 11212-4	20
995	Fused in sarcoma (FUS) protein lacking nuclear localization signal (NLS) and major RNA binding motifs triggers proteinopathy and severe motor phenotype in transgenic mice. 2013 , 288, 25266-25274	66
994	Rho guanine nucleotide exchange factor is an NFL mRNA destabilizing factor that forms cytoplasmic inclusions in amyotrophic lateral sclerosis. 2013 , 34, 248-62	24
993	The FTD/ALS-associated RNA-binding protein TDP-43 regulates the robustness of neuronal specification through microRNA-9a in Drosophila. 2013 , 22, 218-25	32
992	Glucocorticoids exacerbate cognitive deficits in TDP-25 transgenic mice via a glutathione-mediated mechanism: implications for aging, stress and TDP-43 proteinopathies. 2013 , 33, 906-13	28
991	PolyQ disease: misfiring of a developmental cell death program?. 2013 , 23, 168-74	42
990	Exacerbated inflammatory responses related to activated microglia after traumatic brain injury in progranulin-deficient mice. 2013 , 231, 49-60	82

989	Transcranial magnetic stimulation and amyotrophic lateral sclerosis: pathophysiological insights. 2013 , 84, 1161-70	167
988	Spliceosome integrity is defective in the motor neuron diseases ALS and SMA. 2013 , 5, 221-34	134
987	C9ORF72 repeat expansions in the frontotemporal dementias spectrum of diseases: a flow-chart for genetic testing. 2013 , 34, 485-99	80
986	Detection of a novel frameshift mutation and regions with homozygosity within ARHGEF28 gene in familial amyotrophic lateral sclerosis. 2013 , 14, 444-51	27
985	TDP-43 loss-of-function causes neuronal loss due to defective steroid receptor-mediated gene program switching in Drosophila. 2013 , 3, 160-72	45
984	Progress in frontotemporal dementia research. 2013 , 28, 15-23	11
983	Identification of RNA bound to the TDP-43 ribonucleoprotein complex in the adult mouse brain. 2013 , 14, 252-60	58
982	Reduction of polyglutamine toxicity by TDP-43, FUS and progranulin in Huntington's disease models. 2013 , 22, 782-94	28
981	Characterization of E-domains in C-terminal fragments of TDP-43 by scanning tunneling microscopy. 2013 , 181, 11-6	23
980	[Frontotemporal dementias]. 2013 , 84, 20-32	11
979	Overexpression of human wild-type FUS causes progressive motor neuron degeneration in an age- and dose-dependent fashion. 2013 , 125, 273-88	186
978	TDP-43 skeins show properties of amyloid in a subset of ALS cases. 2013 , 125, 121-31	78
977	The JNK/c-Jun signaling axis contributes to the TDP-43-induced cell death. 2013 , 372, 241-8	21
976	Biomarkers of mild traumatic brain injury in cerebrospinal fluid and blood. 2013 , 9, 201-10	390
975	Unconventional translation of C9ORF72 GGGGCC expansion generates insoluble polypeptides specific to c9FTD/ALS. 2013 , 77, 639-46	783
974	Extracellular aggregated Cu/Zn superoxide dismutase activates microglia to give a cytotoxic phenotype. 2013 , 61, 409-19	66
973	Proteome analysis of body fluids for amyotrophic lateral sclerosis biomarker discovery. 2013 , 7, 123-35	27
972	Pharmacological reduction of ER stress protects against TDP-43 neuronal toxicity in vivo. 2013 , 55, 64-75	97

971	Molecular mechanism of oxidation-induced TDP-43 RRM1 aggregation and loss of function. 2013 , 587, 575-82	47
970	Identification of in vivo, conserved, TAF15 RNA binding sites reveals the impact of TAF15 on the neuronal transcriptome. 2013 , 3, 301-8	22
969	TDP-43 pathology in a patient carrying G2019S LRRK2 mutation and a novel p.Q124E MAPT. 2013 , 34, 2889.e5-9	33
968	Neuronal-specific overexpression of a mutant valosin-containing protein associated with IBMPFD promotes aberrant ubiquitin and TDP-43 accumulation and cognitive dysfunction in transgenic mice. 2013 , 183, 504-15	32
967	Investigation of C9orf72 repeat expansions in Parkinson's disease. 2013 , 34, 1710.e7-9	21
966	Disruption of large-scale neural networks in non-fluent/agrammatic variant primary progressive aphasia associated with frontotemporal degeneration pathology. 2013 , 127, 106-20	63
965	Phosphorylated neurofilament heavy subunit (pNF-H) in peripheral blood and CSF as a potential prognostic biomarker in amyotrophic lateral sclerosis. 2013 , 84, 467-72	106
964	Mutation analysis and immunopathological studies of PFN1 in familial and sporadic amyotrophic lateral sclerosis. 2013 , 34, 2235.e7-10	15
963	Evaluation of longevity enhancing compounds against transactive response DNA-binding protein-43 neuronal toxicity. 2013 , 34, 2175-82	16
962	Increased lysosomal biogenesis in activated microglia and exacerbated neuronal damage after traumatic brain injury in progranulin-deficient mice. 2013 , 250, 8-19	99
961	TAR DNA-binding protein 43 pathology in a case clinically diagnosed with facial-onset sensory and motor neuronopathy syndrome: an autopsied case report and a review of the literature. 2013 , 332, 148-53	18
960	Frontotemporal degeneration, the next therapeutic frontier: molecules and animal models for frontotemporal degeneration drug development. 2013 , 9, 176-88	45
959	The clinical and pathological phenotypes of frontotemporal dementia with C9ORF72 mutations. 2013 , 335, 26-35	20
958	Altered astrocytic expression of TDP-43 does not influence motor neuron survival. 2013 , 250, 250-9	38
957	Clinical neurogenetics: amyotrophic lateral sclerosis. 2013 , 31, 929-50	29
956	Genetic analysis and SOD1 mutation screening in Iranian amyotrophic lateral sclerosis patients. 2013 , 34, 1516.e1-8	25
955	Mechanisms of granulin deficiency: lessons from cellular and animal models. 2013 , 47, 337-60	49
954	RANTing about C9orf72. 2013 , 77, 597-8	19

953	Premature death of TDP-43 (A315T) transgenic mice due to gastrointestinal complications prior to development of full neurological symptoms of amyotrophic lateral sclerosis. 2013 , 94, 56-64	55
952	Regionally different immunoreactivity for Smurf2 and pSmad2/3 in TDP-43-positive inclusions of amyotrophic lateral sclerosis. 2013 , 39, 144-56	4
951	Nuclear carrier and RNA-binding proteins in frontotemporal lobar degeneration associated with fused in sarcoma (FUS) pathological changes. 2013 , 39, 157-65	18
950	Mutations in SQSTM1 encoding p62 in amyotrophic lateral sclerosis: genetics and neuropathology. 2013 , 125, 511-22	170
949	TARDBP mutations in Parkinson's disease. 2013 , 19, 312-5	31
948	Identification of genetic modifiers of TDP-43 neurotoxicity in Drosophila. 2013 , 8, e57214	27
947	Genetic syndromes caused by mutations in epigenetic genes. 2013 , 132, 359-83	121
946	hnRNP A3 binds to GGGGCC repeats and is a constituent of p62-positive/TDP43-negative inclusions in the hippocampus of patients with C9orf72 mutations. 2013 , 125, 413-23	250
945	Loss of TDP-43 causes age-dependent progressive motor neuron degeneration. 2013 , 136, 1371-82	120
944	Loss of ALS-associated TDP-43 in zebrafish causes muscle degeneration, vascular dysfunction, and reduced motor neuron axon outgrowth. 2013 , 110, 4986-91	103
943	ALS-linked TDP-43 mutations produce aberrant RNA splicing and adult-onset motor neuron disease without aggregation or loss of nuclear TDP-43. 2013 , 110, E736-45	284
942	The changing scene of amyotrophic lateral sclerosis. 2013 , 14, 248-64	716
941	Protein misfolding in the late-onset neurodegenerative diseases: common themes and the unique case of amyotrophic lateral sclerosis. 2013 , 81, 1285-303	62
940	Chronic neuropathologies of single and repetitive TBI: substrates of dementia?. 2013 , 9, 211-21	449
939	Tat-activating regulatory DNA-binding protein regulates glycolysis in hepatocellular carcinoma by regulating the platelet isoform of phosphofructokinase through microRNA 520. 2013 , 58, 182-91	64
938	Overexpression of human mutated G93A SOD1 changes dynamics of the ER mitochondria calcium cycle specifically in mouse embryonic motor neurons. 2013 , 247, 91-100	31
937	Rodent models of amyotrophic lateral sclerosis. 2013 , 1832, 1421-36	119
936	A small molecule screen in stem-cell-derived motor neurons identifies a kinase inhibitor as a candidate therapeutic for ALS. 2013 , 12, 713-26	231

935 Animal Models of Amyloid Diseases. **2013**, 245-262

934 Neuron enriched nuclear proteome isolated from human brain. **2013**, 12, 3193-206 52

933 Current insights into the C9orf72 repeat expansion diseases of the FTL/ALS spectrum. **2013**, 36, 450-9 129

932 Activation of transforming growth factor- β /Smad signaling reduces aggregate formation of mislocalized TAR DNA-binding protein-43. **2013**, 11, 182-93 9

931 The wobbler mouse, an ALS animal model. **2013**, 288, 207-29 66

930 Stages of pTDP-43 pathology in amyotrophic lateral sclerosis. **2013**, 74, 20-38 588

929 Protein truncation as a common denominator of human neurodegenerative foldopathies. **2013**, 48, 516-32 12

928 The neurotrophic properties of progranulin depend on the granulin E domain but do not require sortilin binding. **2013**, 34, 2541-7 50

927 Expression of ALS-linked TDP-43 mutant in astrocytes causes non-cell-autonomous motor neuron death in rats. **2013**, 32, 1917-26 123

926 Loss of function of C9orf72 causes motor deficits in a zebrafish model of amyotrophic lateral sclerosis. **2013**, 74, 180-7 238

925 Selective forelimb impairment in rats expressing a pathological TDP-43 25 kDa C-terminal fragment to mimic amyotrophic lateral sclerosis. **2013**, 21, 1324-34 35

924 Fused in sarcoma (FUS): an oncogene goes awry in neurodegeneration. **2013**, 56, 475-86 95

923 Eukaryotic stress granules are cleared by autophagy and Cdc48/VCP function. **2013**, 153, 1461-74 457

922 RNA quality control and protein aggregates in amyotrophic lateral sclerosis: a review. **2013**, 47, 330-8 17

921 RNA-mediated toxicity in neurodegenerative disease. **2013**, 56, 406-19 70

920 Mutations in the 3' untranslated region of FUS causing FUS overexpression are associated with amyotrophic lateral sclerosis. **2013**, 22, 4748-55 78

919 Dipeptide repeat protein pathology in C9ORF72 mutation cases: clinico-pathological correlations. **2013**, 126, 859-79 248

918 Recruitment into stress granules prevents irreversible aggregation of FUS protein mislocalized to the cytoplasm. **2013**, 12, 3194-202 38

917	Emerging complexity of the HuD/ELAVL4 gene; implications for neuronal development, function, and dysfunction. 2013 , 19, 1019-37	68
916	ALS/FTLD-linked TDP-43 regulates neurite morphology and cell survival in differentiated neurons. 2013 , 319, 1998-2005	21
915	From frontotemporal lobar degeneration pathology to frontotemporal lobar degeneration biomarkers. 2013 , 25, 210-20	11
914	How it all started: tau and protein phosphatase 2A. 2013 , 37, 483-94	19
913	Neuroscience. RNA that gets RAN in neurodegeneration. <i>Science</i> , 2013 , 339, 1282-3	33-3 8
912	Molecular basis of UG-rich RNA recognition by the human splicing factor TDP-43. 2013 , 20, 1443-9	197
911	Early and selective reduction of NOP56 (Asidan) and RNA processing proteins in the motor neuron of ALS model mice. 2013 , 35, 744-54	6
910	Keap1 is localized in neuronal and glial cytoplasmic inclusions in various neurodegenerative diseases. 2013 , 72, 18-28	55
909	WITHDRAWN: A mutation in the chaperone β -receptor impairs mitochondrial ATP production in amyotrophic lateral sclerosis. 2014 ,	
908	Sustainable Learning for Sustainability. 2013 , 10, 124-147	3
907	Clinical and Molecular Aspects of Motor Neuron Disease. 2013 , 2, 1-60	10
906	Reducing TDP-43 aggregation does not prevent its cytotoxicity. 2013 , 1, 49	18
905	Degeneration of serotonergic neurons in amyotrophic lateral sclerosis: a link to spasticity. 2013 , 136, 483-93	53
904	Corticospinal tract degeneration associated with TDP-43 type C pathology and semantic dementia. 2013 , 136, 455-70	30
903	Oligodendrocyte dysfunction in the pathogenesis of amyotrophic lateral sclerosis. 2013 , 136, 471-82	158
902	Frontotemporale Demenzen - Eine der hufigsten presenilen Demenzformen. 2013 , 42, 226-232	
901	Bildgebende Verfahren bei amyotropher Lateralsklerose und frontotemporaler Demenz. 2013 , 44, 145-153	
900	[Diagnostics and therapy for amyotrophic lateral sclerosis]. 2013 , 81, 592-603; quiz 604	4

899	Expanded GGGGCC repeat RNA associated with amyotrophic lateral sclerosis and frontotemporal dementia causes neurodegeneration. 2013 , 110, 7778-83	255
898	The truncated C-terminal RNA recognition motif of TDP-43 protein plays a key role in forming proteinaceous aggregates. 2013 , 288, 9049-57	70
897	Genetic analysis of SIGMAR1 as a cause of familial ALS with dementia. 2013 , 21, 237-9	25
896	The C9ORF72 expansion mutation is a common cause of ALS+/-FTD in Europe and has a single founder. 2013 , 21, 102-8	159
895	Repeat-associated non-ATG (RAN) translation in neurological disease. 2013 , 22, R45-51	125
894	The Department of Veterans Affairs Biorepository Brain Bank: a national resource for amyotrophic lateral sclerosis research. 2013 , 14, 591-7	11
893	Concurrent amyotrophic lateral sclerosis and cystic fibrosis supports common pathways of pathogenesis. 2013 , 14, 473-5	3
892	THEME 9 IN VIVO EXPERIMENTAL MODELS. 2013 , 14, 177-199	
891	The role of s-nitrosylation and s-glutathionylation of protein disulphide isomerase in protein misfolding and neurodegeneration. 2013 , 2013, 797914	44
890	Protein aggregates and regional disease spread in ALS is reminiscent of prion-like pathogenesis. 2013 , 61, 107-10	9
889	Profilin-1 mutations are rare in patients with amyotrophic lateral sclerosis and frontotemporal dementia. 2013 , 14, 463-9	23
888	Disease animal models of TDP-43 proteinopathy and their pre-clinical applications. 2013 , 14, 20079-111	32
887	Clinicopathologic variability of the GRN A9D mutation, including amyotrophic lateral sclerosis. 2013 , 80, 1771-7	19
886	Clinical implications of recent breakthroughs in amyotrophic lateral sclerosis. 2013 , 26, 466-72	18
885	Limelight on alpha-synuclein: pathological and mechanistic implications in neurodegeneration. 2013 , 3, 415-59	58
884	Molecular chaperone Hsp110 rescues a vesicle transport defect produced by an ALS-associated mutant SOD1 protein in squid axoplasm. 2013 , 110, 5428-33	43
883	An elderly woman with difficulty reading and abnormal eye movements. 2013 , 33, 296-301	3
882	Calcium channel agonists protect against neuromuscular dysfunction in a genetic model of TDP-43 mutation in ALS. 2013 , 33, 1741-52	54

881	Loss and gain of Drosophila TDP-43 impair synaptic efficacy and motor control leading to age-related neurodegeneration by loss-of-function phenotypes. 2013 , 22, 1539-57	89
880	Tardbp1 splicing rescues motor neuron and axonal development in a mutant tardbp zebrafish. 2013 , 22, 2376-86	26
879	Targeted degradation of sense and antisense C9orf72 RNA foci as therapy for ALS and frontotemporal degeneration. 2013 , 110, E4530-9	420
878	Pathological mechanisms underlying TDP-43 driven neurodegeneration in FTLD-ALS spectrum disorders. 2013 , 22, R77-87	111
877	Targeting RNA binding proteins involved in neurodegeneration. 2013 , 18, 967-83	19
876	Glia as primary drivers of neuropathology in TDP-43 proteinopathies. 2013 , 110, 4439-40	12
875	Syndromes dominated by apraxia of speech show distinct characteristics from agrammatic PPA. 2013 , 81, 337-45	114
874	Decreased number of Gemini of coiled bodies and U12 snRNA level in amyotrophic lateral sclerosis. 2013 , 22, 4136-47	59
873	Cognitive decline and reduced survival in C9orf72 expansion frontotemporal degeneration and amyotrophic lateral sclerosis. 2013 , 84, 163-9	112
872	ALS mutant FUS disrupts nuclear localization and sequesters wild-type FUS within cytoplasmic stress granules. 2013 , 22, 2676-88	154
871	Deciphering amyotrophic lateral sclerosis: what phenotype, neuropathology and genetics are telling us about pathogenesis. 2013 , 14 Suppl 1, 5-18	120
870	Characterizing TDP-43 interaction with its RNA targets. 2013 , 41, 5062-74	64
869	Drosophila TDP-43 dysfunction in glia and muscle cells cause cytological and behavioural phenotypes that characterize ALS and FTLD. 2013 , 22, 3883-93	58
868	RNA binding mediates neurotoxicity in the transgenic Drosophila model of TDP-43 proteinopathy. 2013 , 22, 4474-84	61
867	Astrocyte pathology and the absence of non-cell autonomy in an induced pluripotent stem cell model of TDP-43 proteinopathy. 2013 , 110, 4697-702	238
866	Accelerated disease onset with stabilized familial amyotrophic lateral sclerosis (ALS)-linked mutant TDP-43 proteins. 2013 , 288, 3641-54	75
865	Trehalose delays the progression of amyotrophic lateral sclerosis by enhancing autophagy in motoneurons. 2013 , 9, 1308-20	243
864	Reduced CSF p-Tau181 to Tau ratio is a biomarker for FTLD-TDP. 2013 , 81, 1945-52	78

863	The ALS disease-associated mutant TDP-43 impairs mitochondrial dynamics and function in motor neurons. 2013 , 22, 4706-19	176
862	The FTL risk factor TMEM106B and MAP6 control dendritic trafficking of lysosomes. 2014 , 33, 450-67	92
861	Abundant FUS-immunoreactive pathology in the skin of sporadic amyotrophic lateral sclerosis. 2013 , 128, 257-64	13
860	Lack of unique neuropathology in amyotrophic lateral sclerosis associated with p.K54E angiogenin (ANG) mutation. 2013 , 39, 562-71	13
859	The involvement of the cerebellum in amyotrophic lateral sclerosis. 2013 , 14, 507-15	54
858	Human stem cell-derived astrocytes and their application to studying Nrf2-mediated neuroprotective pathways and therapeutics in neurodegeneration. 2013 , 75, 907-18	28
857	CDC7 inhibition blocks pathological TDP-43 phosphorylation and neurodegeneration. 2013 , 74, 39-52	75
856	Optineurin and amyotrophic lateral sclerosis. 2013 , 13, 528-32	29
855	Reduced expression of BTBD10 in anterior horn cells with Golgi fragmentation and pTDP-43-positive inclusions in patients with sporadic amyotrophic lateral sclerosis. 2013 , 33, 397-404	7
854	Accumulation of phosphorylated TDP-43 in the CNS of a patient with Cockayne syndrome. 2013 , 33, 673-7	9
853	What is the key player in TDP-43 pathology in ALS: Disappearance from the nucleus or inclusion formation in the cytoplasm?. 2013 , 1, 11-17	5
852	Genetic dissection of a cell-autonomous neurodegenerative disorder: lessons learned from mouse models of Niemann-Pick disease type C. 2013 , 6, 1089-100	18
851	Genomic editing opens new avenues for zebrafish as a model for neurodegeneration. 2013 , 127, 461-70	46
850	Capillary electrophoresis-mass spectrometry-based metabolome analysis of serum and saliva from neurodegenerative dementia patients. 2013 , 34, 2865-72	74
849	Stress granules in neurodegeneration--lessons learnt from TAR DNA binding protein of 43 kDa and fused in sarcoma. 2013 , 280, 4348-70	131
848	Stress granules as crucibles of ALS pathogenesis. 2013 , 201, 361-72	599
847	Fruitful research: drug target discovery for neurodegenerative diseases in Drosophila. 2013 , 8, 1503-13	9
846	Reversible acetylation regulates salt-inducible kinase (SIK2) and its function in autophagy. 2013 , 288, 6227-37	29

845	Parkin ubiquitinates Tar-DNA binding protein-43 (TDP-43) and promotes its cytosolic accumulation via interaction with histone deacetylase 6 (HDAC6). 2013 , 288, 4103-15	87
844	The dual functions of the extreme N-terminus of TDP-43 in regulating its biological activity and inclusion formation. 2013 , 22, 3112-22	119
843	Aberrant assembly of RNA recognition motif 1 links to pathogenic conversion of TAR DNA-binding protein of 43 kDa (TDP-43). 2013 , 288, 14886-905	48
842	Single-molecule studies on individual peptides and peptide assemblies on surfaces. 2013 , 371, 20120311	12
841	Yeast genetic screen reveals novel therapeutic strategy for ALS. 2013 , 1, e24420	17
840	Mice deficient in Epg5 exhibit selective neuronal vulnerability to degeneration. 2013 , 200, 731-41	93
839	Frontal lobe dementia, motor neuron disease, and clinical and neuropathological criteria. 2013 , 84, 713-4	11
838	Role of Epg5 in selective neurodegeneration and Vici syndrome. 2013 , 9, 1258-62	42
837	Structural transformation of the amyloidogenic core region of TDP-43 protein initiates its aggregation and cytoplasmic inclusion. 2013 , 288, 19614-24	85
836	Phenotypes in Swiss patients with familial ALS carrying TARDBP mutations. 2013 , 12, 150-5	9
835	The effect of smoke emission amount on changes in cloud properties and precipitation: A case study of Canadian boreal wildfires of 2007. 2013 , 118, 11,777-11,793	14
834	Motor neurons and glia exhibit specific individualized responses to TDP-43 expression in a <i>Drosophila</i> model of amyotrophic lateral sclerosis. 2013 , 6, 721-33	58
833	Recent progress in the discovery of small molecules for the treatment of amyotrophic lateral sclerosis (ALS). 2013 , 9, 717-32	28
832	[Cellular pathology of neurodegenerative disorders]. 2013 , 53, 609-17	2
831	[110th Scientific Meeting of the Japanese Society of Internal Medicine: Symposium: 2. Diseases originated from stem cell abnormalities; 3) iPS cell technology for neurodegenerative disease]. 2013 , 102, 2267-72	
830	Neuropathology of frontotemporal lobar degeneration: a review. 2013 , 7, 19-26	16
829	Clinical Characteristics of C9ORF72-Linked Frontotemporal Lobar Degeneration. 2013 , 3, 251-62	23
828	A 43-kDa TDP-43 species is present in aggregates associated with frontotemporal lobar degeneration. 2013 , 8, e62301	7

827	Inhibition of TDP-43 aggregation by nucleic acid binding. 2013 , 8, e64002	43
826	The pathological phenotypes of human TDP-43 transgenic mouse models are independent of downregulation of mouse Tdp-43. 2013 , 8, e69864	14
825	Molecular chaperone mediated late-stage neuroprotection in the SOD1(G93A) mouse model of amyotrophic lateral sclerosis. 2013 , 8, e73944	40
824	ALS-associated TDP-43 induces endoplasmic reticulum stress, which drives cytoplasmic TDP-43 accumulation and stress granule formation. 2013 , 8, e81170	108
823	The Wobbler mouse model of amyotrophic lateral sclerosis (ALS) displays hippocampal hyperexcitability, and reduced number of interneurons, but no presynaptic vesicle release impairments. 2013 , 8, e82767	17
822	Multiple kernel learning captures a systems-level functional connectivity biomarker signature in amyotrophic lateral sclerosis. 2013 , 8, e85190	44
821	The puzzling case of hyperexcitability in amyotrophic lateral sclerosis. 2013 , 9, 65-74	91
820	Differential autophagy power in the spinal cord and muscle of transgenic ALS mice. 2013 , 7, 234	42
819	An emerging role for misfolded wild-type SOD1 in sporadic ALS pathogenesis. 2013 , 7, 253	147
818	Antisense therapy in neurology. 2013 , 3, 144-76	50
817	Redox regulation in amyotrophic lateral sclerosis. 2013 , 2013, 408681	56
816	Evidence for prion-like mechanisms in several neurodegenerative diseases: potential implications for immunotherapy. 2013 , 2013, 473706	26
815	Oligonucleotide-Based Therapy for FTD/ALS Caused by the C9orf72 Repeat Expansion: A Perspective. 2013 , 2013, 208245	4
814	Human Pluripotent Stem Cells Modeling Neurodegenerative Diseases. 2013 ,	2
813	The Use of Human Samples to Study Familial and Sporadic Amyotrophic Lateral Sclerosis: New Frontiers and Challenges. 2013 ,	
812	Defects in RNA Metabolism links FTD and ALS Pathogenesis: TDP-43, FUS, and C9orf72. 2013 , 9, 28-40	1
811	[Overlapping features of frontotemporal dementia and amyotrophic lateral sclerosis]. 2014 , 142, 867-79	8
810	A nonsense mutation in mouse Tardbp affects TDP43 alternative splicing activity and causes limb-clasping and body tone defects. 2014 , 9, e85962	15

809	TDP-43 inclusion bodies formed in bacteria are structurally amorphous, non-amyloid and inherently toxic to neuroblastoma cells. 2014 , 9, e86720	54
808	Casein kinase II induced polymerization of soluble TDP-43 into filaments is inhibited by heat shock proteins. 2014 , 9, e90452	32
807	Dexpramipexole is ineffective in two models of ALS related neurodegeneration. 2014 , 9, e91608	20
806	Specificity of anti-tau antibodies when analyzing mice models of Alzheimer's disease: problems and solutions. 2014 , 9, e94251	77
805	Cerebellar integrity in the amyotrophic lateral sclerosis-frontotemporal dementia continuum. 2014 , 9, e105632	60
804	Analysis of nuclear export sequence regions of FUS-Related RNA-binding proteins in essential tremor. 2014 , 9, e111989	8
803	The emerging use of in vivo optical imaging in the study of neurodegenerative diseases. 2014 , 2014, 401306	12
802	Axonal transport and neurodegenerative disease: vesicle-motor complex formation and their regulation. 2014 , 4, 29-47	5
801	Neurodegeneration models in <i>Drosophila</i> . 135-161	0
800	Worming forward: amyotrophic lateral sclerosis toxicity mechanisms and genetic interactions in <i>Caenorhabditis elegans</i> . 2014 , 5, 85	43
799	Increased metal content in the TDP-43(A315T) transgenic mouse model of frontotemporal lobar degeneration and amyotrophic lateral sclerosis. 2014 , 6, 15	30
798	Therapeutic and diagnostic challenges for frontotemporal dementia. 2014 , 6, 204	16
797	A seeded propagation of Cu, Zn-superoxide dismutase aggregates in amyotrophic lateral sclerosis. 2014 , 8, 83	22
796	Rac1 at the crossroad of actin dynamics and neuroinflammation in Amyotrophic Lateral Sclerosis. 2014 , 8, 279	31
795	The emerging role of guanine nucleotide exchange factors in ALS and other neurodegenerative diseases. 2014 , 8, 282	20
794	Elevated mRNA-levels of distinct mitochondrial and plasma membrane Ca(2+) transporters in individual hypoglossal motor neurons of endstage SOD1 transgenic mice. 2014 , 8, 353	14
793	Ubiquitin pathways in neurodegenerative disease. 2014 , 7, 63	100
792	The role of D-serine and glycine as co-agonists of NMDA receptors in motor neuron degeneration and amyotrophic lateral sclerosis (ALS). 2014 , 6, 10	38

791	D-beta-hydroxybutyrate extends lifespan in <i>C. elegans</i> . 2014 , 6, 621-44	108
790	Neuronal Inclusions. 2014 , 441-455	
789	. 2014 ,	2
788	CGG repeats in RNA modulate expression of TDP-43 in mouse and fly models of fragile X tremor ataxia syndrome. 2014 , 23, 5906-15	20
787	A new cellular model of pathological TDP-43: The neurotoxicity of stably expressed CTF25 of TDP-43 depends on the proteasome. 2014 , 281, 88-98	20
786	Wild-type bone marrow transplant partially reverses neuroinflammation in progranulin-deficient mice. 2014 , 94, 1224-36	2
785	Progranulin transcripts with short and long 5' untranslated regions (UTRs) are differentially expressed via posttranscriptional and translational repression. 2014 , 289, 25879-89	18
784	Evolutionarily conserved heterogeneous nuclear ribonucleoprotein (hnRNP) A/B proteins functionally interact with human and <i>Drosophila</i> TAR DNA-binding protein 43 (TDP-43). 2014 , 289, 7121-7130	33
783	Deciphering genetic interactions between ALS genes using <i>C. elegans</i> . 2014 , 3, e29047	2
782	Partial loss of TDP-43 function causes phenotypes of amyotrophic lateral sclerosis. 2014 , 111, E1121-9	105
781	Reversible behavioral phenotypes in a conditional mouse model of TDP-43 proteinopathies. 2014 , 34, 15244-59	35
780	Reversing deleterious protein aggregation with re-engineered protein disaggregases. 2014 , 13, 1379-83	31
779	Disease causing mutants of TDP-43 nucleic acid binding domains are resistant to aggregation and have increased stability and half-life. 2014 , 111, 4309-14	51
778	The crystal structure of TDP-43 RRM1-DNA complex reveals the specific recognition for UG- and TG-rich nucleic acids. 2014 , 42, 4712-22	87
777	ER-mitochondria associations are regulated by the VAPB-PTPIP51 interaction and are disrupted by ALS/FTD-associated TDP-43. 2014 , 5, 3996	341
776	Astrocytic TDP-43 pathology in Alexander disease. 2014 , 34, 6448-58	51
775	TAR DNA-binding protein 43 pathology in Alzheimer's disease with psychosis. 2014 , 26, 987-94	8
774	Expression of one important chaperone protein, heat shock protein 27, in neurodegenerative diseases. 2014 , 6, 78	7

773	Analysis of microRNA from archived formalin-fixed paraffin-embedded specimens of amyotrophic lateral sclerosis. 2014 , 2, 173	25
772	A high-content screen identifies novel compounds that inhibit stress-induced TDP-43 cellular aggregation and associated cytotoxicity. 2014 , 19, 44-56	43
771	Inclusion body myositis: clinical review and current practice. 2014 , 11, 623-637	
770	A visual MRI atrophy rating scale for the amyotrophic lateral sclerosis-frontotemporal dementia continuum. 2014 , 15, 226-34	24
769	The underestimation of familial ALS and counseling patients with sporadic ALS. 2014 , 82, 13-4	2
768	TDP-43 regulates <i>Fladducin (Add2)</i> transcript stability. 2014 , 11, 1280-90	27
767	Aggregation properties of the small nuclear ribonucleoprotein U1-70K in Alzheimer disease. 2014 , 289, 35296-313	28
766	Atypical Alzheimer's disease in an elderly United States resident with amyotrophic lateral sclerosis and pathological tau in spinal motor neurons. 2014 , 15, 466-72	1
765	Confirmatory double-blind, parallel-group, placebo-controlled study of efficacy and safety of edaravone (MCI-186) in amyotrophic lateral sclerosis patients. 2014 , 15, 610-7	185
764	Theme 10 in vivo experimental models. 2014 , 15 Suppl 1, 179-96	
763	Methyl pyruvate rescues mitochondrial damage caused by SIGMAR1 mutation related to amyotrophic lateral sclerosis. 2014 , 1840, 3320-34	40
762	Hereditary spastic paraplegia is not associated with C9ORF72 repeat expansions in a Danish cohort. 2014 , 52, 77-9	4
761	Pu-erh tea extract induces the degradation of FET family proteins involved in the pathogenesis of amyotrophic lateral sclerosis. 2014 , 2014, 254680	16
760	RNA-processing protein TDP-43 regulates FOXO-dependent protein quality control in stress response. 2014 , 10, e1004693	30
759	Use of <i>Caenorhabditis elegans</i> as a model to study Alzheimer's disease and other neurodegenerative diseases. 2014 , 5, 279	158
758	TDP-43 causes differential pathology in neuronal versus glial cells in the mouse brain. 2014 , 23, 2678-93	21
757	Differential roles of the ubiquitin proteasome system and autophagy in the clearance of soluble and aggregated TDP-43 species. 2014 , 127, 1263-78	166
756	Roles of vascular endothelial growth factor in amyotrophic lateral sclerosis. 2014 , 2014, 947513	33

755	The tau tubulin kinases TTBK1/2 promote accumulation of pathological TDP-43. 2014 , 10, e1004803	64
754	Clinicopathologic report of ocular involvement in ALS patients with C9orf72 mutation. 2014 , 15, 569-80	19
753	Sequestration of multiple RNA recognition motif-containing proteins by C9orf72 repeat expansions. 2014 , 137, 2040-51	207
752	Differential motor neuron involvement in progressive muscular atrophy: a comparative study with amyotrophic lateral sclerosis. 2014 , 4, e005213	41
751	Heterogeneous nuclear ribonucleoproteins in amyotrophic lateral sclerosis: what do we know?. 2014 , 9, 173-185	1
750	TDP-43-The key to understanding amyotrophic lateral sclerosis. 2014 , 2, e944443	12
749	Genetik und Neurochemische Biomarker bei Amyotropher Lateralsklerose und Frontotemporaler Lobendegeneration. 2014 , 41, 239-247	5
748	Amyotrophic Lateral Sclerosis. 2019 , 322-346	1
747	Tau-mediated Disruption of the Spliceosome Triggers Cryptic RNA-splicing and Neurodegeneration in Alzheimer's Disease.	1
746	Notch Signaling: From Neurogenesis to Neurodegeneration. 2019 , 185-221	
745	SarkoSpin: A Technique for Biochemical Isolation and Characterization of Pathological TDP-43 Aggregates. 2019 , 9, e3424	1
744	White matter changes in the perforant path in patients with amyotrophic lateral sclerosis.	
743	Pleiotropic requirements for human TDP-43 in the regulation of cell and organelle homeostasis.	
742	The TMEM106B rs1990621 protective variant is also associated with increased neuronal proportion.	1
741	TDP-43 proteinopathy impairs neuronal mRNP granule mediated postsynaptic local translation and mRNA metabolism.	
740	Widespread FUS mislocalization is a molecular hallmark of ALS.	0
739	Cryo-EM Structures of Four Polymorphic TDP-43 Amyloid Cores.	1
738	Endogenous TDP-43 prevents retrotransposons activation through Dicer-2 activity and the RNA silencing machinery in Drosophila neurons.	

- 737 Stem cell-derived cranial and spinal motor neurons reveal proteostatic differences between ALS resistant and sensitive motor neurons.
- 736 TDP-43 Helical structure tunes liquid-liquid phase separation and function. 4
- 735 Natural and Pathogenic Protein Sequence Variation Affecting Prion-Like Domains Within and Across Human Proteomes.
- 734 Cdc48/VCP and endocytosis regulate TDP-43 and FUS toxicity and turnover.
- 733 Defining and predicting transdiagnostic categories of neurodegenerative disease.
- 732 Nucleocytoplasmic Proteomic Analysis Uncovers eRF1 and Nonsense Mediated Decay as Modifiers of ALS C9orf72 Toxicity.
- 731 Salience network atrophy links neuron type-specific pathobiology to loss of empathy in frontotemporal dementia.
- 730 Blood-spinal cord barrier leakage is independent of motor neuron pathology in ALS.
- 729 TDP-43 regulates the expression levels of Disc-large in skeletal muscles to promote the assemble of the neuromuscular synapses in Drosophila.
- 728 Deciphering the amyloid foldome of TDP-43
- 727 TDP-43 proteinopathy.
- 726 C9orf72-associated arginine-rich dipeptide repeats induce RNA-dependent accumulation of Staufen in nucleus.
- 725 Uncovering active modulators of native macroautophagy through novel high-content screens.
- 724 C9orf72 arginine-rich dipeptide repeat proteins disrupt importin mediated nuclear import. 0
- 723 Abnormal Local Translation in Dendrites Impairs Cognitive Functions in Neuropsychiatric Disorders. **2020**, 179-186
- 722 RNA-binding protein altered expression and mislocalization in multiple sclerosis.
- 721 Emerging Perspectives on DNA Double-strand Breaks in Neurodegenerative Diseases. **2019**, 17, 1146-1157 3
- 720 Chronic Traumatic Encephalopathy. **2020**, 399-419

719	Regional and hemispheric susceptibility of the temporal lobe to FTLD-TDP type C pathology.	
718	Redox-mediated regulation of a labile, evolutionarily conserved cross- β structure formed by the TDP43 low complexity domain.	
717	Genetic contributions to sporadic frontotemporal dementia. 2020 , 71-88	
716	Sirtuin-1 Sensitive Lysine-136 Acetylation Drives Phase Separation and Pathological Aggregation of TDP-43.	0
715	MRI-guided histology of TDP-43 knock-in mice implicates parvalbumin interneuron loss, impaired neurogenesis and aberrant neurodevelopment in ALS-FTD.	
714	Inclusion bodies formed by polyglutamine and poly(glycine-alanine) are enriched with distinct proteomes but converge in proteins that are risk factors for disease and involved in protein degradation.	
713	Amyotrophic lateral sclerosis associated mislocalisation of TDP-43 to the cytoplasm causes cortical hyperexcitability and reduced excitatory neurotransmission in the motor cortex.	
712	Effects of aging on protein expression in mice brain microvessels: ROS scavengers, mRNA/protein stability, glycolytic enzymes, mitochondrial complexes, and basement membrane components. 2021 , 1	2
711	Single Nucleotide Resolution RNA-Protein Cross-Linking Mass Spectrometry: A Simple Extension of the CLIR-MS Workflow. 2021 , 93, 14626-14634	1
710	SC75741, A Novel c-Abl Inhibitor, Promotes the Clearance of TDP25 Aggregates ATG5-Dependent Autophagy Pathway. 2021 , 12, 741219	0
709	Insights of Extracellular Vesicles of Mesenchymal Stem Cells: a Prospective Cell-Free Regenerative Medicine for Neurodegenerative Disorders. 2021 , 1	3
708	Regulation of Endoplasmic Reticulum-Mitochondria Tethering and Ca Fluxes by TDP-43 via GSK3 β 2021 , 22,	1
707	Diffusion MRI: Applications in the Brain. 2020 , 1, 605-636	
706	Hereditary inclusion-body myopathies. 2020 , 479-489	
705	The neuroprotective effects of activated $\alpha 7$ nicotinic acetylcholine receptor against mutant copper-zinc superoxide dismutase 1-mediated toxicity. 2020 , 10, 22157	0
704	TDP-43-specific Autoantibody Decline in Patients With Amyotrophic Lateral Sclerosis. 2021 , 8,	4
703	Stabilization and ATP-binding for tandem RRM domains of ALS-causing TDP-43 and hnRNPA1.	
702	Psychiatric Disorders in Dementia. 2021 , 317-385	

- 701 Traumatic and Degenerative Hypothalamic Diseases. **2021**, 479-495
- 700 Machine learning suggests polygenic risk for cognitive dysfunction in amyotrophic lateral sclerosis. **2021**, 13, e12595 3
- 699 Regulation of autophagy by TDP-43. **2022**, 81-95
- 698 TDP-43 proteinopathy mechanisms from non-mammalian model systems. **2022**, 153-181
- 697 New opportunities for treatment of neurodegenerative disease through the modulation of TDP-43. **2022**, 183-250 0
- 696 Prion-like behavior of TDP-43 aggregates and its implication to disease. **2022**, 97-115
- 695 TDP-43 and neurodegenerative diseases. **2022**, 1-26
- 694 Structural dissection of TDP-43. **2022**, 27-44
- 693 Posttranslational modifications of TDP-43. **2022**, 45-79
- 692 Neuropathological fingerprints of survival, atrophy and language in primary progressive aphasia.. **2022**, 0
- 691 Granulins modulate liquid-liquid phase separation and aggregation of TDP-43 C-terminal domain.
- 690 An Autopsy-Proven Case of Limbic-Predominant Age-Related TDP-43 Encephalopathy. **2020**, 61, 731-735 0
- 689 Linking amyotrophic lateral sclerosis and frontotemporal dementia. **2020**, 49-59
- 688 Transcranial magnetic stimulation in the cortical exploration of dementia. **2020**, 327-343 0
- 687 Motoneuronerkrankungen. **2020**, 153-177
- 686 Beatmung bei neuromuskulären Erkrankungen. **2020**, 193-246
- 685 Quantitative Nucleocytoplasmic Transport Assays in Cellular Models of Neurodegeneration. **2020**, 10, e3659 2
- 684 The Cerebral Cortex and Complex Cerebral Functions. **2020**, 831-952

683	Phe-Gly motifs drive fibrillization of TDP-43 ^E prion-like domain droplets.	
682	Induction Of Chronic Stress Reveals An Interplay Of Stress Granules And TDP-43 Pathological Aggregates In Human ALS Fibroblasts And iPSC-Neurons.	
681	Regulation of liquid-liquid phase separation with focus on post-translational modifications. 2021 , 57, 13275-13287	7
680	A conserved role for SFPQ in repression of pathogenic cryptic last exons.	
679	Role ofCNC1gene in TDP-43 aggregation-induced oxidative stress-mediated cell death inS. cerevisiaemodel of ALS.	
678	Therapeutic genetic variation revealed in diverse Hsp104 homologs.	1
677	Reduction of Nemo-like kinase increases lysosome biogenesis and ameliorates TDP-43-related neurodegeneration.	1
676	Proteostasis deregulation as a driver of C9ORF72 pathogenesis. 2021 , 159, 941	1
675	How do protein domains of low sequence complexity work?. 2021 ,	1
674	Neurodegenerative Diseases and Cholesterol: Seeing the Field Through the Players. 2021 , 13, 766587	2
673	Endocannabinoid Metabolism and Traumatic Brain Injury. 2021 , 10,	0
672	Neuropathology of Alzheimer's Disease. 2021 ,	11
671	Tau-tubulin kinase 1 phosphorylates TDP-43 at disease-relevant sites and exacerbates TDP-43 pathology. 2021 , 161, 105548	1
670	Single-cell Transcriptional Changes in Neurodegenerative Diseases. 2021 , 479, 192-205	2
669	Leading individual features of antioxidant systematically classified by the ORAC assay and its single electron transfer and hydrogen atom transfer reactivities; analyzing ALS therapeutic drug Edaravone. 2021 , 1, 100030	1
668	Dysfunction of RNA/RNA-Binding Proteins in ALS Astrocytes and Microglia. 2021 , 10,	0
667	Plasma neurofilament light protein correlates with diffusion tensor imaging metrics in frontotemporal dementia.	
666	TDP-43 proteinopathy alters the ribosome association of multiple mRNAs including the glypican Dally-like protein (Dlp)/GPC6.	

- 665 Tryptophan residues in TDP-43 and SOD1 mediate the cross-seeding and toxicity of SOD1.
- 664 Molecular Network Analysis of Target RNAs and Interacting Proteins of TDP-43, a Causative Gene for the Neurodegenerative Diseases ALS/FTLD. 314-335
- 663 Molecular Network Analysis of Target RNAs and Interacting Proteins of TDP-43, a Causative Gene for the Neurodegenerative Diseases ALS/FTLD. 964-985
- 662 Neurodegenerative dementia and Parkinsonism.
- 661 Novel Proteins in β Synucleinopathies. **2009**, 207-224
- 660 DNAJB chaperones inhibit aggregation of destabilised proteins via a C-terminal region distinct from that used to prevent amyloid formation.
- 659 ATP biphasically modulates LLPS of TDP-43 PLD by specifically binding arginine residues. 0
- 658 In Vivo Validation of Bimolecular Fluorescence Complementation (BiFC) to Investigate Aggregate Formation in Amyotrophic Lateral Sclerosis (ALS).
- 657 Hsp90 and its co-chaperone Sti1 control TDP-43 misfolding and toxicity. 0
- 656 Amyotrophic Lateral Sclerosis and Other Motor Neuron Diseases. **2020**, 26, 1323-1347 2
- 655 TDP-43 stabilizes transcripts encoding stress granule protein G3BP1: potential relevance to ALS/FTD. 0
- 654 NMJ-Analyser: high-throughput morphological screening of neuromuscular junctions identifies subtle changes in mouse neuromuscular disease models.
- 653 AIImaging in Aging, Alzheimer's Disease, and Other Neurodegenerative Conditions. **2021**, 283-343
- 652 Amyotrophic Lateral Sclerosis. **2021**, 759-781
- 651 Different RNA profiles in plasma derived small and large extracellular vesicles of Neurodegenerative diseases patients.
- 650 Sleep in Amyotrophic Lateral Sclerosis. **2021**, 243-253
- 649 Exosomes in Neurodegenerative Disorders. **2021**, 183-206
- 648 Neurofilament Light Chain Related to Longitudinal Decline in Frontotemporal Lobar Degeneration. **2021**, 11, 105-116 2

647	Amyotrophic lateral sclerosis and frontotemporal lobar degeneration. 209-248	2
646	CHAPTER 7. Neuroinflammation and Oxidative Stress in Models of Parkinson's Disease and Protein-Misfolding Disorders. 184-209	1
645	Neuropathology of non-Alzheimer degenerative disorders. 2009 , 3, 1-23	63
644	Cytoplasmic inclusions of TDP-43 in neurodegenerative diseases: a potential role for caspases. 2009 , 24, 1081-6	9
643	Caspase-cleaved TAR DNA-binding protein-43 in Pick's disease. 2009 , 1, 25-32	7
642	Genetics and biology of Alzheimer's disease and frontotemporal lobar degeneration. 2010 , 3, 129-43	16
641	TDP-43 in aging and Alzheimer's disease - a review. 2011 , 4, 147-55	112
640	Nuclear transport, oxidative stress, and neurodegeneration. 2011 , 4, 215-29	75
639	Diagnostic value of markers of muscle degeneration in sporadic inclusion body myositis. 2011 , 30, 103-8	37
638	TARDBP mutations are not a frequent cause of ALS in Finnish patients. 2012 , 31, 134-8	8
637	C9ORF72 hexanucleotide repeats in behavioral and motor neuron disease: clinical heterogeneity and pathological diversity. 2014 , 3, 1-18	20
636	Somatic complaints in frontotemporal dementia. 2014 , 3, 84-92	11
635	Physiological protein aggregation run amuck: stress granules and the genesis of neurodegenerative disease. 2014 , 17, 47-52	49
634	Overexpression of , , improves motor neuron degeneration induced by knockdown of , . 2018 , 7, 11-31	7
633	Unravelling the mysteries of frontotemporal dementia. 2013 , 110, 411-6	
632	Gamma-Carbolines Derivatives As Promising Agents for the Development of Pathogenic Therapy for Proteinopathy. 2018 , 10, 59-62	1
631	Amyotrophic lateral sclerosis with appearance of many skein-like inclusions in anterior horn cells. 2019 , 12, 4156-4161	
630	Ataxin-2 Dysregulation Triggers a Compensatory Fragile X Mental Retardation Protein Decrease in C4da Neurons. 2020 , 43, 870-879	2

629	Neurodegeneration and axonal mRNA transportation. 2021 , 10, 1-12	1
628	RNA-Based Therapies for Neurodegenerative Diseases. 2021 , 118, 340-345	
627	miR-23a suppression accelerates functional decline in the rNLS8 mouse model of TDP-43 proteinopathy. 2021 , 162, 105559	1
626	The panoramic view of amyotrophic lateral sclerosis: A fatal intricate neurological disorder. 2021 , 288, 120156	4
625	A Novel Four-Gene Prognostic Signature for Prediction of Survival in Patients with Soft Tissue Sarcoma. 2021 , 13,	1
624	The Role of Nucleocytoplasmic Transport Defects in Amyotrophic Lateral Sclerosis. 2021 , 22,	3
623	Specific RNA interactions promote TDP-43 multivalent phase separation and maintain liquid properties. 2021 , 22, e53632	11
622	A Novel TFG Mutation in a Korean Family with β Synucleinopathy and Amyotrophic Lateral Sclerosis. 2021 ,	1
621	Mitochondrial Quality Control Strategies: Potential Therapeutic Targets for Neurodegenerative Diseases?. 2021 , 15, 746873	4
620	Nearly 30 Years of Animal Models to Study Amyotrophic Lateral Sclerosis: A Historical Overview and Future Perspectives. 2021 , 22,	6
619	Enrichment of alleles encoding variants with constitutively hyperactive NADase in patients with ALS and other motor nerve disorders. 2021 , 10,	8
618	Inflammasome activation in neurodegenerative diseases. 2021 ,	5
617	Antibody-Based Therapeutic Interventions for Amyotrophic Lateral Sclerosis: A Systematic Literature Review.. 2021 , 15, 790114	1
616	Mitochondria Dysfunction in Frontotemporal Dementia/Amyotrophic Lateral Sclerosis: Lessons From Models.. 2021 , 15, 786076	0
615	Unexpected postmortem diagnoses in cases of clinically diagnosed amyotrophic lateral sclerosis. 2021 , 41, 457	0
614	TBK1 haploinsufficiency results in changes in the K63-ubiquitination profiles in brain and fibroblasts from affected and presymptomatic mutation carriers. 2021 , 1	1
613	Concurrent tau pathologies in frontotemporal lobar degeneration with TDP-43 pathology. 2021 ,	0
612	Axonal TDP-43 condensates drive neuromuscular junction disruption through inhibition of local synthesis of nuclear encoded mitochondrial proteins. 2021 , 12, 6914	7

611	TDP-43 and HERV-K Envelope-Specific Immunogenic Epitopes Are Recognized in ALS Patients. 2021 , 13,	1
610	FTLD-TDP assemblies seed neoaggregates with subtype-specific features via a prion-like cascade. 2021 , 22, e53877	2
609	New perspectives on cytoskeletal dysregulation and mitochondrial mislocalization in amyotrophic lateral sclerosis. 2021 , 10, 46	4
608	Metals in ALS TDP-43 Pathology. 2021 , 22,	2
607	Stage-specific control of oligodendrocyte survival and morphogenesis by TDP-43.	
606	Neuropathologie de la sclérose latérale amyotrophique sporadique. 2021 , 12, 267-276	
605	Parkin beyond Parkinson's Disease-A Functional Meaning of Parkin Downregulation in TDP-43 Proteinopathies.. 2021 , 10,	1
604	Advancing mechanistic understanding and biomarker development in amyotrophic lateral sclerosis. 2021 , 1-18	1
603	Oligodendrocytes are a lifelong source of nuclear and ribosomal material for neurons in the mouse brain.	
602	Parkinsonsyndrome: Fallstricke bei der Diagnose.	1
601	MicroRNA biomarkers in frontotemporal dementia and to distinguish from Alzheimer's disease and amyotrophic lateral sclerosis.. 2022 , 17, 1412-1422	0
600	Mass Spectrometry-Based Proteomic Analysis in Neurodegenerative Disorders[Research. 2022 , 1-22	
599	TDP-43 Cytoplasmic Translocation in the Skin Fibroblasts of ALS Patients.. 2022 , 11,	0
598	USP10 inhibits aberrant cytoplasmic aggregation of TDP-43 by promoting stress granule clearance.. 2022 , MCB0039321	0
597	Human stem cell models of neurodegeneration: From basic science of amyotrophic lateral sclerosis to clinical translation.. 2022 , 29, 11-35	6
596	Therapeutic promise of carotenoids as antioxidants and anti-inflammatory agents in neurodegenerative disorders.. 2022 , 146, 112610	5
595	Genetic architecture of motor neuron diseases.. 2021 , 434, 120099	2
594	Aberrant TDP-43 phosphorylation: a key wind gap from TDP-43 to TDP-43 proteinopathy. 2021 , 7, 119-131	

593	Pathological phase transitions in ALS-FTD impair dynamic RNA-protein granules. 2021 ,	1
592	Genome Editing Technology for the Study and Correction of Neurodegenerative Diseases. 2021 , 15, 339-352	
591	A chemogenomic approach is required for effective treatment of amyotrophic lateral sclerosis.. 2022 , 12, e657	0
590	Identifying Candidate Genes Associated with Sporadic Amyotrophic Lateral Sclerosis via Integrative Analysis of Transcriptome-Wide Association Study and Messenger RNA Expression Profile.. 2022 , 1	
589	Regulation of Neurodegeneration-associated Protein Fragments by the N-degron Pathways.. 2022 , 40, 298-318	0
588	Brain TDP-43 pathology in corticobasal degeneration: topographical correlation with neuronal loss.. 2021 ,	1
587	Matrin3: Disorder and ALS Pathogenesis.. 2021 , 8, 794646	2
586	Microglia influence neurofilament deposition in ALS iPSC-derived motor neurons.	1
585	Hippocampal protein aggregation signatures fully distinguish pathogenic and wildtype UBQLN2 in amyotrophic lateral sclerosis.	0
584	Testing of the therapeutic efficacy and safety of AMPA receptor RNA aptamers in an ALS mouse model.. 2022 , 5,	
583	Military traumatic brain injury: a challenge straddling neurology and psychiatry.. 2022 , 9, 2	0
582	Loss of TDP-43 function and rimmed vacuoles persist after T cell depletion in a xenograft model of sporadic inclusion body myositis.. 2022 , 14, eabi9196	1
581	Genome-wide identification of the genetic basis of amyotrophic lateral sclerosis.. 2022 ,	8
580	Neurodegenerative disease by SRS microscopy. 2022 , 501-514	
579	TDP-43 Proteinopathy Causes Broad Metabolic Alterations including TCA Cycle Intermediates and Dopamine Levels in Drosophila Models of ALS.. 2022 , 12,	1
578	Protein synthesis modulation as a therapeutic approach for amyotrophic lateral sclerosis and frontotemporal dementia.. 2022 , 17, 1423-1430	0
577	Multiple Molecular Pathways Are Influenced by Progranulin in a Neuronal Cell Model-A Parallel Omics Approach.. 2021 , 15, 775391	1
576	Disruption of ER-mitochondria tethering and signalling in C9orf72-associated amyotrophic lateral sclerosis and frontotemporal dementia.. 2022 , e13549	4

575	Advances in Proteomic and Metabolomic Profiling of Neurodegenerative Diseases.. 2021 , 12, 792227	1
574	Genetic testing in motor neurone disease.. 2022 ,	3
573	TDP-43 pathology: from noxious assembly to therapeutic removal.. 2022 , 102229	0
572	Cancer diagnosis is associated with a lower burden of dementia and less Alzheimer's-type neuropathology.. 2022 ,	2
571	Advances in Deep Neuropathological Phenotyping of Alzheimer Disease: Past, Present, and Future.. 2022 ,	1
570	Pathophysiological Underpinnings of Extra-Motor Neurodegeneration in Amyotrophic Lateral Sclerosis: New Insights From Biomarker Studies.. 2021 , 12, 750543	0
569	Tau mRNA Metabolism in Neurodegenerative Diseases: A Tangle Journey.. 2022 , 10,	0
568	Microglia Influence Neurofilament Deposition in ALS iPSC-Derived Motor Neurons.. 2022 , 13,	1
567	Emerging Connections between Nuclear Pore Complex Homeostasis and ALS.. 2022 , 23,	0
566	Neurodegenerative Disease-Associated TDP-43 Fragments Are Extracellularly Secreted with CASA Complex Proteins.. 2022 , 11,	1
565	An ALS-associated variant of the autophagy receptor SQSTM1/p62 reprograms binding selectivity towards the autophagy-related hATG8 proteins.. 2021 , 101514	0
564	Liquid-Liquid Phase Separation of TDP-43 and FUS in Physiology and Pathology of Neurodegenerative Diseases.. 2022 , 9, 826719	3
563	Amyloid fibrils in frontotemporal lobar degeneration with TDP-43 inclusions are composed of TMEM106B, rather than TDP-43.	
562	Disease-linked TDP-43 hyperphosphorylation suppresses TDP-43 condensation and aggregation.. 2022 , e108443	7
561	The amyloid state of proteins: A boon or bane?. 2022 , 200, 593-617	0
560	TDP-43-associated atrophy in brains with and without frontotemporal lobar degeneration.. 2022 , 34, 102954	0
559	TDP-43 Pathology and Prionic Behavior in Human Cellular Models of Alzheimer's Disease Patients.. 2022 , 10,	0
558	Cortical Hyperexcitability in the Driver's Seat in ALS. 2022 , 6, 5	

557	Modeling seeding and neuroanatomic spread of pathology in amyotrophic lateral sclerosis.. 2022 , 251, 118968	0
556	RNA-assisted sequestration of RNA-binding proteins by cytoplasmic inclusions of the C-terminal 35-kDa fragment of TDP-43.. 2022 ,	0
555	Molecular determinants and modifiers of Matrin-3 toxicity, condensate dynamics, and droplet morphology.. 2022 , 25, 103900	2
554	Flexibility of brain dynamics predicts clinical impairment in Amyotrophic Lateral Sclerosis.	0
553	Different saccadic profile in bulbar versus spinal-onset amyotrophic lateral sclerosis.. 2022 ,	1
552	Limbic-Predominant Age-Related TDP-43 Encephalopathy: Medical and Pathologic Factors Associated With Comorbid Hippocampal Sclerosis.. 2022 ,	0
551	Tau Ubiquitination in Alzheimer's Disease.. 2021 , 12, 786353	1
550	The severity of behavioural symptoms in FTD is linked to the loss of GABRQ-expressing VENs and pyramidal neurons.. 2022 ,	0
549	Endoplasmic reticulum-mitochondria signaling in neurons and neurodegenerative diseases.. 2022 , 135,	4
548	Computational strategies to identify new drug candidates against neuroinflammation.. 2022 ,	1
547	Low-level overexpression of wild type TDP-43 causes late-onset, progressive neurodegeneration and paralysis in mice.. 2022 , 17, e0255710	1
546	Suppression of premature transcription termination leads to reduced mRNA isoform diversity and neurodegeneration.. 2022 ,	2
545	Small molecule v-ATPase inhibitor Etidronate lowers levels of ALS protein ataxin-2.	
544	Structure of pathological TDP-43 filaments from ALS with FTLD. 2021 ,	16
543	Human neural networks with sparse TDP-43 pathology reveal NPTX2 misregulation in ALS/FTLD.	1
542	Proteinopathies as Hallmarks of Impaired Gene Expression, Proteostasis and Mitochondrial Function in Amyotrophic Lateral Sclerosis.. 2021 , 15, 783624	1
541	Aetiology and pathophysiology of neurodegenerative disorders. 2022 , 1-16	
540	Detecting Stress Granules in Drosophila Neurons.. 2022 , 2428, 229-242	

539	Targeting DNA topoisomerases or checkpoint kinases results in an overload of chaperone systems, triggering aggregation of a metastable subproteome.. 2022 , 11,	3
538	Biomarkers in Human Peripheral Blood Mononuclear Cells: The State of the Art in Amyotrophic Lateral Sclerosis.. 2022 , 23,	1
537	Glycogen Synthase Kinase 3 Involvement in Neuroinflammation and Neurodegenerative Diseases.. 2022 ,	1
536	Mechanism underlying a risk gene in neurodegeneration.. 2022 , 603, 33-34	1
535	Extracellular Vesicles Derived From Plasma of Patients With Neurodegenerative Disease Have Common Transcriptomic Profiling.. 2022 , 14, 785741	2
534	TDP-43 loss and ALS-risk SNPs drive mis-splicing and depletion of UNC13A.. 2022 , 603, 131-137	14
533	TDP-43 represses cryptic exon inclusion in the FTD-ALS gene UNC13A.. 2022 ,	14
532	The Role of VCP Mutations in the Spectrum of Amyotrophic Lateral Sclerosis-Frontotemporal Dementia.. 2022 , 13, 841394	0
531	Partners in crime: Proteins implicated in RNA repeat expansion diseases.. 2022 , e1709	0
530	TDP-43 promotes tau accumulation and selective neurotoxicity in bigenic <i>C. elegans</i> .. 2022 ,	2
529	Proximity proteomics of C9orf72 dipeptide repeat proteins identifies molecular chaperones as modifiers of poly-GA aggregation.. 2022 , 10, 22	2
528	Biomarker discovery and development for frontotemporal dementia and amyotrophic lateral sclerosis.. 2022 ,	0
527	Emerging Roles for Phase Separation of RNA-Binding Proteins in Cellular Pathology of ALS.. 2022 , 10, 840256	1
526	RNA targets of TDP-43: Which one is more important in neurodegeneration?. 2022 , 11, 12	
525	Selective Loss of MATR3 in Spinal Interneurons, Upper Motor Neurons and Hippocampal CA1 Neurons in a MATR3 S85C Knock-In Mouse Model of Amyotrophic Lateral Sclerosis.. 2022 , 11,	1
524	ALS monocyte-derived microglia-like cells reveal cytoplasmic TDP-43 accumulation, DNA damage, and cell-specific impairment of phagocytosis associated with disease progression.. 2022 , 19, 58	4
523	Frontotemporal Dementia and Glucose Metabolism.. 2022 , 16, 812222	0
522	Stress induced TDP-43 mobility loss independent of stress granules.	

521	TAR DNA-binding protein 43 oligomers in physiology and pathology.. 2022,	0
520	Therapeutic modulation of GSTO activity rescues FUS-associated neurotoxicity via deglutathionylation in ALS disease models.. 2022,	1
519	Dysregulation of Translation in TDP-43 Proteinopathies: Deficits in the RNA Supply Chain and Local Protein Production.. 2022, 16, 840357	1
518	Markers of cognitive resilience and a framework for investigating clinical heterogeneity in ALS.. 2022,	
517	Intracellular Energy Controls Dynamics of Stress-induced Ribonucleoprotein Granules.	
516	John Q. Trojanowski.. 2022,	0
515	Body Complexion and Circulating Lipids in the Risk of TDP-43 Related Disorders.. 2022, 14, 838141	1
514	A tribute to John Q. Trojanowski (1946-2022), neuropathologist extraordinaire.. 2022, e13066	0
513	Uncovering Essential Tremor Genetics: The Promise of Long-Read Sequencing.. 2022, 13, 821189	2
512	New developments of biofluid-based biomarkers for routine diagnosis and disease trajectories in frontotemporal dementia.. 2022,	2
511	Identification of multiple TAR DNA binding protein retropseudogene lineages during the evolution of primates.. 2022, 12, 3823	
510	Network Theoretical Approach to Explore Factors Affecting Signal Propagation and Stability in Dementia's Protein-Protein Interaction Network.. 2022, 12,	1
509	Loss of mouse Stmn2 function causes motor neuropathy.. 2022,	2
508	Impaired glymphatic function in the early stages of disease in a TDP-43 mouse model of amyotrophic lateral sclerosis.. 2022, 11, 17	2
507	Improper Proteostasis: Can It Serve as Biomarkers for Neurodegenerative Diseases?. 2022, 1	
506	Frontotemporal Lobar Degeneration Case with an N-Terminal Mutation Exhibits Reduced TUBA4A Levels in the Brain and TDP-43 Pathology.. 2022, 12,	
505	Amyloid fibrils in disease FTL-DTP are composed of TMEM106B not TDP-43.. 2022,	5
504	Sirtuin-1 sensitive lysine-136 acetylation drives phase separation and pathological aggregation of TDP-43.. 2022, 13, 1223	0

503	Chemical and genetic screens identify new regulators of tetracycline-inducible gene expression system in mammalian cells.	
502	Motor neuron TDP-43 proteinopathy in progressive supranuclear palsy and corticobasal degeneration.. 2022 ,	0
501	The Multifaceted Neurotoxicity of Astrocytes in Ageing and Age-Related Neurodegenerative Diseases: A Translational Perspective.. 2022 , 13, 814889	1
500	Proteomic characterization of spinal cord synaptoneurosomes from Tg-SOD1/G93A mice supports a role for MNK1 and local translation in the early stages of amyotrophic lateral sclerosis.	
499	Casein Kinase 1 Inhibitors as Promising Therapeutic Agents for Neurodegenerative Disorders.. 2022 ,	1
498	John Q. Trojanowski: neuropathology icon.. 2022 , 143, 419-425	0
497	Physiological tissue-specific and age-related reduction of mouse TDP-43 levels is regulated by epigenetic modifications.. 2022 ,	0
496	New pathogenic insights from large animal models of neurodegenerative diseases.. 2022 , 1	1
495	Small but Mighty-Exosomes, Novel Intercellular Messengers in Neurodegeneration.. 2022 , 11,	0
494	Modelling amyotrophic lateral sclerosis in rodents.. 2022 ,	1
493	Stage-specific control of oligodendrocyte survival and morphogenesis by TDP-43.. 2022 , 11,	1
492	Spatial sequestration of misfolded proteins in neurodegenerative diseases.. 2022 ,	1
491	Solving neurodegeneration: common mechanisms and strategies for new treatments.. 2022 , 17, 23	5
490	Seed amplification and RT-QuIC assays to investigate protein seed structures and strains.. 2022 , 1	0
489	ALS sensitive spinal motor neurons enter a degenerative downward spiral of impaired splicing and proteostasis.	0
488	ALS-linked KIF5A Exon27 mutant causes neuronal toxicity through gain of function.	0
487	Proteomic analysis of heat-stable proteins revealed an increased proportion of proteins with compositionally biased regions.. 2022 , 12, 4347	0
486	Apolipoprotein E proteinopathy is a major dementia-associated pathologic biomarker in individuals with or without the APOE epsilon 4 allele.. 2021 ,	0

485	Genotype-phenotype association of TARDBP mutations in Chinese patients with amyotrophic lateral sclerosis: a single-center study and systematic review of published literature.. 2022 , 1	1
484	John Q. Trojanowski, MD, PhD (1946-2022).. 2022 , 110, 1095-1096	0
483	A mouse model with widespread expression of the C9orf72-linked glycine-arginine dipeptide displays non-lethal ALS/FTD-like phenotypes.. 2022 , 12, 5644	0
482	Chaperone-Mediated Autophagy in Neurodegenerative Diseases and Acute Neurological Insults in the Central Nervous System.. 2022 , 11,	2
481	InFUSing antisense oligonucleotides for treating ALS.. 2022 ,	0
480	An unexpected protein aggregate in diseased and ageing brains.. 2022 ,	
479	Cell environment shapes TDP-43 function with implications in neuronal and muscle disease.. 2022 , 5, 314	1
478	West Nile Virus Neuroinfection in Humans: Peripheral Biomarkers of Neuroinflammation and Neuronal Damage.. 2022 , 14,	0
477	Patterns of amygdala region pathology in LATE-NC: subtypes that differ with regard to TDP-43 histopathology, genetic risk factors, and comorbid pathologies.. 2022 , 1	1
476	Neuroprotection by Mucuna pruriens in Neurodegenerative Diseases.. 2022 , 1	0
475	Mass Spectrometry for Neurobiomarker Discovery: The Relevance of Post-Translational Modifications.. 2022 , 11,	0
474	Deciphering the prion-like behavior of pathogenic protein aggregates in neurodegenerative diseases.. 2022 , 155, 105307	1
473	Phases of volume loss in patients with known frontotemporal lobar degeneration spectrum pathology.. 2022 , 113, 95-107	0
472	Invited review: Unearthing the mechanisms of age-related neurodegenerative disease using Caenorhabditis elegans.. 2022 , 267, 111166	0
471	TDP-43 is a ubiquitylation substrate of the SCF complex.. 2022 , 105673	3
470	The molecular mechanisms that drive intracellular neutralization by the antibody-receptor and RING E3 ligase TRIM21. 2021 ,	0
469	Increased levels of TAR DNA-binding protein 43 in the hippocampus of subjects with bipolar disorder: a postmortem study.. 2021 ,	
468	Meta-analysis of human and mouse ALS astrocytes reveals multi-omic signatures of inflammatory reactive states.. 2021 ,	5

467	TDP-43 Pathology in Alzheimer's Disease.. 2021 , 16, 84	8
466	Random forest modelling of neuropathological features identifies microglial activation as an accurate pathological classifier of C9orf72-related amyotrophic lateral sclerosis.	
465	Pathological manifestation of human endogenous retrovirus K in frontotemporal dementia.. 2021 , 1,	1
464	TREM2 interacts with TDP-43 and mediates microglial neuroprotection against TDP-43-related neurodegeneration.. 2021 ,	8
463	Drosophila as a model to study autophagy in neurodegenerative diseases and digestive tract. 2021 ,	1
462	Neuroinflammation in Amyotrophic Lateral Sclerosis and Frontotemporal Dementia and the Interest of Induced Pluripotent Stem Cells to Study Immune Cells Interactions With Neurons.. 2021 , 14, 767041	3
461	Genetically modified large animal models for investigating neurodegenerative diseases.. 2021 , 11, 218	2
460	Emerging Mechanisms Underpinning Neurophysiological Impairments in Repeat Expansion-Mediated Amyotrophic Lateral Sclerosis/Frontotemporal Dementia.. 2021 , 15, 784833	0
459	New lessons on TDP-43 from old N. furzeri killifish.. 2021 , e13517	1
458	Transcriptomic analysis of frontotemporal lobar degeneration with TDP-43 pathology reveals cellular alterations across multiple brain regions.. 2021 , 143, 383	0
457	Amyotrophic Lateral Sclerosis: A Diet Review.. 2021 , 10,	0
456	Aggregates of TDP-43 protein spiral into view. 2021 ,	0
455	Functional Anatomy of the TDP-43 Redox Sensor.	
454	Novel and known transcriptional targets of ALS/FTD protein TDP-43: Meta-analysis and interactive graphical databases.	
453	SQSTM1-mediated clearance of cytoplasmic mutant TARDBP/TDP-43 in the monkey brain.. 2021 , 1-14	3
452	Distinct characteristics of limbic-predominant age-related TDP-43 encephalopathy in Lewy body disease. 2021 , 143, 15	2
451	A Deletion of the Nuclear Localization Signal Domain in the Fus Protein Induces Stable Post-stress Cytoplasmic Inclusions in SH-SY5Y Cells.. 2021 , 15, 759659	0
450	Synapse-associated astrocyte mitochondria stabilize motor circuits to prevent excitotoxicity.	

449	A cryo-ET survey of microtubules and intracellular compartments in mammalian axons. 2022 , 221,	7
448	Frontotemporal lobar degeneration with TAR DNA-binding protein 43 (TDP-43): its journey of more than 100 years.. 2022 , 1	0
447	Peripheral Pathways to Neurovascular Unit Dysfunction, Cognitive Impairment, and Alzheimer's Disease.. 2022 , 14, 858429	0
446	TDP-43 Oligomerization and Phase Separation Properties Are Necessary for Autoregulation.. 2022 , 16, 818655	1
445	Pathogenic Extracellular Vesicle (EV) Signaling in Amyotrophic Lateral Sclerosis (ALS).. 2022 , 1	2
444	The Multifaceted Role of GPCRs in Amyotrophic Lateral Sclerosis: A New Therapeutic Perspective?. 2022 , 23,	0
443	Neuronal activity regulates Matrin 3 levels and function in a calcium-dependent manner through calpain cleavage and calmodulin binding.	
442	Proteomic characterization of post-mortem human brain tissue following ultracentrifugation-based subcellular fractionation.	1
441	Eye Movement Abnormalities in Amyotrophic Lateral Sclerosis.. 2022 , 12,	1
440	BAG6 prevents the aggregation of neurodegeneration-associated fragments of TDP43.. 2022 , 25, 104273	0
439	Gel-like inclusions of C-terminal fragments of TDP-43 sequester stalled proteasomes in neurons.. 2022 , e53890	1
438	Overexpression of progranulin increases pathological protein accumulation by suppressing autophagic flux.. 2022 , 611, 78-84	0
437	Data_Sheet_1.pdf. 2020 ,	
436	Image_1.TIF. 2018 ,	
435	Data_Sheet_1.PDF. 2018 ,	
434	Table_1.DOCX. 2020 ,	
433	Table_2.DOCX. 2020 ,	
432	Data_Sheet_1.docx. 2019 ,	

431 DataSheet1.ZIP. **2018,**

430 Presentation1.pdf. **2018,**

429 Table_1.DOCX. **2020,**

428 Data_Sheet_1.docx. **2018,**

427 Table_1.docx. **2018,**

426 Presentation1.pdf. **2018,**

425 Table_1.XLSX. **2018,**

424 Table_1.PDF. **2020,**

423 Data_Sheet_1.docx. **2018,**

422 Data_Sheet_2.xlsx. **2018,**

421 Data_Sheet_1.PDF. **2019,**

420 Table_1.docx. **2019,**

419 Data_Sheet_1.PDF. **2019,**

418 Image_1.TIF. **2020,**

417 Image_2.TIF. **2020,**

416 Image_3.TIF. **2020,**

415 Image_4.JPEG. **2020,**

414 Image_5.JPEG. **2020,**

413	Image_6.TIF. 2020 ,	
412	Image_7.TIF. 2020 ,	
411	Image_8.TIF. 2020 ,	
410	Table_1.DOCX. 2020 ,	
409	Data_Sheet_1.docx. 2019 ,	
408	How can we interpret the relationship between liquid-liquid phase separation and amyotrophic lateral sclerosis?. 2022 ,	0
407	Aptamers Targeting Hallmark Proteins of Neurodegeneration.. 2022 ,	0
406	The tauopathies: Neuroimaging characteristics and emerging experimental therapies.. 2022 ,	
405	Macroscopic findings of brain with dementia.. 2022 ,	2
404	Metal content and kinetic properties of yeast RNA lariat debranching enzyme.. 2022 ,	2
403	Frontotemporal dementia-associated protein "phosphorylated TDP-43" localizes to atherosclerotic lesions of human carotid and main cerebral arteries. 2020 , 35, 159-167	1
402	Phosphorylated TDP-43 localizes to chronic cerebral infarctions in human brains. 2020 , 35, 1023-1028	0
401	Defects of Nutrient Signaling and Autophagy in Neurodegeneration.. 2022 , 10, 836196	1
400	Nuclear pore complexes - a doorway to neural injury in neurodegeneration.. 2022 ,	0
399	Computational Insights of Unfolding of N-Terminal Domain of TDP-43 Reveal the Conformational Heterogeneity in the Unfolding Pathway.. 2022 , 15, 822863	3
398	Advanced Gene-Targeting Therapies for Motor Neuron Diseases and Muscular Dystrophies.. 2022 , 23,	1
397	Entorhinal Subfield Vulnerability to Neurofibrillary Tangles in Aging and the Preclinical Stage of Alzheimer's Disease.. 2022 ,	0
396	Proteostasis Perturbations and Their Roles in Causing Sterile Inflammation and Autoinflammatory Diseases.. 2022 , 11,	0

395	Charge and Redox States Modulate Granulin-TDP-43 Coacervation Toward Phase Separation or Aggregation.. 2022,	0
394	Singling out motor neurons in the age of single-cell transcriptomics.. 2022,	1
393	Molecular Biomarkers and Their Implications for the Early Diagnosis of Selected Neurodegenerative Diseases.. 2022, 23,	1
392	Glymphatic System Dysfunction in Central Nervous System Diseases and Mood Disorders.. 2022, 14, 873697	0
391	Correlation of Ferroptosis and Other Types of Cell Death in Neurodegenerative Diseases.. 2022, 1	1
390	Cellular Stress Induces Nucleocytoplasmic Transport Deficits Independent of Stress Granules. 2022, 10, 1057	
389	Sequence Determinants of TDP-43 Ribonucleoprotein Condensate Formation and Axonal Transport in Neurons. 2022, 10,	0
388	Cracking the cryptic code in amyotrophic lateral sclerosis and frontotemporal dementia: Towards therapeutic targets and biomarkers.. 2022, 12, e818	0
387	Ultrastructural and biochemical classification of pathogenic tau, Synuclein and TDP-43.. 2022, 143, 613-640	1
386	Graph theory network analysis provides brain MRI evidence of a partial continuum of neurodegeneration in patients with UMN-predominant ALS and ALS-FTD. 2022, 103037	0
385	Bringing the Spotlight to tau and TDP-43 in Frontotemporal Dementia: A Review of Promising Chemical Compounds.. 2022,	
384	Stress granules in the spinal muscular atrophy and amyotrophic lateral sclerosis: The correlation and promising therapy.. 2022, 105749	0
383	TARDBP Inhibits Porcine Epidemic Diarrhea Virus Replication through Degrading Viral Nucleocapsid Protein and Activating Type I Interferon Signaling.. 2022, e0007022	1
382	Divergent magnetic resonance imaging atrophy patterns in Alzheimer's disease and primary age-related tauopathy. 2022,	1
381	Sequestration of TDP-43 Aggregates by Cytoplasmic Expression of the proSAAS Chaperone.. 2022,	0
380	Biological basis and psychiatric symptoms in frontotemporal dementia.. 2022,	0
379	Spinal cord extracts of amyotrophic lateral sclerosis spread TDP-43 pathology in cerebral organoids.	
378	New forms of dementia in neurodegenerative diseases: molecular basis, phenomenology, and diagnostic capability. 2022, 27, 5-13	

377	Slow motor neurons resist pathological TDP-43 and mediate motor recovery in the rNLS8 model of amyotrophic lateral sclerosis.. 2022 , 10, 75	0
376	A tribute to John Q. Trojanowski (1946-2022).. 2022 , 132,	0
375	TDP-43 regulates cholesterol biosynthesis by inhibiting sterol regulatory element-binding protein 2.. 2022 , 12, 7988	0
374	Development of an endogenously myc-tagged TARDBP (TDP-43) zebrafish model using the CRISPR/Cas9 system and homology directed repair.. 2022 , 110756	0
373	Recognizing common PET patterns in neurodegenerative dementia. 06-12	
372	Nuclear RNA transcript levels modulate nucleocytoplasmic distribution of ALS/FTD-associated protein FUS.. 2022 , 12, 8180	1
371	Heat shock protein Grp78/BiP/HspA5 binds directly to TDP-43 and mitigates toxicity associated with disease pathology.. 2022 , 12, 8140	0
370	A retrotransposon storm marks clinical phenoconversion to late-onset Alzheimer's disease.. 2022 ,	1
369	Effect of TDP43-CTFs35 on Brain Endothelial Cell Functions in Cerebral Ischemic Injury.. 2022 ,	0
368	John Q. Trojanowski, 'tour de force' in neurodegeneration (1946-2022).. 2022 ,	0
367	A case of amyotrophic lateral sclerosis presenting with rapid progression of respiratory deterioration due to severe obesity. 2022 ,	
366	Progress in Amyotrophic Lateral Sclerosis Gene Discovery. 2022 , 8, e669	2
365	Protein interaction networks in neurodegenerative diseases: from physiological function to aggregation. 2022 , 102062	1
364	Hetero-oligomerization of TDP-43 carboxy-terminal fragments with cellular proteins contributes to proteotoxicity.	1
363	The Role of Ubiquitin in Regulating Stress Granule Dynamics. 2022 , 13,	0
362	Pathogenic TDP-43 Disrupts Axon Initial Segment Structure and Neuronal Excitability in a Human iPSC Model of ALS.	
361	Recent Advances in Frontotemporal Dementia. 1-34	
360	Targeting ER-Mitochondria Signaling as a Therapeutic Target for Frontotemporal Dementia and Related Amyotrophic Lateral Sclerosis. 2022 , 10,	1

359	How network-based approaches can complement gene identification studies in frontotemporal dementia. 2022,	
358	TDP-43 oligomerization and RNA binding are codependent but their loss elicits distinct pathologies.	0
357	The interface of condensates of the hnRNPA1 low complexity domain promotes formation of amyloid fibrils.	1
356	TDP-43 Accumulation Within Intramuscular Nerve Bundles of Patients With Amyotrophic Lateral Sclerosis.	0
355	Cytoplasmic TDP-43 accumulation drives changes in C-bouton number and size in a mouse model of sporadic Amyotrophic Lateral Sclerosis.	0
354	Critical roles of protein disulfide isomerases in balancing proteostasis in the nervous system. 2022, 102087	1
353	Aberrant Neural Activity in Prefrontal Pyramidal Neurons Lacking TDP-43 Precedes Neuron loss. 2022, 102297	
352	Mitochondrial function determines severity but not risk of amyotrophic lateral sclerosis.	
351	TAR DNA-binding protein of 43 kDa (TDP-43) and amyotrophic lateral sclerosis (ALS): a promising therapeutic target. 1-18	0
350	Generation of an induced pluripotent stem cell line (UCSCi002-A) from a patient with a variant in TARDBP gene associated with familial amyotrophic lateral sclerosis and frontotemporal dementia. 2022, 62, 102825	
349	ALS-associated A315E and A315pT variants exhibit distinct mechanisms in inducing irreversible aggregation of TDP-43312-317 peptide.	3
348	Pathogenic Mutation of TDP-43 Impairs RNA Processing in a Cell Type-Specific Manner: Implications for the Pathogenesis of ALS/FTLD. 2022, 9, ENEURO.0061-22.2022	0
347	Prionoids in amyotrophic lateral sclerosis. 2022, 4,	0
346	Novel molecular targets and mechanisms for neuroprotective modulation in neurodegenerative disorders. 2022, 22,	0
345	Progressive medial temporal degeneration with TDP-43 pathology is associated with upper limb and bulbar onset types of amyotrophic lateral sclerosis.	
344	Effects of pH alterations on stress- and aging-induced protein phase separation. 2022, 79,	2
343	TDP-43 drives synaptic and cognitive deterioration following traumatic brain injury.	0
342	Progress in biophysics and molecular biology proteostasis impairment and ALS. 2022,	0

341	ALS-linked KIF5A Exon27 mutant causes neuronal toxicity through gain-of-function.	3
340	Towards Understanding the Relationship Between ER Stress and Unfolded Protein Response in Amyotrophic Lateral Sclerosis. 14,	0
339	A C-Terminally Truncated TDP-43 Splice Isoform Exhibits Neuronal Specific Cytoplasmic Aggregation and Contributes to TDP-43 Pathology in ALS. 16,	0
338	Metabolic Dysfunction in Motor Neuron Disease: Shedding Light through the Lens of Autophagy. 2022, 12, 574	0
337	Old age amyotrophic lateral sclerosis and limbic TDP-43 pathology.	0
336	Autophagy Dysfunction in ALS: from Transport to Protein Degradation.	0
335	TDP-43 subcellular mislocalisation is correlated with loss of optineurin binding for frontotemporal dementia and amyotrophic lateral sclerosis associated TBK1 missense variants.	0
334	Key Modulators of the Stress Granule Response TIA1, TDP-43, and G3BP1 Are Altered by Polyglutamine-Expanded ATXN7.	0
333	Frequency of LATE neuropathologic change across the spectrum of Alzheimer's disease neuropathology: combined data from 13 community-based or population-based autopsy cohorts. 2022, 144, 27-44	4
332	Staging of Alzheimer's disease: past, present, and future perspectives. 2022,	1
331	Effect of In Vitro Solvation Conditions on Inter- and Intramolecular Assembly of Full-Length TDP-43.	1
330	Optineurin Deficiency and Insufficiency Lead to Higher Microglial TDP-43 Protein Levels. 2022, 23, 6829	1
329	Proximity-based labeling reveals DNA damage-induced phosphorylation of fused in sarcoma (FUS) causes distinct changes in the FUS protein interactome. 2022, 102135	1
328	NUP62 localizes to ALS/FTLD pathological assemblies and contributes to TDP-43 insolubility. 2022, 13,	1
327	A peptide inhibitor that rescues polyglutamine-induced synaptic defects and cell death through suppressing RNA and protein toxicities. 2022, 29, 102-115	1
326	Prolyl Isomerase Pin1 Expression in the Spinal Motor Neurons of Patients With Sporadic Amyotrophic Lateral Sclerosis. 2022, 18, 463	0
325	Mass Spectrometry-Based Proteomic Analysis in Neurodegenerative Disorders Research. 2022, 27-48	0
324	Gene Therapy in Amyotrophic Lateral Sclerosis. 2022, 11, 2066	2

323	Altered Bioenergetics and Metabolic Homeostasis in Amyotrophic Lateral Sclerosis.	0
322	Therapeutic Strategies and Metal-Induced Oxidative Stress: Application of Synchrotron Radiation Microbeam to Amyotrophic Lateral Sclerosis in the Kii Peninsula of Japan. 13,	1
321	An autopsy case of amyotrophic lateral sclerosis with striatonigral and pallidolusian degeneration and cat's-eye-shaped neuronal nuclear inclusions.	
320	Neuronal identity defines β synuclein and tau toxicity.	
319	Regulating FUS Liquid-Liquid Phase Separation via Specific Metal Recognition.	0
318	Targeting Microglia in Alzheimer's Disease: From Molecular Mechanisms to Potential Therapeutic Targets for Small Molecules. 2022, 27, 4124	1
317	Novel insights into the structural changes induced by disease-associated mutations in TDP-43: a computational approach. 1-11	0
316	Myelin loss in C9orf72 hexanucleotide expansion carriers.	0
315	Visual detection of submicroscopic protein clusters with a phase-separation-based fluorescent reporter..	0
314	Modulation of synaptic plasticity, motor unit physiology, and TDP-43 pathology by CHCHD10. 2022, 10,	1
313	Increased surface P2X4 receptors by mutant SOD1 proteins contribute to ALS pathogenesis in SOD1-G93A mice. 2022, 79,	0
312	Mutations linked to neurological disease enhance self-association of low-complexity protein sequences. <i>Science</i> , 2022, 377,	33-3 3
311	Amyotrophic Lateral Sclerosis Proteomic Signature And Treatment With Mesenchymal Stem Cell-derived Extracellular Vesicles.	
310	Multi-omics profiling identifies a deregulated FUS-MAP1B axis in ALS/FTD-associated UBQLN2 mutants. 2022, 5, e202101327	0
309	Regulating Phase Transition in Neurodegenerative Diseases by Nuclear Import Receptors. 2022, 11, 1009	1
308	In-Silico Analysis of pH-Dependent Liquid-Liquid Phase Separation in Intrinsically Disordered Proteins. 2022, 12, 974	0
307	Aberrant NOVA1 function disrupts alternative splicing in early stages of amyotrophic lateral sclerosis.	0
306	Emerging Therapies and Novel Targets for TDP-43 Proteinopathy in ALS/FTD.	1

- 305 Genetically Encoded Aryl Alkyne for Raman Spectral Imaging of Intracellular α -Synuclein Fibrils. **2022**, 167716 0
- 304 Brain structural and perfusion changes in amyotrophic lateral sclerosis-frontotemporal dementia patients with cognitive and motor onset: a preliminary study.
- 303 Conversion of the Native N-Terminal Domain of TDP-43 into a Monomeric Alternative Fold with Lower Aggregation Propensity. **2022**, 27, 4309 1
- 302 Hyperactivity of Purkinje cell and motor deficits in C9orf72 knockout mice. **2022**, 121, 103756 0
- 301 Distinguishing post-translational modifications in dominantly inherited FTD: FTLD-TDP Type A (GRN) versus Type B (C9orf72). 1
- 300 Unravelling the toxic effects mediated by the neurodegenerative disease-associated S375G mutation of TDP-43 and its S375E phosphomimetic variant.. **2022**, 102252 1
- 299 Study of Alzheimer's disease- and Frontotemporal dementia- associated genes in the Cretan Aging Cohort. **2022**,
- 298 Apolipoprotein L1 is increased in frontotemporal lobar degeneration post-mortem brain but not in ante-mortem cerebrospinal fluid. **2022**, 172, 105813
- 297 Amyotrophic lateral sclerosis. **2023**, 233-251
- 296 Frontotemporal lobar degeneration. **2023**, 337-360
- 295 Atypical TDP -43 protein expression in an ALS pedigree carrying a p. Y374X truncation mutation in TARDBP. 0
- 294 Evidence of cerebellar TDP-43 loss of function in FTLD-TDP. **2022**, 10, 0
- 293 Increased pyroptosis activation in white matter microglia is associated with neuronal loss in ALS motor cortex. 1
- 292 Gametogenesis: Exploring an Endogenous Rejuvenation Program to Understand Cellular Aging and Quality Control. **2022**, 56,
- 291 The unique effect of TDP-43 on hippocampal subfield morphometry and cognition. **2022**, 103125
- 290 YKL-40 changes are not detected in post-mortem brain of patients with Alzheimer's disease and frontotemporal lobar degeneration. **2022**, 14, 0
- 289 Locus Coeruleus Degeneration Differs Between Frontotemporal Lobar Degeneration Subtypes. **2022**, 1-9 1
- 288 Endogenous Retroviruses and TDP-43 Proteinopathy Form a Sustaining Feedback to Drive the Intercellular Spread of Neurodegeneration. 0

- 287 Nuclear RNA binding regulates TDP-43 nuclear localization and passive nuclear export. **2022**, 40, 111106 ○
- 286 Neuropathology and cholinesterase expression in the brains of octogenarians and older. **2022**, 110065 ○
- 285 Filter trapping protocol to detect aggregated proteins in human cell lines. **2022**, 3, 101571
- 284 Photodynamic Alzheimer's disease therapy: From molecular catalysis to photo-nanomedicine. **2022**, 470, 214726 ○
- 283 Neuropathology and emerging biomarkers in corticobasal syndrome. **2022**, 93, 919-929 1
- 282 Altered TDP-43 Structure and Function: Key Insights into Aberrant RNA, Mitochondrial, and Cellular and Systemic Metabolism in Amyotrophic Lateral Sclerosis. **2022**, 12, 709 1
- 281 Apolipoprotein B-100-mediated motor neuron degeneration in sporadic amyotrophic lateral sclerosis. **2022**, 4, ○
- 280 Short repeat RNA reduces cytotoxicity by preventing the aggregation of TDP-43 and its 25 kDa carboxy-terminal fragment.
- 279 A quantitative biology approach correlates neuronal toxicity with the largest inclusions of TDP-43. **2022**, 8, 1
- 278 Targeting phosphoglycerate kinase 1 with terazosin improves motor neuron phenotypes in multiple models of amyotrophic lateral sclerosis. **2022**, 104202 1
- 277 Hyperphosphorylation-Mimetic TDP-43 Drives Amyloid Formation and Possesses Neuronal Toxicity at the Oligomeric Stage.
- 276 Interactions of amyloid coaggregates with biomolecules and its relevance to neurodegeneration. **2022**, 36, 1
- 275 The Role of Bioenergetics in Neurodegeneration. **2022**, 23, 9212 2
- 274 The post-translational modification SUMO affects TDP-43 phase separation, compartmentalization, and aggregation in a zebrafish model.
- 273 Disruption of the VAPB-PTPIP51 ER-mitochondria tethering proteins in post-mortem human amyotrophic lateral sclerosis. 10, ○
- 272 Early activation of cellular stress and death pathways caused by cytoplasmic TDP-43 in the rNLS8 mouse model of ALS/FTD.
- 271 Novel and known transcriptional targets of ALS/FTD protein TDP-43: Meta-analysis and interactive graphical database. ○
- 270 Suppression of Linear Ubiquitination Ameliorates Cytoplasmic Aggregation of Truncated TDP-43. **2022**, 11, 2398 ○

- 269 Crosstalk between Biomolecular Condensates and Proteostasis. **2022**, 11, 2415 0
- 268 Amyotrophic lateral sclerosis with TDP-43 abnormalities exhibiting globular glial tau inclusions in frontotemporal lobes and pallido-nigral system. 0
- 267 Development of a 36-Channel Instrument for Assaying Biomarkers of Ultralow Concentrations Utilizing Immunomagnetic Reduction. 0
- 266 Synucleinopathy in Amyotrophic Lateral Sclerosis: A Potential Avenue for Antisense Therapeutics?. **2022**, 23, 9364 0
- 265 Stress granule assembly in vivo is deficient in the CNS of mutant TDP-43 ALS mice. 0
- 264 Trends in global amyotrophic lateral sclerosis research from 2000 to 2022: A bibliometric analysis. 16, 0
- 263 Translocation of Distinct Alpha Synuclein Species from the Nucleus to Neuronal Processes during Neuronal Differentiation. **2022**, 12, 1108 2
- 262 The contribution of brain banks to knowledge discovery in amyotrophic lateral sclerosis: A systematic review. 0
- 261 Sertoli cells require TDP-43 to support spermatogenesis. 0
- 260 Genotype-phenotype correlation in Tunisian patients with Amyotrophic Lateral Sclerosis. **2022**, 0
- 259 An Atypical Presentation of Upper Motor Neuron Predominant Juvenile Amyotrophic Lateral Sclerosis Associated with TARDBP Gene: A Case Report and Review of the Literature. **2022**, 13, 1483 0
- 258 NLRP3 inflammasome in neurodegenerative disease. **2022**, 5
- 257 Biomarkers in Neurodegenerative Diseases: Proteomics Spotlight on ALS and Parkinson's Disease. **2022**, 23, 9299 0
- 256 Old plasma dilution reduces human biological age: a clinical study. 1
- 255 Cyclin F, Neurodegeneration, and the Pathogenesis of ALS/FTD. 107385842211201 0
- 254 RNA-deficient TDP-43 causes loss of free nuclear TDP-43 by sequestration. 0
- 253 Approaches to Gene Modulation Therapy for ALS. 0
- 252 The heterogeneity of microglial activation and its epigenetic and non-coding RNA regulations in the immunopathogenesis of neurodegenerative diseases. **2022**, 79, 1

251	New regulators of the tetracycline-inducible gene expression system identified by chemical and genetic screens.	0
250	Oxytocin in Huntington's disease and the spectrum of amyotrophic lateral sclerosis-frontotemporal dementia. 15,	2
249	Advances in Alzheimer's disease research over the past two decades. 2022 , 21, 866-869	0
248	Functional and structural consequences of TBK1 missense variants in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. 2022 , 174, 105859	0
247	The amyotrophic lateral sclerosis-linked protein TDP-43 regulates interleukin-6 cytokine production by human brain pericytes. 2022 , 123, 103768	0
246	Basic Concepts and Emergent Disease Mechanisms of Amyotrophic Lateral Sclerosis. 2022 ,	0
245	Neuropathology of the temporal lobe. 2022 , 407-427	0
244	Brain Regions Show Different Metabolic and Protein Arginine Methylation Phenotypes in Frontotemporal Dementias and Alzheimer's Disease.	0
243	Invertebrate models in translational research. 2022 , 31-48	0
242	Mitochondrial Dysregulation and the Influence in Neurodegenerative Diseases. 2022 , 109-118	0
241	Emergencies in Motor Neuron Diseases. 2022 , 155-180	0
240	Neuropathology and neuroanatomy of TDP-43 amyotrophic lateral sclerosis. 2022 , 35, 660-671	0
239	Nuclear Pore Dysfunction in Neurodegeneration.	0
238	Functional implication of ubiquitinating and deubiquitinating mechanisms in TDP-43 proteinopathies. 10,	0
237	Array tomography: 15 years of synaptic analysis. 2022 , 6,	1
236	Stress induced TDP-43 mobility loss independent of stress granules. 2022 , 13,	1
235	The Potential Connection between Molecular Changes and Biomarkers Related to ALS and the Development and Regeneration of CNS. 2022 , 23, 11360	1
234	Random forest modelling demonstrates microglial and protein misfolding features to be key phenotypic markers in C9orf72 -ALS .	0

233	Multiple roles of neuronal extracellular vesicles in neurological disorders. 16,	0
232	mRNA isoform balance in neuronal development and disease.	0
231	Atomistic Insights into A315E Mutation-Enhanced Pathogenicity of TDP-43 Core Fibrils. 2022 , 13, 2743-2754	1
230	NOS1AP is a novel molecular target and critical factor in TDP-43 pathology.	0
229	CAPRIN1P512L causes aberrant protein aggregation and associates with early-onset ataxia. 2022 , 79,	2
228	Status of ALS Treatment, Insights into Therapeutic Challenges and Dilemmas. 2022 , 12, 1601	0
227	Conformational change of RNA-helicase DHX30 by ALS/FTD-linked FUS induces mitochondrial dysfunction and cytosolic aggregates. 2022 , 12,	0
226	Slow Evolution toward Super-Aggregation of the Oligomers Formed through the Swapping of RNase A N-Termini: A Wish for Amyloidosis?. 2022 , 23, 11192	0
225	Inhibitory targeting cGAS-STING-TBK1 axis: Emerging strategies for autoimmune diseases therapy. 13,	0
224	Importance of the Q/N-rich segment for protein stability of endogenous mouse TDP-43. 2022 , 12,	0
223	Populations of Tau Conformers Drive Prion-like Strain Effects in Alzheimer's Disease and Related Dementias. 2022 , 11, 2997	1
222	Heat-shock chaperone HSPB1 regulates cytoplasmic TDP-43 phase separation and liquid-to-gel transition. 2022 , 24, 1378-1393	0
221	A scalable screening platform for phenotypic subtyping of ALS patient-derived fibroblasts.	0
220	Intracellular energy controls dynamics of stress-induced ribonucleoprotein granules. 2022 , 13,	1
219	Finding a chaperone for TDP-43. 2022 , 24, 1328-1330	0
218	Synaptic dysfunction in ALS and FTD: anatomical and molecular changes provide insights into mechanisms of disease. 15,	1
217	CK2 and protein kinases of the CK1 superfamily as targets for neurodegenerative disorders. 9,	0
216	Limbic-Predominant Age-Related TDP-43 Encephalopathy: LATE-Breaking Updates in Clinicopathologic Features and Biomarkers.	0

215	SBT-272 improves TDP-43 pathology in the ALS motor cortex by modulating mitochondrial integrity, motility, and function.	0
214	Axon Biology in ALS: Mechanisms of Axon Degeneration and Prospects for Therapy.	1
213	A perturbed network in neurodegeneration. 2022 , 378, 28-29	0
212	Proteinopathies: Deciphering Physiology and Mechanisms to Develop Effective Therapies for Neurodegenerative Diseases.	1
211	Multiple gene variants linked to Alzheimer's-type clinical dementia via GWAS are also associated with non-Alzheimer's neuropathologic entities. 2022 , 174, 105880	0
210	Liquid-liquid phase separation: A new perspective to understanding aging and pathogenesis. 2022 ,	0
209	Amyotrophic Lateral Sclerosis: Neurochemical Biomarkers. 2022 , 295-310	0
208	Neurodegenerative Diseases: Implications of Environmental and Climatic Influences on Neurotransmitters and Neuronal Hormones Activities. 2022 , 19, 12495	2
207	Importin β and the tug of war to keep TDP-43 in solution: quo vadis ?. 2200181	0
206	CuATSM effectively ameliorates ALS patient astrocyte-mediated motor neuron toxicity in human in vitro models of amyotrophic lateral sclerosis.	0
205	Development of new tools to study membrane-anchored mammalian Atg8 proteins. 1-20	0
204	Serum total TDP-43 levels are decreased in frontotemporal dementia patients with C9orf72 repeat expansion or concomitant motoneuron disease phenotype. 2022 , 14,	1
203	Finding Common Ground on the Site of Onset of Amyotrophic Lateral Sclerosis. 10.1212/WNL.000000000201387	
202	Clinical heterogeneity in a family with flail arm syndrome and review of hnRNPA1 -related spectrum.	0
201	Head-to-Head Comparison of Tau-PET Radioligands for Imaging TDP-43 in Post-Mortem ALS Brain.	0
200	Brain DNA methylomic analysis of frontotemporal lobar degeneration reveals OTUD4 and CEBPZ in shared dysregulated signatures across pathological subtypes.	0
199	Genome-wide CRISPR screen reveals v-ATPase as a drug target to lower levels of ALS protein ataxin-2. 2022 , 41, 111508	0
198	Efficient Gene Expression in Human Stem Cell Derived-Cortical Organoids Using Adeno Associated Virus. 2022 , 11, 3194	2

- 197 TDP-43 and NEAT long non-coding RNA: Roles in neurodegenerative disease. 16, ○
- 196 Biophysical Studies of LLPS and Aggregation of TDP-43 LCD. **2023**, 497-513 ○
- 195 Granulin Loss of Function in Human Mature Brain Organoids Implicates Astrocytes in TDP-43 Pathology. ○
- 194 Changing perspectives on frontotemporal dementia: A review. 1
- 193 Molecular Dissection of TDP-43 as a Leading Cause of ALS/FTLD. **2022**, 23, 12508 ○
- 192 Reversing lysosome-ribosome circuit dysregulation mitigates C9FTD/ALS neurodegeneration and behaviors. ○
- 191 A TDP-43 acetylation-mimic mutation that disrupts RNA-binding drives FTLD-like neurodegeneration in a mouse model of sporadic TDP-43 proteinopathy. ○
- 190 In Vitro Interaction of a C-Terminal Fragment of TDP-43 Protein with Human Serum Albumin Modulates Its Aggregation. 1
- 189 Gasdermin-E mediates mitochondrial damage in axons and neurodegeneration. ○
- 188 Fluid biomarkers in Alzheimer's disease. **2022**, ○
- 187 Drug repurposing: Clemastine fumarate and neurodegeneration. **2023**, 157, 113904 ○
- 186 Liquid-liquid phase separation in neurodegenerative diseases. **2023**, 619-650 ○
- 185 Aliphatic residues contribute significantly to the phase separation of TDP-43 C-terminal domain. ○
- 184 Biophysical Characterization of Full Length TAR DNA-Binding Protein (TDP -43) Phase Separation. ○
- 183 Proteomic characterization of spinal cord synaptoneurosomes from Tg-SOD1/G93A mice supports a role for MNK1 and local translation in the early stages of amyotrophic lateral sclerosis. **2022**, 103792 ○
- 182 Theme 05 - Human Cell Biology and Pathology (including iPSC studies). **2022**, 23, 83-98 ○
- 181 Deciphering lipid dysregulation in ALS: from mechanisms to translational medicine. **2022**, 11, ○
- 180 Modelling dementia in Drosophila uncovers shared and specific targets of TDP-43 proteinopathy across ALS and FTD relevant circuits. ○

- 179 A canonical chaperone and a heat-resistant obscure (Hero) protein mediate similar conformational modulation and aggregation suppression of TDP-43. ○
- 178 Transthyretin attenuates TDP-43 proteinopathy by autophagy activation via ATF4 in FTLD-TDP. 1
- 177 Pathological 25 kDa C-Terminal Fragments of TDP-43 Are Present in Lymphoblastoid Cell Lines and Extracellular Vesicles from Patients Affected by Frontotemporal Lobar Degeneration and Neuronal Ceroidlipofuscinosis Carrying a GRN Mutation. **2022**, 23, 13753 ○
- 176 Repulsive interaction and secondary structure of highly charged proteins in regulating biomolecular condensation. ○
- 175 Divergent impacts of C9orf72 repeat expansion on neurons and glia in ALS and FTD. ○
- 174 Deep mutational scanning to probe specificity determinants in proteins. **2023**, 31-71 ○
- 173 Modeling amyotrophic lateral sclerosis through Ataxin-2 pathology. **2023**, 95-106 ○
- 172 Event-based modeling of T1-weighted MRI is related to pathology in frontotemporal lobar degeneration due to tau and TDP. **2023**, 37, 103285 ○
- 171 Inflammasome and neurodegenerative diseases. **2023**, 291-326 ○
- 170 PINK1/Parkin-mediated mitophagy in neurodegenerative diseases. **2023**, 84, 101817 2
- 169 Protective effect of human umbilical cord mesenchymal stem cell derived conditioned medium in a mutant TDP-43 induced motoneuron-like cellular model of ALS. **2023**, 193, 106-116 ○
- 168 PSMA2 knockdown impacts expression of proteins involved in immune and cellular stress responses in human lung cells. **2023**, 1869, 166617 ○
- 167 Understanding In Vitro Pathways to Drug Discovery for TDP-43 Proteinopathies. **2022**, 23, 14769 ○
- 166 Allele-specific silencing as therapy for familial amyotrophic lateral sclerosis caused by the p.G376D TARDBP mutation. **2022**, 4, ○
- 165 Role of Triggers on the Structural and Functional Facets of TAR DNA-binding Protein 43. **2022**, ○
- 164 RNA-Binding Proteins as Epigenetic Regulators of Brain Functions and Their Involvement in Neurodegeneration. **2022**, 23, 14622 ○
- 163 Huntingtin and Other Neurodegeneration-Associated Proteins in the Development of Intracellular Pathologies: Potential Target Search for Therapeutic Intervention. **2022**, 23, 15533 ○
- 162 TDP-43 Proteinopathy and Tauopathy: Do They Have Pathomechanistic Links?. **2022**, 23, 15755 ○

161	APOE2 Exacerbates TDP -43 Related Toxicity in the Absence of Alzheimer Pathology.	0
160	How do RNA binding proteins trigger liquid-liquid phase separation in human health and diseases?. 2022 , 16, 389-404	1
159	Relation between pH alterations in cellular models of amyotrophic lateral sclerosis and TDP-43 protein aggregation.	0
158	Multiple pathways of lipid dysregulation in amyotrophic lateral sclerosis.	0
157	Brain regions show different metabolic and protein arginine methylation phenotypes in frontotemporal dementias and Alzheimer's disease. 2022 , 102400	0
156	LATE-NC staging in routine neuropathologic diagnosis: an update.	2
155	Stathmin-2 loss leads to neurofilament-dependent axonal collapse driving motor and sensory denervation.	0
154	Crystal Structure of the RNA Lariat Debranching Enzyme Dbr1 with Hydrolyzed Phosphorothioate RNA Product. 2022 , 61, 2933-2939	0
153	Transgenic mice overexpressing mutant TDP-43 show aberrant splicing of autism associated gene Zmynd11 prior to onset of motor symptoms.	0
152	Exosomal TAR DNA binding protein 43 profile in canine model of amyotrophic lateral sclerosis: a preliminary study in developing blood-based biomarker for neurodegenerative diseases. 2023 , 55, 34-41	0
151	Nuclear import receptors are recruited by FG-nucleoporins to rescue hallmarks of TDP-43 proteinopathy. 2022 , 17,	0
150	Models of Neurodegenerative Diseases. 2023 , 179-209	0
149	Multi-Step Molecular Mechanism of Amyloid-Like Aggregation of Nucleic Acid-Binding Domain of TDP -43.	0
148	MicroRNA -183-5p regulates TAR DNA -binding protein 43 neurotoxicity via SQSTM1 /p62 in amyotrophic lateral sclerosis.	0
147	LATE and potential estrogen-related risk factors collected 30 years earlier: The 90+ Study.	0
146	Brain modulation by the gut microbiota: From disease to therapy. 2022 ,	1
145	Genotype-phenotype correlation in the spectrum of frontotemporal dementia-parkinsonian syndromes and advanced diagnostic approaches. 1-18	0
144	c-Abl Regulates the Pathological Deposition of TDP-43 via Tyrosine 43 Phosphorylation. 2022 , 11, 3972	0

- 143 Amyotrophic lateral sclerosis: a neurodegenerative disorder poised for successful therapeutic translation. 1
- 142 Hsr and Other lncRNAs in Neuronal Functions and Disorders in Drosophila. **2023**, 13, 17 0
- 141 An in situ and in vitro investigation of cytoplasmic TDP-43 inclusions reveals the absence of a clear amyloid signature. **2023**, 55, 72-88 0
- 140 Arg/Lys-containing IDRs are cryptic binding domains for ATP and nucleic acids that interplay to modulate LLPS. **2022**, 5, 1
- 139 Multimodal Assessment of Bottlenose Dolphin Auditory Nuclei Using 7-Tesla MRI, Immunohistochemistry and Stereology. **2022**, 9, 692 1
- 138 Single nucleus multiome analysis of the prefrontal cortex from C9orf72ALS/FTD patients illuminates pathways affected during disease progression. 0
- 137 Neurotoxicity and ALS: Insights into Pathogenesis. **2022**, 1803-1821 0
- 136 The Nuclear Envelope in Ageing and Progeria. **2023**, 53-75 0
- 135 RNA-binding deficient TDP-43 drives cognitive decline in a mouse model of TDP-43 proteinopathy. 0
- 134 Multimodality imaging of neurodegenerative disorders with a focus on multiparametric magnetic resonance and molecular imaging. **2023**, 14, 0
- 133 Neuroprotective Effects of a Multi-Herbal Extract on Axonal and Synaptic Disruption in Vitro and Cognitive Impairment in Vivo. 1-26 0
- 132 Direct evaluation of neuroaxonal degeneration with the causative genes of neurodegenerative diseases in Drosophila using the automated axon quantification system, MeDUSA. 0
- 131 RNA-binding deficient TDP-43 drives cognitive decline in a mouse model of TDP-43 proteinopathy. 0
- 130 Mechanism of pyroptosis in neurodegenerative diseases and its therapeutic potential by traditional Chinese medicine. 14, 0
- 129 Mutated FUS in familial amyotrophic lateral sclerosis involves multiple hnRNPs in the formation of neuronal cytoplasmic inclusions. 0
- 128 How Villains are Made: The Translation of Dipeptide Repeat Proteins in C9ORF72-ALS/FTD. **2023**, 147167 0
- 127 Molecular subtypes of ALS are associated with differences in patient prognosis. **2023**, 14, 0
- 126 The role of STING signaling in central nervous system infection and neuroinflammatory disease. 1

- 125 Identification of dysregulated canonical pathways associated with pathogenesis and progression of Amyotrophic Lateral Sclerosis: An integrated bioinformatics approach. **2023**, ○
- 124 Optogenetic interrogation of TDP-43 cytotoxicity in a zebrafish ALS model. **2023**, 158, 16-20 ○
- 123 Reviewing the Potential Links between Viral Infections and TDP-43 Proteinopathies. **2023**, 24, 1581 ○
- 122 Casein Kinase 1 β Phosphorylates TDP-43 and Suppresses Its Function in Tau mRNA Processing. **2023**, 1-13 ○
- 121 Pathological Comparison of TDP-43 Between Motor Neurons and Interneurons Expressed by a Tetracycline Repressor System on the Mouse Artificial Chromosome. **2023**, ○
- 120 The Need for Biomarkers in the ALS/FTD Spectrum: A Clinical Point of View on the Role of Proteomics. **2023**, 11, 1 ○
- 119 M1/precuneus ratio as a surrogate marker of upper motor neuron sign in ALS. **2023**, 445, 120548 ○
- 118 Use of the Laboratory in the Diagnostic Workup of Older Adults. **2022**, ○
- 117 TDP-43 dysregulation and neuromuscular junction disruption in amyotrophic lateral sclerosis. **2022**, 11, 1
- 116 Mechanisms Underlying Neurodegenerative Disorders and Potential Neuroprotective Activity of Agrifood By-Products. **2023**, 12, 94 1
- 115 The role of TDP-43 protein in amyotrophic lateral sclerosis. **2022**, 91, e710 ○
- 114 Novel CSF Biomarkers Tracking Autoimmune Inflammatory and Neurodegenerative Aspects of CNS Diseases. **2023**, 13, 73 ○
- 113 Molecular Investigations of Protein Aggregation in the Pathogenesis of Amyotrophic Lateral Sclerosis. **2023**, 24, 704 ○
- 112 Modeling of Neurodegenerative Diseases: Step by Step and Network Organization of the Complexes of Model Systems. **2023**, 24, 604 ○
- 111 Therapeutic Effect of Rapamycin on TDP-43-Related Pathogenesis in Ischemic Stroke. **2023**, 24, 676 ○
- 110 Invertebrate and Vertebrate Models of Tauopathies. **2011**, 69-85 ○
- 109 Animal Models for ALS. **2011**, 177-213 ○
- 108 MAPK/MAK/MRK overlapping kinase (MOK) controls microglial inflammatory/type-I IFN responses via Brd4 and is involved in ALS pathophysiology. ○

- 107 Intracellular conformation of amyotrophic lateral sclerosis-causative TDP-43. 0
- 106 Drug Discovery and Development Targeting Dementia. **2023**, 16, 151 1
- 105 The Role of TAR DNA Binding Protein 43 (TDP-43) as a Candidate Biomarker of Amyotrophic Lateral Sclerosis: A Systematic Review and Meta-Analysis. **2023**, 13, 416 0
- 104 Ataxin-2 polyglutamine expansions aberrantly sequester TDP-43, drive ribonucleoprotein condensate transport dysfunction and suppress local translation. 0
- 103 A fluid biomarker reveals loss of TDP-43 splicing repression in pre-symptomatic ALS. 0
- 102 STING trafficking as a new dimension of immune signaling. **2023**, 220, 0
- 101 Why should we care about astrocytes in a motor neuron disease?. 3, 0
- 100 Metamorphism in TDP-43 prion-like domain determines chaperone recognition. **2023**, 14, 0
- 99 La sclérose latérale amyotrophique : une maladie neurodégénérative emblématique. **2023**, 0
- 98 Alternative polyadenylation transcriptome-wide association study identifies APA-linked susceptibility genes in brain disorders. **2023**, 14, 0
- 97 Biophysical evaluation of the oligomerization and conformational properties of the N-terminal domain of TDP-43. **2023**, 109533 0
- 96 Effect of Serum Perampanel Concentration on Sporadic Amyotrophic Lateral Sclerosis Progression. 19, 0
- 95 Aggregation of Disordered Proteins Associated with Neurodegeneration. **2023**, 24, 3380 1
- 94 Mixed pathology as a rule, not exception: Time to reconsider disease nosology. **2023**, 57-71 0
- 93 Single-molecule techniques to visualize and to characterize liquid-liquid phase separation and phase transition. **2023**, 0
- 92 Integrated tandem affinity protein purification using the polyhistidine plus extra 4 amino acids (HiP4) tag system. 2200334 0
- 91 Long noncoding RNA Lnc530 localizes on R-loops and regulates R-loop formation and genomic stability in mouse embryonic stem cells. **2023**, 18, 952-968 0
- 90 Enterovirus D68 Infection Induces TDP-43 Cleavage, Aggregation, and Neurotoxicity. 0

- 89 TDP-43 and tau concurrence in the entorhinal subfields in primary age-related tauopathy and preclinical Alzheimer's disease. ○
- 88 Antibody-Based Electrochemical Sensor for Detection of the Full-Length Phosphorylated TDP-43 Protein Biomarker of Amyotrophic Lateral Sclerosis. **2023**, 170, 045502 ○
- 87 Cytoplasmic TDP-43 accumulation drives changes in C-bouton number and size in a mouse model of sporadic Amyotrophic Lateral Sclerosis. **2023**, 125, 103840 ○
- 86 The unique neuropathological vulnerability of the human brain to aging. **2023**, 87, 101916 ○
- 85 Metal ratios as possible biomarkers for amyotrophic lateral sclerosis. **2023**, 78, 127163 ○
- 84 Physical activity as an exogenous risk factor for amyotrophic lateral sclerosis: a review of the evidence. ○
- 83 Profiling TREM2 expression in amyotrophic lateral sclerosis. **2023**, 109, 117-126 ○
- 82 SBT-272 improves TDP-43 pathology in ALS upper motor neurons by modulating mitochondrial integrity, motility, and function. **2023**, 178, 106022 ○
- 81 Early-Stage Oligomerization of Prion-like Polypeptides Reveals the Molecular Mechanism of Amyloid-Disrupting Capacity by Proline Residues. **2023**, 127, 1074-1088 ○
- 80 Editorial: Protein misfolding, altered mechanisms and neurodegeneration. 16, ○
- 79 Stratégie diagnostique : quel bilan chez un patient suspect de SLA ? **2023**, 14, 47-54 ○
- 78 lncRNA NEAT1: Key player in neurodegenerative diseases. **2023**, 86, 101878 ○
- 77 Differential exon usage and cryptic exon profiles of TDP-43 loss of function in amyotrophic lateral sclerosis brain tissue. ○
- 76 Spinal cord extracts of amyotrophic lateral sclerosis spread TDP-43 pathology in cerebral organoids. **2023**, 19, e1010606 2
- 75 Dynamic mapping of proteome trafficking within and between living cells by TransitID. ○
- 74 Distribution of ubiquilin 2 and TDP-43 aggregates throughout the CNS in UBQLN2p.T487I-linked amyotrophic lateral sclerosis and frontotemporal dementia. ○
- 73 Masitinib: The promising actor in the next season of the Amyotrophic Lateral Sclerosis treatment series. **2023**, 160, 114378 ○
- 72 TDP-43 Proteinopathy Specific Biomarker Development. **2023**, 12, 597 ○

- 71 Pathology vs pathogenesis: Rationale and pitfalls in the clinicopathology model of neurodegeneration. **2023**, 35-55 ○
- 70 Molecular mechanisms of amyotrophic lateral sclerosis as broad therapeutic targets for gene therapy applications utilizing adeno-associated viral vectors. ○
- 69 Potential roles of the endoplasmic reticulum stress pathway in amyotrophic lateral sclerosis. 15, ○
- 68 A pancreatic player in dementia: pathological role for islet amyloid polypeptide accumulation in the brain. **2023**, 18, 2141 ○
- 67 Shapeshifter TDP-43: Molecular mechanism of structural polymorphism, aggregation, phase separation and their modulators. **2023**, 295, 106972 ○
- 66 In vivo analysis of aggregation propensity of low levels of mislocalized TDP-43 on cytopathological and behavioral phenotype of ALS/FTLD. **2023**, ○
- 65 The Fault in Our Astrocytes - cause or casualties of proteinopathies of ALS/FTD and other neurodegenerative diseases?. 3, ○
- 64 Impact of Plant-Derived Compounds on Amyotrophic Lateral Sclerosis. ○
- 63 Immunotherapy targeting the C-terminal domain of TDP-43 decreases neuropathology and confers neuroprotection in mouse models of ALS/FTD. **2023**, 179, 106050 ○
- 62 Endogenous retroviruses and TDP-43 proteinopathy form a sustaining feedback driving intercellular spread of Drosophila neurodegeneration. **2023**, 14, ○
- 61 Gentherapien bei den Motoneuronerkrankungen ALS und SMA. **2023**, 91, 153-163 ○
- 60 Granulin loss of function in human mature brain organoids implicates astrocytes in TDP-43 pathology. **2023**, 18, 706-719 ○
- 59 The role of astrocytes with genetic mutations linked to amyotrophic lateral sclerosis. **2023**, 100117 ○
- 58 Highly Charged Proteins and Their Repulsive Interactions Antagonize Biomolecular Condensation. **2023**, 3, 834-848 ○
- 57 Novel rAAV vector mediated intrathecal HGF delivery has an impact on neuroimmune modulation in the ALS motor cortex with TDP-43 pathology. ○
- 56 Influence of ALS-linked M337V mutation on the conformational ensembles of TDP-43 321B40 peptide monomer and dimer. 1
- 55 Current State and Future Directions in the Diagnosis of Amyotrophic Lateral Sclerosis. **2023**, 12, 736 ○
- 54 Synaptic Dysfunction and Plasticity in Amyotrophic Lateral Sclerosis. **2023**, 24, 4613 ○

- 53 Proteostasis and Ribostasis Impairment as Common Cell Death Mechanisms in Neurodegenerative Diseases. **2023**, 19, 101 ○
- 52 Bromodomain and Extra-Terminal Proteins in Brain Physiology and Pathology: BET-ing on Epigenetic Regulation. **2023**, 11, 750 1
- 51 Long non-coding RNASNHG8 drives stress granule formation in tauopathies. ○
- 50 Raddeanin A Enhances Mitochondrial DNA-cGAS/STING Axis-Mediated Antitumor Immunity by Targeting Transactive Responsive DNA-Binding Protein 43. 2206737 ○
- 49 Caenorhabditis elegans as a Model System to Study Human Neurodegenerative Disorders. **2023**, 13, 478 ○
- 48 ALS-Linked A315T and A315E Mutations Enhance Barrel Formation of the TDP-43307B19 Hexamer: A REST2 Simulation Study. **2023**, 14, 1310-1320 ○
- 47 An Insect Viral Protein Disrupts Stress Granule Formation in Mammalian Cells. **2023**, 168042 ○
- 46 Codon-optimized TDP-43 mediates neurodegeneration in a Drosophila model of ALS/FTLD. 14, ○
- 45 The Physio-Pathological Role of Group I Metabotropic Glutamate Receptors Expressed by Microglia in Health and Disease with a Focus on Amyotrophic Lateral Sclerosis. **2023**, 24, 5240 ○
- 44 Modulations of SIRTUINS and Management of Brain Disorders. **2023**, 47-81 ○
- 43 Protein amyloid aggregate: Structure and function. ○
- 42 Disturb mitochondrial associated proteostasis: Neurodegeneration and imperfect ageing. 11, ○
- 41 Neuroimmune characterization of optineurin insufficiency mouse model during ageing. ○
- 40 Intracellular Conformation of Amyotrophic Lateral Sclerosis-Causative TDP-43. **2023**, 24, 5513 ○
- 39 Glia in FTLD-GRN: from supporting cast to leading role. **2023**, 133, ○
- 38 The identification of high-performing antibodies for TDP-43 for use in Western Blot, immunoprecipitation and immunofluorescence. 12, 277 ○
- 37 Su(var)3-9 mediates age-dependent increase in H3K9 methylation on TDP-43 promoter triggering neurodegeneration. ○
- 36 Autophagy Function and Benefits of Autophagy Induction in Models of Spinocerebellar Ataxia Type 3. **2023**, 12, 893 ○

- 35 Physical exercise modulates the microglial complement pathway in mice to relieve cortical circuitry deficits induced by mutant human TDP-43. **2023**, 42, 112240 ○
- 34 Autophagy and neurodegeneration: Unraveling the role of C9ORF72 in the regulation of autophagy and its relationship to ALS-FTD pathology. 17, ○
- 33 Mechanism of STMN2 cryptic splice-polyadenylation and its correction for TDP-43 proteinopathies. **2023**, 379, 1140-1149 ○
- 32 Retinal fingerprints of ALS in patients: Ganglion cell apoptosis and TDP-43/p62 misplacement. 15, ○
- 31 Repetitive elements in aging and neurodegeneration. **2023**, 39, 381-400 ○
- 30 Aggregation-prone TDP-43 sequesters and drives pathological transitions of free nuclear TDP-43. **2023**, 80, ○
- 29 Ubiquitin Is Not a Blood Biomarker of an Early Cognitive Decline in the Polish Elderly. **2023**, 45, 2452-2460 ○
- 28 Single cell RNA sequencing in isogenic FUS and TARDBP mutant ALS lines reveals early mitochondrial dysfunction as a common pathway in motor neurons. ○
- 27 Inflammation-Mediated Responses in the Development of Neurodegenerative Diseases. **2023**, 39-70 ○
- 26 TDP-43 pathology and functional deficits in wild-type and ALS/FTD mutant cyclin F mouse models. **2023**, 49, ○
- 25 NLRP3 Inflammasome Activation in Acute and Chronic Brain Diseases: An Update on Pathogenetic Mechanisms and Therapeutic Perspectives with Respect to Other Inflammasomes. **2023**, 11, 999 ○
- 24 Homozygous ALS-linked mutations in TARDBP/TDP-43 lead to progressive synaptic dysfunction in human iPSC-derived motor neurons. ○
- 23 The era of cryptic exons: implications for ALS-FTD. **2023**, 18, ○
- 22 Disrupted myelin lipid metabolism differentiates frontotemporal dementia caused by GRN and C9orf72 gene mutations. **2023**, 11, ○
- 21 Chitinase Signature in the Plasticity of Neurodegenerative Diseases. **2023**, 24, 6301 ○
- 20 Structural polymorphism of the low-complexity C-terminal domain of TDP-43 amyloid aggregates revealed by solid-state NMR. 10, ○
- 19 Disease-modifying pharmacological treatments for amyotrophic lateral sclerosis/motor neuron disease: an overview of intervention reviews. **2023**, 2023, ○
- 18 Neuronal biomolecular condensates and their implications in neurodegenerative diseases. 15, ○

- 17 Early activation of cellular stress and death pathways caused by cytoplasmic TDP-43 in the rNLS8 mouse model of ALS and FTD. ○
- 16 Moving beyond amyloid and tau to capture the biological heterogeneity of Alzheimer's disease. **2023**, ○
- 15 C-terminal frameshift variant of TDP-43 with pronounced aggregation-propensity causes rimmed vacuole myopathy but not ALS/FTD. ○
- 14 Contribution of A-to-I RNA editing, M6A RNA Methylation, and Alternative Splicing to physiological brain aging and neurodegenerative diseases.. **2023**, 111807 ○
- 13 Amyotrophic lateral sclerosis: translating genetic discoveries into therapies. ○
- 12 Mitigating a TDP-43 proteinopathy using RNA-targeting CRISPR effector proteins. ○
- 11 Thermodynamic modulation of folding and aggregation energy landscape by DNA binding of functional domains of TDP-43. **2023**, 1871, 140916 ○
- 10 Loss of hypothalamic MCH decreases food intake in amyotrophic lateral sclerosis. ○
- 9 Transfer of nuclear and ribosomal material from Sox10-lineage cells to neurons in the mouse brain. **2023**, 220, ○
- 8 C9ORF72 knockdown triggers FTD-like symptoms and cell pathology in mice. 17, ○
- 7 TDP-1 and FUST-1 co-inhibit exon inclusion and control fertility together with transcriptional regulation. ○
- 6 Suppression of TDP-43 aggregation by artificial peptide binder targeting to its low complexity domain. **2023**, ○
- 5 Integrated transcriptome landscape of ALS identifies genome instability linked to TDP-43 pathology. **2023**, 14, ○
- 4 Molecular mechanisms of cellular senescence in neurodegenerative diseases. **2023**, 168114 ○
- 3 Degradation of neurodegenerative disease-associated TDP-43 aggregates and oligomers via a proteolysis-targeting chimera. **2023**, 30, ○
- 2 A novel gene, TARDBP, and the protein it encodes can predict glioma patient prognosis and establish a prediction model. **2023**, 23, ○
- 1 TDP-43 pathology in *Drosophila* induces glial-cell type specific toxicity that can be ameliorated by knock-down of SF2/SRSF1. ○